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ABSTRACT 
Julie Lynn Elam 
 
PREDICTORS OF SLEEP-WAKE DISTURBANCES IN BREAST CANCER 
SURVIVORS COMPARED TO WOMEN WITHOUT BREAST CANCER 
 Current evidence shows that sleep-wake disturbances are a persistent problem in 
women surviving breast cancer. The purpose of this study was to refine the knowledge 
regarding the incidence, prevalence, and predictive factors of sleep-wake disturbances in 
breast cancer survivors (BCS) compared to age-matched women without breast cancer 
(WWBC).  
 The cross-sectional, convenience-sample consisted of secondary data from BCS 
and WWBC who were recruited by two parent quality of life studies. Subjects were 
matched within +/- 5 years of age. The sample consisted of 246 BCS and 246 WWBC 
who were a mean age of 48 years old (SD=8.50), Caucasian (70%), employed (69%), 
married or partnered (76%), postmenopausal (59%), with a college education (56%), and 
with at least one concurrent medical problem (95%).  
 Results showed that BCS had more prevalent sleep-wake disturbances (65%) 
compared to WWBC (55%). The poorest sleepers were BCS, women with hot flashes, 
poor physical functioning, depressive symptoms, or with moderate or high levels of 
distress related to a life event. BCS had higher PSQI scores indicating poorer sleep 
quality and higher sleep disturbances compared to WWBC. Predictors of the severity of 
poor sleep quality and sleep disturbances were BCS, women with higher number of co-
morbidities, women with hot flashes, lower levels of physical functioning, higher 
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depressive symptoms, and greater impact of a life event. Disease and treatment related 
factors did not predict poor sleep or sleep quality in BCS.  
 Sleep disturbances are a problem in long-term BCS. Knowledge of contributing 
factors provides useful information during clinical evaluations and treatment of BCS 
reporting poor sleep. Additional research is needed to determine the impact of poor sleep 
on quality of life and develop/test effective interventions for long-term BCS. 
 
 
Janet S. Carpenter, PhD, RN Chair 
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CHAPTER ONE 
INTRODUCTION 
 
 The following research focuses on predictors of sleep-wake disturbances in breast 
cancer survivors (BCS) compared to age-matched women without breast cancer 
(WWBC). The main objective was to provide information regarding factors that predict 
the occurrence and severity of sleep-wake disturbances that linger after treatment for 
breast cancer and how they differ from a group of age-matched women with no history of 
cancer. This research provides information regarding specific predictors of prevalence of 
poor sleep and severity of sleep disturbances in BCS. The conceptualization of sleep-
wake disturbances provided a new and unique method of describing this problem and 
expanded on current theories of sleep research. Ultimately, information gained from this 
research will lead to targeted interventions that reduce potential negative consequences of 
sleep disruption and increase quality of life in various cancer populations. 
Background and Significance 
 BCS represent a significant and growing population. Although breast cancer is the 
most common malignancy in women, with an estimated 182,460 new cases projected in 
2008 (Jemal et al., 2008), the number of women who survive breast cancer continues to 
increase each year (Jemal et al., 2008). However, the five-year relative survival rates by 
stage at diagnosis are 98% for local stage tumors, 84% for regional stage tumors, and 
27% for metastatic breast cancer (American Cancer Society, 2008). Because of the high 
survival rates, it has been reported that 2.2 million BCS are living in the United States 
(National Center for Chronic Disease Prevention and Health Promotion, 2004). The 
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decreased breast cancer mortality combined with (a) the relatively high five-year survival 
rates for local and regional stage tumors, (b) the aging of the United States population 
(U.S. Bureau of the Census, 1996), and (c) the potential medical issues encountered by 
survivors due to lingering treatment effects (Dow, Ferrell, Leigh, Ly, & Gulasekaram, 
1996) suggest that BCS constitute an important population of interest. For this study, 
BCS are defined as women at least 1 year post completion of primary forms of treatment 
(surgery, chemotherapy, radiotherapy) and without residual breast disease. 
 Current evidence suggests that a significant proportion of BCS suffer from sleep-
wake disturbances. Sleep-wake disturbances, defined as chronic disruptions in nighttime 
rest and/or wakefulness that result in physical, psychological, emotional, and/or social 
dysfunction, are reported at various times in the cancer trajectory (before, during, and 
after treatment). Studies are variable and show that 19-90% of BCS have chronic 
problems with sleep and wakefulness using self-report measures (e.g., Pittsburgh Sleep 
Quality Index) (Beck, Schwartz, Towsley, Dudley, & Barsevick, 2004; Berger et al., 
2002; Berger et al., 2003; Buysse, Reynolds, Monk, Berman, & Kupfer, 1989; Carpenter 
& Andrykowski, 1998; Clark, Cunningham, McMillan, Vena, & Parker, 2004; Fortner, 
Stepanski, Wang, Kasprowicz, & Durrence, 2002; Owen, Parker, & McGuire, 1999) or 
objective wrist actigraphy (Ancoli-Israel et al., 2005; Berger et al., 2002; Davidson, 
MacLean, Brundage, & Schulze, 2002; Engstrom, Strohl, Rose, Lewandowski, & 
Stefanek, 1999; Hunter et al., 2004; Lee, Cho, Miaskowski, & Dodd, 2004). 
 Consequences of sleep-wake disturbances in BCS can be immediate or delayed, 
affecting general physiological, social, and/or emotional functioning (Ancoli-Israel, 
Moore, & Jones, 2001; Anderson et al., 2003; Beck et al., 2004; Berger & Higginbotham, 
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2000; Bower et al., 2000; Carpenter et al., 2004; Davidson et al., 2002; Dow et al., 1996; 
Engstrom et al., 1999; Fortner et al., 2002; Koopman et al., 2002; Lee et al., 2004; 
Miaskowski & Lee, 1999; Okuyama et al., 2000; Roscoe et al., 2002; Savard & Morin, 
2001). Decreased immune function related to lack of sleep can result in illness, infection, 
or mortality (Benca, 2005; Davidson et al., 2002; Fava, 2004; Shaver & Zenk, 2000; 
Thase, 2005). Social activities such as job performance, ability to do tasks at home, and 
socialization can also decrease (Anderson et al., 2003; Berger & Higginbotham, 2000; 
Lee et al., 2004; Miaskowski & Lee, 1999). Emotional/mental acuity and mood can 
decrease resulting in decreased mental alertness, depressive symptoms, emotional 
lability, anxiety, and distress (Anderson et al., 2003; Berger & Higginbotham, 2000; Lee 
et al., 2004; Miaskowski & Lee, 1999). These consequences are significant for the BCS 
population and have the potential to negatively impact overall quality of life (Deimling, 
Kahana, Bowman, & Schaefer, 2002; Ganz et al., 2002). 
 The reason sleep is such a salient topic for BCS is reflected by a powerful 
statement made during a qualitative exit survey following a behavioral intervention for 
hot flashes in a breast survivor (Carpenter, Neal, Payne, Kimmick, & Storniolo, 2007); 
“…It is the sleep (lack of) that is just killing every one of us…I really 
think that that’s the part that critically needs to be looked at for most of 
us.” 
 
 Although cancer patients in general are twice as likely to report sleep-wake 
disturbances, it is unclear what unique predictors are prevalent in long-term BCS. Studies 
have shown risk factors  (Savard & Morin, 2001). The BCS literature shows a lack of 
conceptual clarity and variable prevalence rates of sleep-wake disturbances due to 
inconsistent terminology, inconsistent measures, and lack of longitudinal-comparative 
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studies. The result is evident by the lack of effective interventions specific for BCS with 
sleep-wake disturbances. Ultimately, additional descriptive work will provide guidance to 
develop effective interventions that enhance sleep, reduce negative consequences and 
improve quality of life during survivorship. 
Statement of the Problem 
 The purpose of this study was to further refine the knowledge regarding the 
incidence, prevalence, and predictor factors of sleep-wake disturbances in BCS compared 
to age-matched WWBC. Based on the findings, the Psychobiological Model for Sleep-
Wake Disturbances was refined. 
Elements of the Problem  
1. To compare the prevalence and severity of sleep-wake disturbances between BCS 
and age-matched WWBC. 
2. To compare physiological, psychological, and environmental predictors of the 
occurrence and severity of sleep-wake disturbances in BCS and age-matched 
WWBC. 
3. To refine the exploratory Psychobiological Model for Sleep-Wake Disturbances 
for BCS. 
Theoretical Framework 
 The Psychobiological Model for Sleep-Wake Disturbances was the exploratory 
model for this study (Elam, unpublished). The model postulates relationships among 
variables (e.g., precipitating and perpetuating factors) thought to contribute to the 
occurrence of sleep-wake disturbances and negative outcomes in BCS using components 
of four related multi-disciplinary sleep models (described in Chapter Two) (Benca, 2005; 
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Berger & Walker, 2001; Blesch et al., 1991; Clark et al., 2004; Davidson et al., 2002; 
Espie, 2002; Hall et al., 1998; Hall et al., 2004; Harvey, 2002; Lacks & Rotert, 1986; Lee 
et al., 2004; Manber & Bootzin, 1997; Miaskowski & Lee, 1999; Owens & Matthews, 
1998; Roscoe et al., 2002; Sadeh, Keinan, & Daon, 2004; Servaes, Prins, Verhagen, & 
Bleijenberg, 2002; Shaver & Zenk, 2000; Vena, Parker, Cunningham, Clark, & 
McMillan, 2004; Young, Rabago, Zgierska, Austin, & Laurel, 2003). 
 The Psychobiological Model for Sleep-Wake Disturbances in BCS postulates 
relationships among variables (e.g., precipitating, and perpetuating factors) thought to 
contribute to the occurrence of sleep-wake disturbances and negative outcomes in BCS 
(see APPENDIX A for critical attributes) (Benca, 2005; Berger & Walker, 2001; Blesch 
et al., 1991; Clark et al., 2004; Davidson et al., 2002; Espie, 2002; Hall et al., 1998; Hall 
et al., 2004; Harvey, 2002; Lacks & Rotert, 1986; Lee et al., 2004; Manber & Bootzin, 
1997; Miaskowski & Lee, 1999; Owens & Matthews, 1998; Roscoe et al., 2002; Sadeh et 
al., 2004; Servaes, Prins et al., 2002; Shaver & Zenk, 2000; Vena et al., 2004; Young et 
al., 2003). The model was developed to enhance conceptual clarity for sleep-wake 
disturbances in the BCS population. The model uses components of the four models 
reviewed in Chapter Two adding specific factors related to BCS and is the proposed 
model for this research. 
 Visually and conceptually, the model proposes an interaction of potential 
predictors that contribute to the occurrence of sleep-wake disturbances in BCS. The bi-
directional arrows among predictors indicate that one or several factors contribute to 
sleep problems. Specifics of these predictors are detailed later in this section. 
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 The middle portion of the model explains the primary outcome of interest which 
is sleep-wake disturbance(s). Sleep is operationalized by subjective (Pittsburgh Sleep 
Quality Index) and/or objective (actigraphy or polysomnography) measures of sleep. 
These measures have been validated for use in the cancer literature. As the model is 
developed, additional serum tests might be added to provide a clinical diagnostic 
component to the model for further identification of specific etiology (e.g., thyroid 
dysfunction). The bi-directional arrows from sleep back to predictors are to explain how 
predictive factors can change over time. Thus, the precipitating factor(s) creating 
disturbances can be different than the perpetuating factor(s) (Espie, 2002). For example, a 
woman experiencing hot flashes could experience nighttime awakenings that disturb 
sleep. If the hot flashes subside, the nighttime awakenings can persist due to thoughts of 
concern of recurrence. 
 Lastly, the distal consequences of sleep-wake disturbances are classified as 
immediate and delayed. Conceptually, there is a bi-directional relationship between 
sleep-wake and resulting consequences to represent how immediate and delayed 
outcomes can be the result of and/or contribute to the continuation (perpetuation) of 
sleep-wake problems. 
 Immediate outcomes can include daytime sleepiness and distress related to the 
lack of sleep (Vena et al., 2004). Lack of sleep causes the body to put forth cues 
evidenced by feelings of daytime sleepiness and fatigue. These cues are often 
characterized by heaviness of the eyes during times of stimulus, heaviness of the body, 
and inability to stay awake during the day (Berger, 1998). As sleep-wake disturbances 
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progress over days, there is a tendency for the mind to become preoccupied about the 
need for sleep creating distress prior to bedtime (Espie, 2002; Harvey, 2002). 
 Delayed outcomes occur when sleep is disrupted over time. The models suggests 
that these outcomes are categorized as physiological (e.g., daytime sleepiness, fatigue), 
psychological (e.g., depression, anxiety), and social ramifications (e.g., loss of work time, 
disinterest in social engagements) that can negativity impact quality of life (Bleiker, 
Pouwer, van der Ploeg, Leer, & Ader, 2000). The outcomes of this model are shaded in 
grey denoting that this category will not be tested in this research study but rather 
addressed in future research. In addition, since this study used an existing dataset (see 
Chapter Three), the use of objective measurement such as wrist actigraphy was not 
feasible and will not be evaluated in this research study, thus also shaded in grey (see 
Figure 1). 
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Figure 1: Elam Psychobiological Model of Sleep-Wake Disturbances 
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Research Questions 
 This study investigated and compared sleep-wake disturbances and their 
predictors in BCS and WWBC. The following research questions were addressed. 
1. Was there a difference in the prevalence of sleep-wake disturbances between BCS 
compared to age-matched WWBC? 
2. Was there a difference in the severity of sleep-wake disturbances (defined by 
PSQI global scores and 7 component scores) between BCS compared to age-
matched WWBC? 
3. What were the physiological, psychological, and environmental predictors of poor 
sleep (defined by PSQI scores >5) in BCS and age-matched WWBC? 
4. What were the physiological, psychological, and environmental predictors of the 
severity of sleep-wake disturbances (defined by PSQI global scores) of BCS and 
age-matched WWBC? 
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Table 1 
Definitions of Key Terms Used in Sleep-Wake Literature 
Key Terms Definition 
Breast cancer survivor 
(BCS) 
Women at least 1 year post completion of 
primary treatment (surgery, chemotherapy, 
radiotherapy) and without residual breast 
disease. 
Circadian rhythm  Daily fluctuation of physiological and/or 
behavioral functions such as sleep-wake 
linked to an internal 24-hour light/dark cycle. 
The rhythm can be increased or decreased 
when light cues are added or removed. 
Signals of time of day are called zeitgebers 
(time cues such as sunlight, noise, social 
interaction, or an alarm clock that entrains the 
internal clock). 
Daytime sleepiness The result of poor sleep; evidence by 
difficulty in maintaining an alert or awake 
state which causes rapid entrance into sleep 
when sedentary.  
Electroencephalography 
(EEG) 
Electrodes placed on the scalp to detect brain-
wave activity- used in benchmark research to 
define the stages of sleep. EEG is now one 
component of polysomnography. 
Homeostasis The inherent tendency of an organism toward 
maintenance of physiological and 
psychological stability. 
Insomnia   A type of sleep-wake disturbance related to 
the inability to fall asleep and stay asleep.  
Non-rapid eye movement  
(NREM) 
Non-rapid eye movement phases of sleep that 
constitute the first four stages of the sleep 
cycle.  
Neurotransmitter Specialized chemical messenger that sends a 
message from one nerve cell to another. 
Polysomnography 
(PSG) 
The objective recoding, analysis, and 
interpretation of multiple, simultaneous 
physiologic parameters of sleep-wake activity 
through a complex system of electrodes 
placed on the scalp, face and chest.  
Rapid eye movement  
(REM) 
Rapid eye movement phase of sleep, the 
dream phase.  
Restless leg syndrome  A type of sleep-wake disturbance caused by 
the inability to relax the legs. 
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Key Terms Definition 
Sleep  The state of rest as opposed to the state of 
activity (wakefulness).  
Sleep apnea A type of sleep-wake disturbance 
characterized by repetitive episodes of 
decreased or absent breathing during sleep 
causing decreased blood oxygen levels. 
Sleep duration 
(total sleep time) 
The amount of time in bed spent in actual 
sleep. 
Sleep efficiency The % or proportion of time in bed that was 
spent in actual sleep (total sleep time/total 
time in bed). 
Sleep hygiene Behavioral practices that promote continuous 
and effective sleep (e.g., no caffeine 2 hours 
prior to sleep). 
Sleep latency The time in bed with lights out to the onset of 
the initial stages of sleep. 
Sleep medicine Refers to the discipline or specialty of sleep. 
Sleep-wake disturbance Chronic disruptions in nighttime rest and/or 
wakefulness that result in physical, 
psychological, emotional, and/or social 
dysfunction. 
Translation Integrating research findings (assessment 
practices and interventions) into clinical 
practice to maximize patient outcomes.  
Wakefulness State of alertness and activity. 
Women without breast cancer 
(WWBC) 
In lieu of using the term ‘healthy women’ to 
represent the age-matched control group, this 
group will be termed ‘women without breast 
cancer’ to avoid the assumption that BCS are 
not healthy. 
  
 
 Definitions for the above table were obtained from the following sources 
(American Sleep Disorders Association, 1994; Bowman, 2003; Bowman & Moshenin, 
2003; Faruque, Bowman, & Sisson, 2003; Kerner, Rimer, & Emmons, 2005; Vena et 
al., 2004). 
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Summary 
 Sleep-wake disturbances are problematic in BCS. Due to the lack of knowledge 
regarding prevalence, severity, and predictors of this problem in BCS compared to 
WWBC, the following study evaluated the prevalence, severity, physiological, 
psychological, and environmental predictors of sleep-wake disturbances in BCS 
compared to age-matched WWBC.  
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CHAPTER TWO 
REVIEW OF LITERATURE 
 
 Sleep is a restorative process essential for proper human functioning. Humans 
spend one-third of their entire lifespan in a state of nighttime sleep (Bowman & 
Moshenin, 2003). Disruptions in sleep have the potential to disrupt vital human processes 
such as immune and endocrine function. Sleep and wake are also linked to cognitive, 
behavioral, and environmental factors that contribute to sleep maintenance and quality. 
Because sleep-wake disturbances are so prevalent in BCS, knowledge of sleep 
physiology helps us to better understand potential etiologies of sleep-wake disturbances 
in this population. Therefore, the purpose of this chapter is to link the science of sleep 
research and sleep-wake disturbances in BCS. The chapter is divided into two parts and 
provides (1) an overview of sleep and (2) an overview of sleep in BCS. Since the topic of 
sleep is a multi-disciplinary topic, this chapter includes perspectives from medicine, 
psychology, and nursing. 
Part I: Overview of Sleep 
 Part I of this chapter provides an overview of sleep essential for understanding 
why sleep is so important for normal human functioning. This discussion is divided into 
six sections; (a) sleep physiology, (b) classification of sleep and sleep disorders, (c) 
measurement of sleep, (d) negative consequences of poor sleep, (e) conceptual and 
theoretical aspects of sleep-wake, and (f) interventions for sleep-wake disturbances. 
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Sleep physiology 
 Sleep can be defined as a state of rest, as opposed to a state of activity 
(wakefulness) (Parker, Kutner, Bliwise, Bailey, & Rye, 2003). Sleep research began in 
the 20th century and resulted in a better understanding of sleep physiology, sleep 
problems, and the negative consequences of disturbed sleep (Bowman & Moshenin, 
2003). Early research identified the stages of sleep using a device called the 
electroencephalogram (EEG) that evaluated wave inputs from the nervous system via 
electrodes that attached to the scalp (Aschoff, 1965; Dement & Vaughan, 2000; Purves et 
al., 2004). Researchers found that brain wave activity is distinctly different at various 
stages of sleep and wakefulness based on these neural inputs (Bowman & Moshenin, 
2003). These benchmark findings provided the foundation for the current discipline of 
sleep medicine. When discussing the physiology of sleep, it is important to cover several 
topics. This section reviews the following; stages of sleep, neurobiology of sleep, 
circadian regulation of sleep, and homeostatic processes of sleep, including endocrine, 
thermoregulatory, immune function, and genetics. 
Stages of sleep 
 Sleep begins with a non-rapid eye movement phase (NREM) and then transitions 
into a cyclic pattern of NREM and rapid eye movement (REM) sleep. Each cycle of 
NREM and REM sleep recurs approximately every 90 minutes, with the average cycle 
lasting 90-110 minutes (Aschoff, 1965; Bowman, 2003). Stages of sleep are often 
referred to as ‘sleep architecture’ to reflect the structure and timing of events (Bowman & 
Moshenin, 2003; Vena et al., 2004). 
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 Non-rapid eye movement. 
 Non-rapid eye movement in adults is divided into four stages (stage 1-4). Each 
succeeding stage consists of progressively deeper sleep and higher arousal thresholds 
making it more difficult to awaken (Bowman, 2003; Miaskowski & Lee, 1999). The 
initial drowsiness experienced before sleep is considered stage I and reflected by 
increased EEG amplitude (height of wave) and decreased frequency (number of waves) 
(Ancoli-Israel et al., 2005; Aschoff, 1965; Aserinsky & Kleitman, 1953; Bowman & 
Moshenin, 2003; Krauchi & Wirz-Justice, 2001; Purves et al., 2004). Stage I progresses 
into stage II (light sleep) as reflected by further increases in amplitude and decreases 
frequency. Sleep spindles, (bursts of waves visible on an EEG), are noted with 
intermittent, high-frequency clusters of activity spikes lasting 1-2 seconds. These spindles 
reflect communications between the thalamic and cortical neurons in the brain. Stage I 
and II are easily disrupted because the body’s threshold for arousal is low (Purves et al., 
2004). 
 Stages III and IV are considered moderate to deep sleep. Stage IV is the deepest 
phase of sleep and also referred to as slow-wave sleep. Delta waves (one specific type of 
wave pattern on the EEG) are characteristic of stage IV where arousal is most difficult. 
At the end of stage IV sleep, EEG readings show marked changes in amplitude and 
frequency which signals the brain is entering the rapid eye-movement phase of sleep 
(Bowman & Moshenin, 2003). 
 Rapid eye movement. 
 The rapid eye movement (REM) phase of sleep is markedly different from the 
first, four stages of NREM. EEG readings show activity similar to wakefulness with 
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highly irregular amplitude and frequency waves. This unique stage of sleep, also known 
as the dream phase, remains a mystery. When deprived of REM, humans show minimal 
effects in normal functioning as stages I-IV are essential for maintenance of essential 
physiological processes (Purves et al., 2004). However, research has linked increased 
REM duration to depression symptoms and recently the target of sleep interventions such 
purposeful reduction of REM cycles (Savard, Simard, Ivers, & Morin, 2005a; Thase, 
2005). 
 If one or more stages of NREM-REM cycles are disrupted, the body tries to 
recover those specific stages of sleep in the subsequent nights (Zee & Harsanyi, 2003). 
Thus, variability in nighttime sleep patterns is expected and normal for most individuals 
and typically resolves the next night (Espie, 2002). It is the constant disruption over time 
that results in negative consequences (Zee & Harsanyi, 2003). 
Neurobiology of sleep 
 Sleep is controlled by a complex relationship between the central (brain and 
spinal cord) and peripheral nervous system (links rest of body to central system), and 
circadian rhythm functions (internal clock) (Guyton & Hall, 1997). The central and 
peripheral nervous systems work with the circadian rhythms within the body through 
complex circuits of neurons (signals) that produce changes in breathing, heart rate, and 
immune function during sleep. 
 Central regulation of the sleep-wake cycles involve inhibitory and excitatory 
signals to and from neural pathways (Moruzzi & Magoun, 1995; Purves et al., 2004). 
These pathways communicate information to the reticular activating system, cholinergic 
nuclei in the pons/midbrain, ventrolateral pre-optic nucleus, and areas of the thalamus. 
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Pathways are typically stimulated to cause wakefulness and inhibited for resting states 
(Purves et al., 2004). 
 The major inhibitory neurotransmitter in the central nervous system involved in 
sleep regulation is gamma-aminobutyric acid (GABA). Knowledge of central 
neurotransmitter action has evolved though the study of pharmacologic hypnotics that 
induce sleep. GABAnergic neurons, located on the basal forebrain and anterior 
hypothalamus, are released in response to the body’s need for sleep. When the eyes are 
closed to induce sleep, GABA is produced and continuously released during NREM 
(Siegel, 2004). The function of GABA is to inhibit arousal functions within the basal 
forebrain, thus, deactivating the central mechanisms for wakefulness (Siegel, 2004). This 
deactivation is the result of GABA blocking neurotransmitters such as histamine, 
serotonin, and norepinephrine which are linked to arousal (Siegel, 2004). 
 As signals from the central nervous system are processed, messages are sent to the 
autonomic branch of the peripheral nervous system promoting physiological changes 
within the body. The autonomic system consists of nerve fibers that leave the brain and 
sacral portion of the spinal cord that are connected to blood vessels, glands, and other 
internal organs. During NREM, there is a reduction in the parasympathetic and 
sympathetic activity of the autonomic system causing decreased cardiopulmonary (e.g., 
heart function, breathing), skeletal muscular (e.g., postural tension, eye movements), core 
body temperature, and cognitive (e.g., memory functions) processes (Bowman & 
Moshenin, 2003; Purves et al., 2004). Conversely, during REM sleep, activity in the 
autonomic systems are highly activated even though some muscles are in a paralytic state 
(Vena et al., 2004). 
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Circadian regulation of sleep 
 In addition to the complex system of neurological functions, sleep is regulated by 
an internal circadian rhythm (Taheri, 2004). The following section will provide links 
between circadian function and normal homeostatic processes such as endocrine 
regulation, temperature regulation, and immune function. Information regarding the 
genetics of circadian rhythms will provide new links between genetic polymorphisms 
(variations in genetic codes) and sleep-wake disorders. 
 The circadian rhythm is the daily fluctuation of physiological and/or behavioral 
functions of a 24-hour light/dark cycle dependent on environmental cues (zeitgebers) 
(Aschoff, 1965; Borbely, 1982; Buysse et al., 1991; Claustrat, Brun, & Chazot, 2005; 
Jean-Louis, Kripke, Assmus, & Langer, 2000; Purves et al., 2004; Roscoe et al., 2002; 
Uchiyama et al., 2000). The circadian rhythm is a free running cycle dependent on cues 
such as light and dark (entrainment) that reset the clock every 23-24 hours. 
 Through studies of mammalian brain activity, researchers discovered the 
suprachiasmatic nuclei (SCN ), now considered the pacemaker of the circadian rhythm in 
humans (Aschoff, 1965; Cermakian & Boivin, 2003; Moore, 1990; Purves et al., 2004). 
The SCN is dependent on zeitgebers to regulate the release of hormones to the 
neurological system (e.g., melatonin) thought to maintain sleep. The SCN is critical for 
sleep-wake circadian rhythmicity, thus, malfunction of the SCN or entrainment pathway 
can lead to random distributions of sleep cycles and frequent nighttime awakenings 
(Faruque et al., 2003; Moore, 1990). If these cues are removed, the body is unable to 
maintain the cycle causing disruptions in normal homeostatic processes. 
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Homeostatic processes 
 Endocrine function. 
 The human endocrine system is linked to circadian function through the 
production and release of neuroendocrine hormones such as growth hormone, cortisol, 
estrogen, thyroid stimulating hormone, glucose, and estrogen (Faruque et al., 2003). 
Disrupted circadian cycles result in abnormal production and release of these hormones 
which can result in organ failure (e.g., kidney or thyroid) (Rich et al., 2005; Vena et al., 
2004). The importance of these hormones is outlined below. 
 Growth hormone (GH), responsible for growth and cell repair (Merriam-Webster 
Inc., 1991), is secreted from anterior pituitary during the first few stages of sleep 
(Faruque et al., 2003). The secretion of GH is thought to promote NREM sleep and new 
cell growth. As humans age, GH secretion decreases in response to the body’s diminished 
need for new cell growth (compared to a growing adolescent). In addition, lower levels of 
GH over time decreases NREM as reflected by the decreased sleep experienced by the 
aging population (Faruque et al., 2003). 
 Cortisol, a hormone produced in the adrenal cortex, is secreted during the late 
phases of sleep. Cortisol has several important functions such as synthesizing 
carbohydrates from proteins for maintenance of blood glucose levels necessary for 
normal endocrine function. Sleep-wake cycles are a timing mechanism for cortisol 
release, thus, if sleep is erratic, cortisol levels significantly increase and result in 
nighttime awakenings (Sephton, Sapolsky, Kraemer, & Spiegel, 2000). It remains unclear 
if altered cortisol indicates poor sleep patterns or if they are the result of poor sleep. 
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 The thyroid, a gland located beneath larynx, produces a hormone called thyroid 
stimulating hormone that regulates growth and metabolism (Guyton & Hall, 1997). 
Thyroid function also decreases with aging (especially in women) resulting in chronic 
hyper- or hypothyroidism. Abnormal thyroid function has been linked to sleep-wake 
disturbances due to heightened metabolism rates that cause increased alertness (Faruque 
et al., 2003). Sleep disturbances re a consequence or outcome of abnormal thyroid 
function. For example, individuals with hyperthyroidism are prone to obstructive sleep 
apnea because the gland becomes enlarged (goiter) causing pressure on the larynx during 
sleep. 
 Estrogen has been implicated in sleep and thermoregulatory processes (see next 
sub-section), although its role is largely unclear (Leibenluft, 1993; Scharf, McDannold, 
Stover, Zaretsky, & Berkowitz, 1997; Schiff, Regestein, Schinfeld, & Ryan, 1980). 
Estrogen production is synchronized with circadian cycles and secreted during NREM 
sleep (Empson & Purdie, 1999). Researchers suggest that increases in estrogen lengthen 
total sleep time, decrease sleep latency, and improves sleep efficiency (Schiff et al., 
1980). Because estrogen is an important hormone in women, studies typically evaluate 
estrogen’s role in sleep comparing pre-and postmenopausal subjects. Schiff et al. (1980) 
compared postmenopausal women who were given conjugated estrogen therapy vs. 
placebo to evaluate differences in adrenal and pituitary hormone function during their 
sleep. Results indicated that compared to the placebo group, those on estrogen therapy 
had significant increases in total REM sleep and significantly shorter sleep latency 
(time to fall asleep) equating to increased sleep efficiency. This provides support that 
estrogen plays a role in the process of sleep (Schiff et al., 1980). 
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 Thermoregulation. 
 In addition to endocrine function, sleep helps regulate normal body temperature. 
Thermoregulation is the internal processes (e.g., shivering, sweating) that maintains a 
stable internal temperature (Faruque et al., 2003). Thermoregulation during sleep 
regulates the body’s metabolic rate needed to sustain cellular function. There is a 
circadian temperature rhythm activated during sleep that assists in thermoregulation. 
During sleep, this circadian rhythm lowers core body temperature during NREM. 
However, during REM temperature regulation is inhibited and an entry point for sleep-
disturbances such as menopausal hot flashes (Siegel, 2004). The inability to maintain a 
stable nighttime core temperature due to decreased NREM can cause frequent 
awakenings and poor, fragmented sleep. 
Immune function 
 Cytokines, regulatory proteins of the immune system, are synthesized and 
released for destruction of abnormal cells during illness and trauma. Cytokine (e.g., 
tumor necrosis factor, interleukins) production requires an increased amount of sleep for 
adequate disbursement throughout the body (Guyton & Hall, 1997). The drive for sleep 
during illness is reflected by the body’s desire for increased NREM sleep (Faruque et al., 
2003). In chronic illness, sleep duration and quality are not always optimal due to 
treatment side effects (e.g., nausea vomiting), pain, or other illness-related factors. 
Although studies show that healing is compromised, the long-term effects of chronic 
sleep problems and immune function remains under-reported (Dogan, Ertekin, & Dogan, 
2005). 
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Genetics of sleep 
 There is a genetic link between circadian function and sleep. This link was first 
discovered by researchers through examination of abnormal circadian rhythms in fruit 
flies (Konopka & Benzer, 1971; Purves et al., 2004). Ten unique genes manufactured 
during the day and nighttime have been identified and labeled as clock genes (B-mal 1, 
Period (Per), Timeless (Tim), Casein Kinase 1 (CK1), Cryptochrome (Cry1 and Cry2)) 
(Taheri, 2004). Polymorphisms in clock genes have been linked to restless leg syndrome, 
obstructive sleep apnea, and narcolepsy in adults. This exciting new area of research will 
produce important links in future identification of additional polymorphisms and other 
types of sleep-wake disturbances in various populations. 
 In sum, sleep and wake is a system of physiological stages linked by 
neurobiological, circadian, and homeostatic processes. Sleep occurs in series of stages 
dependent on various neurological, circadian, endocrine, thermoregulatory, immune, and 
genetic functions. The complexity of sleep-wake physiology provides a foundation for 
further discussion of how disruptions in sleep can cause potential negative outcomes. 
Classification of sleep and sleep disorders 
 The following will review the types of sleep-wake disturbances and two common 
categories of diagnostic criteria used in research and clinical practice. Disparities among 
disciplines are noted regarding which terms and criteria should be used in clinical and 
research settings. 
Types of sleep-wake disturbances 
 Generic categories of sleep-wake disturbances include; (a) decreased hours of 
sleep (sleep duration or total sleep time), (b) increased number of minutes to fall asleep 
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(sleep latency), (c) number and length of nighttime awakenings (sleep disruptions), (d) 
quality of perceived sleep (sleep quality), (e) amount of time in bed spent asleep (sleep 
efficacy), and (f) inability to function fully during the day without naps (daytime 
dysfunction) (Berger, 1998; Buysse et al., 1989; Miaskowski & Lee, 1999). These 
disturbances can occur alone or in combination affecting overall sleep quality and 
daytime function (Ancoli-Israel et al., 2003; Buysse et al., 1989; Espie, 2002; Fry, 1987). 
Although useful for research, generic sleep categories are not adequate for clinical 
diagnosis. 
Diagnostic criteria 
 Diagnostic criteria used to diagnose sleep-wake disturbances are variable. 
Common etiologies in healthy populations are obstructive sleep apnea, insomnia, restless 
leg syndrome, and excessive daytime sleepiness. The two main categories for the clinical 
diagnosis of sleep disorders are listed in detail below.  
 ICDS-R categories. 
 Sleep and wake problems can be diagnosed using three International 
Classification of Sleep Disorders (ICDS-R) categories: dyssomnias, parasomnias, and 
mental/neurological/other medical disorders (American Sleep Disorders Association, 
1994). Dyssomnias involve difficulty initiating sleep (sleep latency), maintaining sleep 
(sleep disruption, sleep duration), and/or excessive sleepiness (daytime dysfunction). 
Parasomnias are abnormal behaviors and/or sensations during sleep (sleep disruptions) 
such as sleepwalking, nightmares, and/or sleep talking. The third category is a catch-all 
for all other types of sleep-wake disturbances including mental (e.g., anxiety), 
neurological (e.g., dementia, Parkinsonism) and/or other medical disorders (e.g., 
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nighttime cardiac ischemia) (American Sleep Disorders Association, 1994; Vena et al., 
2004). 
 DSM-IV categories. 
 Sleep-wake disturbances can also be diagnosed using the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV) criteria for primary and secondary 
insomnia (American Psychiatric Association, 1994). Primary insomnia refers to difficulty 
initiating and/or maintaining sleep (sleep latency, sleep duration) or non-restorative sleep 
for at least 1 month resulting in feelings of distress (daytime dysfunction) (American 
Psychiatric Association, 1994; Thase, 2005). Secondary insomnias are due to psychiatric 
(e.g., depression), neurological (e.g., restless leg syndrome), and/or medical contributors 
(e.g., obesity) to sleep disturbances (American Psychiatric Association, 1994). Primary or 
secondary insomnia can be transient (sporadic-days), acute (less than 3 weeks), or 
chronic (more than 3-4 weeks). 
 There is currently no agreement among researchers as to which classification 
system is more precise. Use is highly dependent on the discipline in which the sleep 
disturbance is being evaluated. Classification of sleep disorders is dependent on the 
specialty performing the clinical evaluation. The ICDS-R originates in the fields of 
medicine and psychiatry whereas the DSM-IV is derived from psychology. Some nurse 
researchers suggest solely using the ICDS-R, but this remains merely a suggestion and its 
use continues to be inconsistent within the nursing literature (Vena et al., 2004). 
Measurement of sleep-wake disturbances 
 Proper identification of sleep-wake disturbances can be accomplished through 
subjective and objective measures. Both types of measures have been validated in various 
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populations including BCS. Measurement is stated to be one of the major challenges of 
sleep research due to the various methods used to capture sleep variables (Berger et al., 
2005). The following sections summarize common objective and subjective 
measurements of sleep-wake disturbances. 
Objective sleep 
The gold standard of sleep measures is polysomnography (PSG). This tool 
provides understanding of both normal and disturbed sleep through a collective process 
of monitoring and recording physiologic data (Keenan, 2003). Subjects spend 1-2 nights 
in a controlled sleep lab managed by certified sleep technicians. The process includes the 
attachment of electrodes to the face, neck, and chest to detect nervous system activity 
(Keenan, 2003). These currents are transmitted as waveform tracings evaluated for 
initiation and progression of sleep cycles. Three separate waveform tracings are 
evaluated: electroencephalogram (EEG) (brain waves), electrooculogram (eye 
movements), and electromyogram (muscle tension) (Bowman & Moshenin, 2003). 
Results provide clinicians with the timing of sleep cycles and disruptions to determine 
underlying etiologies of sleep disturbances (Keenan, 2003). Although polysomnography 
is the gold standard of sleep, it is more expensive and time consuming compared to less 
invasive measures such as wrist actigraphy and self-report (Kushida et al., 2001). 
Wrist actigraphy has been used as a sensitive objective measure of sleep in both 
cancer and healthy populations (Ancoli-Israel et al., 2003; de Souza et al., 2003; Kushida 
et al., 2001; Means, Edinger, & Husain, 2002; Wilson, Watson, & Currie, 1998). The 
device is worn on the non-dominant wrist, typically for 3-7 days (Ancoli-Israel et al., 
2003; de Souza et al., 2003; Hauri & Wisbey, 1992; Littner et al., 2003). The device 
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contains an accelerometer that is able to sense any motion with a minimal force greater 
than 0.01g (Mini Mitter Company Inc., 2003). The sensor integrates the speed and degree 
of motion, which produces an electrical current that varies in magnitude. Studies show a 
high correlation between wrist actigraphy and polysomnography in the assessment of 
total sleep time and number of nighttime awakenings in healthy individuals, with 
correlations of 0.95 for sensitivity, 0.36 for specificity, and 0.80 for accuracy (Kushida et 
al., 2001). These correlations have been replicated in various other validation studies 
(Ancoli-Israel et al., 2003; de Souza et al., 2003). 
Subjective sleep 
 There are numerous subjective measurements of sleep variables (e.g., quality, 
latency, duration). The following discussion will focus on the common assessment of 
sleep quality in the cancer population providing brief overviews of the other options for 
sleep measurement (Carpenter et al., 1998; Carpenter, Johnson, Wagner, & Andrykowski, 
2002; Savard & Morin, 2001; Vena et al., 2004). 
 First, the Pittsburgh Sleep Quality Index (PSQI) was designed for use in clinical 
populations as a simple and valid assessment of sleep (Buysse et al., 1989). The tool 
contains 19-items that produce a global sleep quality score based on 7 component scores: 
sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, 
use of sleep medications, and daytime dysfunction. PSQI items use varying response 
categories including Likert-type responses. Responses are based on the prior month’s 
habits. Psychometric properties of the PSQI such as content validity and internal 
consistency reliability have been widely supported in a variety of populations,(Gentili, 
Weiner, Kuchibhatla, & Edinger, 1995; Pasternak et al., 1994; Tiffin, Ashton, Marsh, & 
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Kamali, 1995) including healthy individuals (n=52; α=0.83) (Buysse et al., 1989) and 
BCS (n=102; α=0.80) (Carpenter & Andrykowski, 1998). 
 A second questionnaire receiving more attention in the cancer literature is the 
Insomnia Severity Index (ISI), a tool recently developed to detect insomnia in cancer 
patients (Savard, Savard, Simard, & Ivers, 2004). This 7-item questionnaire evaluates the 
perceived severity of insomnia over the past 2 weeks. Items are scored using a Likert-
type scale with 5 response options (0=not at all to 4=very much). Total scores are 
obtained by summation of the 7-items for scores ranging from 0 to 28 (Savard, Savard et 
al., 2004). Higher scores indicate greater perception by subjects of insomnia severity. 
Internal consistency-reliability and content validity have been established in healthy 
individuals (n=145 α=0.74) and cancer patients (n=1634; α=0.90) (Bastien, Vallieres, & 
Morin, 2001; Savard, Savard et al., 2004). The recent validation of this tool will provide 
additional means to screen for clinical insomnia in cancer patients. 
 Other questionnaires that assess sleep quality include the Verran and Snyder-
Halpern Sleep Scale (Snyder-Halpern & Verran, 1987) and the Sleep Timing 
Questionnaire (Monk et al., 2003). Both measures provide frequency and severity scores 
for sleep disturbances. Although both are stated to be valid and reliable measures, they 
have not been validated in cancer populations, and, thus, are rarely used in cancer 
research. 
 Sleep diaries are often used to determine time to bed, time awake, perceived sleep 
quality, pre-sleep routines, and napping. The Karolinska Sleep Diary (Akerstedt, Hume, 
Minors, & Waterhouse, 1994), the Sleep Log (Spielman, Nunes, & Glovinsky, 1996), and 
the Pittsburgh Sleep Dairy (Monk et al., 1994) have similar formats that include either 1 
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or 7 day assessment of sleep. Sleep diaries are often combined with the use of wrist 
actigraphy to determine the time to bed and time awake for data analysis. 
 In sum, there are numerous measures of sleep that are validated for use. However, 
there is one major problem with the use of both subjective and objective measures. Data 
shows that the correlation between subjective and objective measures is variable (Harvey, 
2002; Harvey & Espie, 2004; Hauri & Wisbey, 1992). It has been noted that self-reported 
sleep is perceived to be much worse compared to PSG or actigraphy findings (Ancoli-
Israel et al., 2003; Elam & Carpenter, 2004a; Savard et al., 2005a). Without consistent 
measurements of sleep, the scope of negative outcomes that results from poor sleep are 
uncertain. In addition, it remains unclear whether the disconnect between subjective and 
objective measures impacts the efficacy of interventions. 
Negative outcomes of sleep-wake disturbances 
 Once the specific sleep-wake disturbance has been classified and measured, it is 
important to determine how this disturbance is impacting the individual’s health. The 
occurrence of sleep-wake disturbances can negatively impact physical and psychosocial 
well-being (Benca, 2005; Savard & Morin, 2001). Although negative consequences can 
be acute or chronic depending on the chronicity of sleep disturbances, research typically 
focuses on the long-term problems associated with disturbed sleep. The following will 
provide a discussion of; (a) physiological outcomes, (b) psychosocial outcomes, and (c) 
measurement of negative outcomes of sleep-wake disturbances. 
Physiological outcomes 
 As noted above, fragmented sleep can lead to disruptions in homeostatic 
processes thereby leading to the exacerbation of disease, inability to heal, and altered 
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metabolic and endocrine function. For example, essential cytokines required for immune 
function can be compromised due to fragmented sleep (frequent awakenings) thereby 
compromising the ability to heal. Although these effects may not be immediate, they 
require close attention during clinical evaluation to prevent co-morbid conditions.  
Psychosocial outcomes 
 In addition, psychosocial consequences from chronic sleep-wake disturbances 
include depression, anxiety, decreased in job performance, lack of desire for 
socialization, inability to perform activities of daily living, and cognitive impairments 
resulting in poor quality of life. These issues are typically related to daytime sleepiness 
which creates overwhelming fatigue and increased desire for sleep (Sateia & Nowell, 
2004). Lastly, the social burden of sleep problems has gained increased interest (NIH 
State of the Science Panel, 2005). Consequences of chronic sleep-wake disturbances not 
only impact the person, but create a public health burden. There are few reports of large 
population studies regarding the economic impact of missed work days and job related 
disability due to sleep-wake disturbances (NIH State of the Science Panel). Future 
research is needed to address these issues and further expand our knowledge of the 
overall impact on society. 
Measurement of negative outcomes 
 There are numerous measurements of negative outcomes. Such measurements 
include physical functioning (e.g., Medical Outcomes Short Form-36) (Ware & 
Sherbourne, 1992), psychological status (e.g., Center for Epidemiologic Studies 
Depression Scale) (Radloff, 1977), cognitive function (e.g., Mini Mental State 
Examination) (Folstein & Whitehouse, 1983) and social function (e.g., Functional 
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Outcomes) (Weaver et al., 1997). In addition, there are serum blood tests that are helpful 
to identify endocrine (e.g., thyroid stimulating hormone) and immune (e.g., cytokine 
assays) dysfunction during clinical evaluations of sleep (Chernecky & Berger, 2004). 
Future technology will undoubtedly produce methods of serum genetic testing that are 
readily available in the clinical setting that are now reserved for clinical research labs. 
Together, self-report and serum measurements provide crucial information regarding 
clinical and quality of life outcomes that have the potential to direct effective 
interventions.  
Conceptual and theoretical aspects of sleep research 
 In research, underlying conceptual and theoretical clarity is essential to 
understand the problem under investigation. The following discussion provides a 
synthesis of: (a) conceptual terminology; (b) four theoretical sleep models; and (c) 
limitations of each model.  
Theoretical models provide statements of relationships between concepts that 
explain or predict a certain phenomena (Polit & Hungler, 1999; Reed, Shearer, & Nicoll, 
2004; Walker & Avant, 2005). Concepts within the theory provide labels, categories, or 
selected properties to be studied (Reed et al., 2004). The structure of the model ties 
together these relationships that should be operationally defined through validated 
measure (Polit & Hungler, 1999, Reed, 2004 #648). 
Conceptual terminology 
 Predictors, also referred to as contributing factors, help describe the reason or 
reasons sleep-wake disturbances occur. Predictors of sleep-wake disturbances have been 
categorized in the literature as predisposing, precipitating, and perpetuating factors, each 
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of which will be discussed in detail below (Davidson et al., 2002; Espie, 2002; Fortner et 
al., 2002; Harvey, 2002; Spielman, Caruso, & Glovinsky, 1987; Spielman et al., 1996). 
 Predisposing factors. 
 Predisposing factors are individual differences that contribute to the onset of 
sleep-wake disturbances. Predisposing factors include; (a) age, (b) gender, (c) education 
status, (d) socioeconomics, and (e) pre-existing psychiatric disorders (e.g., depression, 
anxiety) (Ancoli-Israel et al., 2001; Clark, Flowers, Boots, & Shettar, 1995; Clark et al., 
2004; Crandall, Petersen, Ganz, & Greendale, 2004; Espie, 2002; Lin, Ng, Chen, Hu, & 
Chen, 2005; Rosenthal, 2003; Vena et al., 2004). Because these are known factors that 
contribute to sleep-wake disturbances, they are often controlled for during statistical 
analysis. 
 Precipitating factors. 
 Precipitating factors contribute to the initial start point of sleep-wake disturbances 
(Espie, 2002; Harvey, 2002; Savard & Morin, 2001; Spielman et al., 1987). Precipitating 
factors can be physical, psychological, environmental, and/or sleep hygiene practice (pre-
sleep routines) problems. Physical factors include pain, co-morbid conditions (e.g., heart 
and lung disease) and medication side effects that disrupt sleep. Co-morbid conditions 
such as heart and lung disease are often related to sleep apnea and frequent nighttime 
awakenings (Savard & Morin, 2001). Research suggests that lack of sleep often precedes 
the onset of heart and lung disease because of poor sleep. Furthermore, the medications 
taken for illness-related problems can disrupt the sleep cycle. 
 Common psychological illnesses associated with disturbed sleep are depression 
and anxiety disorders. Conversely, depression and anxiety have also been noted to be 
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consequences of sleep disorders. Due to the complexity of these psychological co-
morbidities it is challenging to determine the trajectory (onset, diagnosis, and treatment) 
of insomnia related to the trajectory of other complex psychological disorders. 
 Environmental factors can influence sleep and include factors such as room 
temperature, noise, bedding, companion sleep, and/or child-rearing responsibilities 
(O'Connell, 2005). Environmental factors are rarely evaluated and it is unclear how they 
contribute to the occurrence and severity of prolonged sleep-wake disturbances. Sleep 
hygiene practices are often combined with environmental factors, and are the routine 
behaviors performed by an individual before bedtime such as reading, watching 
television, eating, smoking, drinking caffeine and/or alcohol, and exercising before 
bedtime (Cheek, Shaver, & Lentz, 2004). Because these practices are known to contribute 
to sleep-wake disturbances and can be modified, they have great potential as 
interventions to manage or reduce sleep-wake disturbances. 
 Perpetuating factors. 
 Perpetuating factors are factors that contribute to the continuation of sleep 
disturbances over time (Espie, 2002; Harvey, 2002; Savard & Morin, 2001; Spielman et 
al., 1987). Certain sleep models propose that precipitating factors can become 
perpetuating factors when sleep is disrupted over several nights. However, perpetuating 
factors can be different from those that contribute to the initial onset and also from 
physical, psychological, environmental, and sleep hygiene practices. It is difficult to 
differentiate the first occurrence of sleep-wake disturbances from subsequent occurrences 
(e.g., we cannot study sleep-wake disturbances before they occur to truly understand 
precipitating) since factors that precipitate the disturbances can be different from those 
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factors that perpetuate or continue the problem (e.g., stress). Therefore, precipitating and 
perpetuating factors are often discussed together. 
Theoretical models of sleep 
 The above terminology is often used in current theoretical models of sleep. The 
following will address the critical attributes of four common models used in sleep 
research (see APPENDIX A). These models are based on physiological, cognitive, or 
bio-behavioral perspectives of sleep, wake and sleep-disturbances. Although the models 
provide useful perspectives regarding sleep, there are limitations to general use in 
research. 
 Physiological model. 
 The Two-Process Model of Sleep attempts to explain the physiological basis of 
sleep (Borbely, 1982; Borbely & Achermann, 1999). The model states that sleep and 
wakefulness are maintained by a set of neuroendocrine and hormonal balances essential 
to physical and mental functioning. Sleep is stated to be the physiological process 
regulated by: (a) the homeostatic processes that mediate the rise of sleep propensity 
during wake and dissipation of sleep propensity during sleep (Process S), and, (b) the 
circadian process (Process C) which determines alterations of high and low sleep 
propensity that is independent of prior sleep-waking (the timing to sleep and 
wakefulness) (Borbely, 1982; Borbely & Achermann, 1999). Furthermore, sleep is a 
balance of the autonomic nervous system (increased parasympathetic activation and 
decreased sympathetic drive), actions of the hypothalamic-pituitary-adrenal axis, and 
homeostatic sleep drive (Process S) and circadian sleep-wake rhythms (Process C) (Lee-
Chiong, 2004).  
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 Construct validity of the relationships among concepts of the model has been 
established and it is the predominate model used in fields of medicine and nursing 
(Berger et al., 2005; Clark et al., 2004; Vena et al., 2004). Although the two process 
model provides explanations for relationships among physiological sleep-wake processes 
(Borbely, 1982), it does not address how these disruptions lead to negative quality of life 
outcomes. 
 Cognitive model of insomnia. 
 The cognitive model presented by Harvey (2002) provides a framework for the 
interaction of sleep and cognitions (thoughts). The model was developed to explain 
characteristics between sporadic and chronic insomnia. The model suggests that people 
with insomnia experience unpleasant, intrusive thoughts or worry during pre-sleep (lying 
in bed) (Harvey, 2002). The entry point or initiation phase of the model is attributed to 
excessive thoughts about sleep and how the lack of sleep might impact health and 
daytime functioning (e.g., work performance). Positive thoughts can also lead to 
decreased sleep and can often turn negative when sleep does not occur. When excessive 
worries or intrusive thoughts (ruminations) persist, the onset of sleep is delayed due to 
physiological and emotional responses to stress. After the initiation phase of sleep 
disturbance, the mind continues to reevaluate surrounding stressors and thoughts and 
either continues or extinguishes these thoughts allowing for the onset of sleep (Harvey, 
2002).  
 Harvey suggests that individuals overestimate the extent of perceived sleep 
deficits and daytime dysfunction. Distortions of perceived sleep create a positive 
feedback creating additional anxiety and erroneous beliefs regarding sleep. 
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The result is further negative thoughts before bed and continued disrupted sleep. In 
addition to nighttime cognitions, the model states daytime thoughts have an equivocal 
emphasis on negative cognitions. Daytime thoughts tend to focus on the need for better 
sleep in the upcoming night and inability to stay awake during the day. 
 Although this cognitive model provides relationships between cognitions and 
sleep disturbances there are several limitations. First, the model lacks validation with 
empirical research to support construct and content validity. Second, the model lacks 
inclusion of physiological, co-morbid conditions that can negatively impact sleep such as 
thyroid dysfunction. Third, because the model is specific for insomnia, it may not explain 
other types of sleep disturbances. 
 Psychobiological models. 
 The first multidimensional model of chronic insomnia provided interactions 
between predisposing, precipitating, and perpetuating factors of insomnia (Spielman et 
al., 1987). These factors were used to explain the evolution of insomnia and how 
individual differences contribute to the initiation of disturbed sleep. People with 
heightened arousal states (wake up easily) are typically poor sleepers (do not maintain 
normal sleep stages) and they often have precipitating factors such as anxiety, depression, 
and stress. As the lack of sleep continues, perpetuating factors of frustration and agitation 
about the inability sleep, contributes to further cognitive and physiological arousal, thus, 
further sleep disruptions. Maladaptive strategies include increased time to fall asleep, 
anxiety about daytime performance, and progression of psychological disorders such as 
anxiety and depression (Spielman et al., 1987). The unique contribution of this model 
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was the combination of biological interactions (arousals) with psychological factors of 
stress. 
 The major limitation of this model is inability to translate into various research 
settings since it focuses solely on aspects of chronic insomnia. The model proposes some 
relationships among psychobiological factors related to poor sleep, but does not explain 
how other disturbances such as restless leg syndrome and sleep apnea fit into this model. 
A second limiting factor is the lack of available statistical validation of the model which 
limits our knowledge of whether the concepts are statistically relevant in other research 
settings. 
 Espie (2002) developed a Psychobiological Model of Sleep Inhibition which 
combines biological (circadian function) and psychological (affect, cognitions and 
behaviors) factors that directly affect sleep and daytime functioning. The model 
postulates that chronic sleep disturbances are a function of precipitating and perpetuating 
factors that interfere with the automaticity and plasticity (night to night variations) of 
normal homeostatic and circadian sleep. Variations in sleep are expected but typically 
resolve when a restful night’s sleep is experienced. Espie focuses on those sleepers that 
are unable to return back to a normal sleep pattern after disrupted sleep leading to 
daytime dysfunction. Poor sleepers then identify changes in sleep as a function of a 
progressive and serious sleep problem leading to further loss of sleep (Sateia & Nowell, 
2004). 
 Espie’s model provides a slight variation from Spielman’s model, but is 
complementary to the underlying theoretical underpinnings of the links between sleep 
and arousal. The unique contributing factor is the explanation of how the normal night-to-
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night variations of sleep become chronic problems for some sleepers. However, the 
model does not fully describe how other biological problems (e.g., pain) impact sleep.  
As with Spielman and Harvey, Espie focuses solely on the concepts related to insomnia 
limiting its use in other sleep-wake disturbances. 
In summary, there are a variety of theoretical models that attempt to conceptualize 
the problem of sleep-wake disturbances. Although the models provide important links 
between physiological and psychological factors, they are generally unsupported by 
research and lack generalizability to various population. Without accurate 
conceptualization through empirically tested theoretical models, it is difficult to develop 
effective individualized interventions and ascertain what types of interventions may be 
effective for a specific problem or population. 
Interventions for sleep-wake disturbances 
 Interventions for sleep-wake disturbances include both pharmacologic and non-
pharmacologic treatments. Although not the focus of this study, intervention remains an 
important topic to review in order to build the case for the study of predictors of sleep-
wake disturbances. In order to effectively treat sleep-wake disturbances it is essential to 
evaluate the underlying factor(s), or predictors, causing the disturbance. Therefore, this 
section will provide a brief overview of the pharmacologic and non-pharmacologic 
treatments used for sleep-wake disturbances. 
Pharmacologic interventions 
Pharmacologic agents have been refined as scientists discovered the relationship 
between neurotransmitter action and sleep. The study of neurotransmitter activity 
prompted the development of drug classifications called benzodiazepines and non-
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benzodiazepines. Benzodiazepines are the traditional agents used for short-term treatment 
of sleep-wake disturbances (Holbrook, Crowther, Lotter, Cheng, & King, 2000b; 
Mendelson et al., 2004; Wagner, Wagner, & Hening, 1998). Benzodiazepine compounds 
are agonists that mimic the action of the neurotransmitter GABA. Non-benzodiazepines 
are considered the new generation of sedative-hypnotics (Mendelson et al., 2004; 
Terzano, Rossi, Palomba, Smerieri, & Parrino, 2003; Wagner et al., 1998). The 
mechanism of action for non-benzodiazepines is similar to benzodiazepines but binding 
is selective to certain receptor sites, thus are more selective in their action. The increased 
selectivity has reduced the side effect profiles and the drug treatment of choice for sleep-
disturbances (Wagner et al., 1998). Both types of drugs remain the most prescribed 
hypnotics for the treatment of sleep-wake disturbances (Benca, 2005). 
Non-pharmacological interventions 
Non-pharmacological treatments, known as cognitive-behavioral therapy (CBT), 
attempts to identify, challenge, and alter dysfunctional beliefs and attitudes about sleep 
(Quesnel, Savard, Simard, Ivers, & Morin, 2003). Types of CBT include behavioral (e.g., 
stimulus control, sleep restriction, exercise), cognitive (e.g., cognitive restructuring), and 
educational (e.g., sleep hygiene, stress management) (Morin et al., 1999; Savard et al., 
2005a; Savard, Simard, Ivers, & Morin, 2005b). Although efficacy has been established 
through controlled trials, these interventions are time intensive, require a trained sleep 
specialist for delivery, and are limited to specific types of sleep-wake disturbances (e.g., 
poor sleep hygiene, insomniacs) (Petit, Azad, Byszewski, Sarazan, & Power, 2003; 
Quesnel et al., 2003; Savard et al., 2005a).  
 39 
 The following section reviews sleep in BCS. This extensive overview was 
intended to show the complexity of sleep physiology, how sleep is operationally defined, 
pertinent classifications for clinical diagnosis, negative consequences associated with 
sleep-wake disturbances, and common interventions used to promote better sleep in BCS. 
Knowledge gained from this section shows multiple areas for potential physiological 
etiologies in BCS with disturbed sleep. 
Part II: Sleep in BCS 
Part II of this chapter links the overview of sleep with sleep-wake disturbances 
that occur during breast cancer survivorship. In order to better understand why this is an 
important problem in this population the following section focuses on; (a) 
methodological issues of sleep-wake research in BCS, (b) theoretical issues of sleep-
wake research in BCS, (c) predictors of sleep-wake disturbances in BCS, and (d) sleep 
interventions studied in BCS. 
Searches were conducted to find descriptive and intervention research related to 
sleep-wake disturbances in breast cancer. Using MEDLINE®, CINAHL®, PubMed, and 
the American Psychological Association’s Psych INFO, 515 articles were found using 
sleep and cancer, sleep-wake and cancer, and sleep-wake and breast cancer survivor, 
treatment, intervention as search terms. Of these articles, 35 addressed sleep as a primary 
or secondary outcome and 5 addressed interventions specifically for sleep-wake 
disturbances in BCS (see APPENDIX B). Articles were a mix of descriptive findings, 
pertinent reviews, and experimental designs. One note of interest, the most recent 
descriptive article specific to BCS was last published in 2004 showing the limited nature 
of current findings. 
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Methodological issues of sleep-wake research in BCS 
 The following section addresses the current methodological issues of sleep-wake 
research in BCS. The section covers seven main topics; (a) prevalence; (b) comparative 
studies; (c) sleep studies over-time; (d) sleep as a primary variable; (e) measurement of 
sleep; (f) sleep terminology and diagnosis in BCS research; and (g) consequences of 
sleep-wake disturbances in BCS. 
Prevalence 
 Beast cancer survivors (BCS) represent the largest proportion of cancer survivors. 
It is estimated that 22% or 2.2 million of the 9.8 million cancer survivors in the United 
States are BCS (National Center for Chronic Disease Prevention and Health Promotion, 
2004). This number is projected to increase each year (Jemal et al., 2008). Current 
evidence suggests that a significant proportion of BCS suffer from poor sleep quality. 
Researchers have found that 19-90% of BCS complained of poor sleep or insomnia 
(Carpenter & Andrykowski, 1999; Carpenter et al., 2004; Crandall et al., 2004; Davidson 
et al., 2002; Fortner et al., 2002; Northouse et al., 1999; Savard, Simard, Blanchet, Ivers, 
& Morin, 2001; Schultz, Klein, Beck, Stava, & Sellin, 2005) which can last several years 
after the original diagnosis (Berger et al., 2005; Carpenter et al., 2004; Elam & Carpenter, 
2004b; Savard et al., 2001). The prevalence of sleep problems in BCS is stated to be 
higher than the general population (20% in both male and female) and other cancer types 
(e.g., 32% in gastrointestinal) (Davidson et al., 2002; Savard et al., 2001). Although 
studies consistently report that sleep is a problem in BCS, findings are plagued with 
inconsistent theoretical models, terminology, and measures of sleep. 
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 The accuracy of prevalence statistics of sleep-wake disturbances in BCS is 
unclear due to several methodological issues. Issues included lack of comparative studies 
(BCS vs. non-cancer women), inconsistent diagnostic terminology (DSM-IV vs. ICSD-9 
vs. generic terminology), lack of consistent measurement of sleep (objective vs. 
subjective), lack of longitudinal studies, and lack of ethnically diverse samples. In 
addition, current studies focus on subgroups of women (e.g., metastatic breast patients, 
newly diagnosed) leaving gaps in the survivorship literature (Berger & Higginbotham, 
2000; Fortner et al., 2002; Koopman et al., 2002). In the following section the 
methodological limitations are discussed in detail. 
Comparative studies 
 It is unclear whether the prevalence, severity, or predictors of sleep-wake 
disturbances differ between BCS and age-matched WWBC. It seems logical to compare 
BCS with WWBC since survivors tend to re-enter regular health practices after treatment 
is completed. The salient difference between BCS and WWBC is the experience and 
treatment of cancer. Although findings show as many as 23-51% of healthy women 
report sleep-wake disturbances, few studies directly compare the two populations 
(Fortner et al., 2002; Kravitz et al., 2003; Shaver & Zenk, 2000). In one comparative 
study of BCS (n=15) and healthy women (n=15), a majority of participants in both 
groups had poor sleep quality and high sleep disturbance (73% of BCS and 67% of 
healthy women above a cutoff score of 5) (Carpenter et al., 2004). 
 In terms of predictors, some BCS experience poorer sleep quality and higher sleep 
disturbance in comparison to their age-matched counterparts without cancer due to 
intense menopausal symptoms related to hormonal therapy, (Carpenter & Andrykowski, 
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1999; Mourits et al., 2002; Savard, Davidson et al., 2004), residual side effects from 
cancer treatment (Hunter et al., 2004), increased circadian rhythm disruptions due to 
cancer-related treatment (Carpenter, Gautam, Freedman, & Andrykowski, 2001; Roscoe 
et al., 2002), more intrusive thoughts (Bleiker et al., 2000), greater psychological distress 
related to diagnosis and treatment (Savard et al., 2001), poorer sleep hygiene behaviors 
(Berger et al., 2003), and/or more intrusive sleep environments (Davidson et al., 2002). 
Sleep duration was significantly shorter for BCS (n=15) compared to WWBC (n=15) 
(p<0.05), but for both survivors and controls, global sleep scores were significantly, 
positively correlated with fatigue and depression (Carpenter et al., 2004). Predictors of 
sleep-wake problems in either population were not evaluated in this study. Similarly, a 
comparative study of disease-free BCS (n=150) and WWBC (n=78), researchers found 
that sleep problems and depressive symptoms are significantly higher among highly 
fatigued BCS compared to those who are not as fatigued (Servaes, Verhagen, & 
Bleijenberg, 2002). Based on these results, BCS seem to have greater sleep disturbance, 
more depressive symptoms, and greater levels of fatigue compared to WWBC. 
Sleep over time in BCS 
 There have been few large, longitudinal comparative studies focusing on sleep in 
breast cancer (Davidson et al., 2002). The majority of research focuses on breast cancer 
patients undergoing adjuvant high-dose treatment or treatment for metastatic disease and 
rarely follow subjects over time (Berger & Farr, 1999; Berger et al., 2002; Berger et al., 
2003; Fortner et al., 2002; Kopelman, Apps, Cope, & Empey, 1985). During treatment, 
more daytime and less nighttime sleeping are related to higher on-treatment fatigue 
(Berger & Farr, 1999; Roscoe et al., 2002) and higher depressive symptoms (Roscoe). 
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Although Berger reassessed sleep one year after cancer treatment, the results did not 
address potential sources of the continued sleep problems (Berger et al., 2002; Berger et 
al., 2003). Other studies focusing on BCS, those with metastatic disease, or those with 
other co-morbidities were not cross-sectional and did not evaluate whether sleep 
problems existed before treatment and/or when they developed during treatment 
(Davidson et al., 2002; Deimling et al., 2002; Fortner et al., 2002; Servaes, Verhagen et 
al., 2002). Therefore, we do not know whether or how sleep problems may change over 
the course of the cancer trajectory. 
 Researchers suggest sleep changes initially encountered during cancer treatment 
may become chronic (Ancoli-Israel et al., 2005; Savard, Davidson et al., 2004; Savard et 
al., 2001) and that the respective relationships between sleep and fatigue and sleep and 
depressive symptoms continue post-treatment and into the period of cancer survivorship. 
Despite using different measures for sleep, findings across studies of BCS indicate that 
chronic poor sleep quality does occur and is correlated moderately with post-treatment 
fatigue (r=|0.38-0.68|, p<0.05) (Broeckel, Jacobsen, Horton, Balducci, & Lyman, 1998; 
Carpenter & Andrykowski, 1998; Okuyama et al., 2000) and with post-treatment 
depressive symptoms (r=0.50-0.63, p<0.001) (Carpenter & Andrykowski, 1998; 
Okuyama et al., 2000). 
Sleep as a primary variable 
 The existing literature focuses on sleep problems in BCS as a secondary variable 
or outcome of another research variable (e.g., fatigue). Of the descriptive articles 
reviewed, 13 focused on fatigue and other quality of life issues listing sleep as an 
outcome. Literature suggests that sleep-wake disturbances frequently emerge as a 
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significant problem in studies primarily examining fatigue, depression, decreased quality 
of life, and/or menopausal symptoms (Ancoli-Israel et al., 2001; Bleiker et al., 2000; 
Northouse et al., 1999). This limits our understanding of sleep and cancer to certain 
symptomatic conditions (e.g., chronically fatigued BCS) (Savard & Morin, 2001; Savard 
et al., 2001). Whether sleep was the primary complaint in these women is unclear 
limiting knowledge regarding the etiology and timing of sleep problems in BCS. 
Measurement of sleep in BCS 
 Part of the struggle in the BCS literature is lack of sonsistent measures to evaluate 
sleep. Eight of the reviewed studies used the Pittsburgh Sleep Quality Index (PSQI) 
(Andrykowski, Curran, & Lightner, 1998; Berger et al., 2003; Broeckel et al., 1998; 
Carpenter & Andrykowski, 1998; Carpenter et al., 2004; Fortner et al., 2002; Spelten et 
al., 2003; Weitzner, Moncello, Jacobsen, & Minton, 2002), 5 studies used actigraphy 
(Berger & Higginbotham, 2000; Berger et al., 2002; Berger et al., 2003; Miaskowski & 
Lee, 1999; Roscoe et al., 2002), and only one used PSG (Roscoe et al., 2002) to measure 
sleep (see APPENDIX B). Because sleep was not the primary outcome for most of the 
reviewed studies, this lack of consistent measures limits overall knowledge and 
contributes to the variability in prevalence rates. In addition, since there are validated 
measures for use in cancer populations, it remains unclear why there is such inconsistent 
use of measurements of sleep. Recommendations have been made for the standardization 
of sleep measurement in order to facilitate meta-analyses within the descriptive work in 
cancer populations (Clark et al., 2004; Vena et al., 2004). 
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Terminology and diagnosis in BCS 
 There is a lack of consistent terminology used to describe sleep-wake 
disturbances in BCS. In addition, there are no current studies that evaluate how 
practitioners assess sleep problems in the cancer population (Berger et al., 2005; Clark et 
al., 2004). This can be attributed to several research issues.  
 First, research studies typically use generic terms that are intermixed with clinical 
terminology (e.g., sleep latency and insomnia). Although descriptive findings provide 
valuable information regarding sleep-wake disturbances in BCS, inconsistencies in 
terminology make translation of findings into guidelines for clinical practice difficult. For 
example, Savard et al. (2005) studied the prevalence of insomnia using DSM-IV criteria 
in breast cancer patients (n=145) and found 61% experienced high sleep latency (longer 
than 30 minutes to fall asleep) and frequent nighttime awakenings (73%) lasting several 
months after diagnosis of cancer (M=60 months). In addition, Davidson et al. (2002) used 
a sleep survey with general sleep questions and reported women with breast cancer 
(n=302, in-treatment and survivors) experienced symptoms of restless leg syndrome 
(42.7%, range=37-49%), insomnia (37.8%, range=32-44%), and interruptions in 
breathing during sleep (9.6%, range=6.5-14%). Conversely, Carpenter et al. (2004) used 
general terms from PSQI results (e.g., sleep quality, global sleep scores) and found 73% 
of BCS experienced poor sleep quality (above cutoff of 5 for poor sleep quality), high 
sleep disturbance, and short sleep duration (<6 hours per night). For the clinician, these 
inconsistencies provide little information about the true prevalence and etiology of the 
problem. Without clear prevalence and etiology, it is difficult to formulate clinical 
practice guidelines for evaluation and treatment of sleep problems in cancer patients. 
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Thus, there is currently no established evidence based guidelines for the diagnosis of 
sleep-wake disorders in the cancer population. 
 Second, ICDS-R and DSM-IV criteria are typically used by trained sleep 
specialists and/or psychologists and are rarely used in general practice (e.g., oncology or 
general medicine) (Berger et al., 2005). Oncology practitioners and clinicians rarely have 
the time or expertise to perform the intensive sleep assessment required to diagnose 
ICDS-R or DSM-IV disorders. Thus, there is a need for consistent diagnostic criteria 
(generic or ICDS-R) to help provide conceptual clarity in order to formulate future 
diagnostic guidelines for specific populations such as cancer. There is current support for 
the use of ICDS-R since it originates from the American Academy of Sleep Medicine 
(Berger et al. 2005). However, clinicians outside of the discipline of sleep medicine need 
additional training in order to use these categories appropriately. Ultimately, better 
diagnostic practices will contribute to better interventions for this problem. 
Immediate and delayed consequences 
 It is difficult to ascertain the negative effects of sleep-wake disturbances specific 
to BCS. Because studies do not consistently use sleep as a primary outcome, similar 
measurements, or similar terminology, the immediate and delayed outcomes for BCS are 
unclear. In addition, studies often report the characteristics of sleep disturbances but fail 
to assess potential negative consequences (Davidson et al., 2002; Fortner et al., 2002; 
Savard et al., 2001). 
 In studies where consequences were reported, findings suggest that fatigue, 
impaired daytime functioning, mood disturbance, social dysfunction, and altered 
cognitive function result from poor sleep (Anderson et al., 2003; Carpenter et al., 2004; 
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Savard, Laroche, Simard, Ivers, & Morin, 2003; Savard & Morin, 2001). One study 
linked consequences to quality of life scores using a standardized quality of life 
questionnaire (SF-36) and found higher sleep disturbance scores resulted in significant 
deficits in health related quality of life (n=72) (Fortner et al., 2002).  
Because studies do not report sleep-wake disturbances over-time, the chronicity of 
negative consequences is also unclear. Future studies are needed to determine specific 
consequences to BCS. 
Theoretical aspects of sleep-wake research in BCS 
 Although there are theoretical models (e.g., Two Process Model) that provide 
valuable sources of information regarding concepts of sleep, the BCS literature has failed 
to produce an overarching model that encompasses predictors and outcomes of sleep-
wake disturbances. Therefore, the purpose of this last section is to describe the; (a) 
current theories used in the BCS literature and (b) support for the list of predictors 
selected for inclusion in the Elam Psychobiological Model. 
Current theories in BCS literature 
 Of the descriptive BCS studies reviewed with sleep as the primary outcome, only 
5 articles used theoretical models to guide their research (see APPENDIX B) (Berger et 
al., 2003; Carpenter et al., 2004; Savard et al., 2001). Of these models, only two were 
specific to sleep (Spielman’s Psychobiological Model and Borbely's Two-Process Model) 
(Clark et al., 2004; Savard et al., 2001; Vena et al., 2004). As noted in the above review, 
these two models are limited to either physiological and/or psychological factors that 
contribute to sleep-wake disturbances. Although there are known factors that contribute 
to sleep disruptions in BCS (e.g., being female, increased age, depression, general 
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anxiety), current models do not adequately explain how physiological (e.g., pain, cancer 
treatment side effects), psychological (e.g., cancer distress), environmental (e.g., 
bedroom temperature), and pre-sleep routines (e.g., sleep hygiene habits) co-contribute to 
the occurrence of sleep-wake disturbances and resulting negative consequences. 
 Because BCS experience multiple predictors (physiological, psychological, 
environmental, sleep-hygiene) that contribute to possible sleep problems, a new model 
was developed to link predictors of sleep-wake disturbances in BCS with the negative 
consequences.  
Predictors in Elam model 
 Since the majority of sleep disturbance studies in the BCS have not evaluated a 
comprehensive set of predictors, the following is a discussion of possible physiological, 
psychological, environmental, and sleep hygiene factors that can negatively impact sleep 
in BCS. This review provides rationale for inclusion in the BCS sleep-wake disturbances 
model. Although included in the exploratory model, not all predictors listed will be 
evaluated for this study (see Chapter Three for list of predictors to be evaluated for this 
study). 
 Person characteristics as predictors. 
 Person characteristics such as age, race, socioeconomic status, education, and 
menopausal status are known predictors of sleep-wake disturbances. Since these factors 
are known predictors of sleep-wake disturbances, they are typically controlled for in 
statistical analyses (Vena et al., 2004). However, it is important when comparing BCS 
and WWBC that these be evaluated as predictors if the populations are uniquely different 
in demographic and other characteristics.  
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 Physiological predictors. 
 Physical factors that predict sleep-wake disturbances in BCS are co-morbid 
conditions (e.g., thyroid dysfunction, immune dysfunction) (Espie, 2002; Harvey, 2002; 
Holbrook, Crowther, Lotter, Cheng, & King, 2000a), menopausal symptoms (e.g., hot 
flashes, urinary frequency) (Carpenter & Andrykowski, 1999; Couzi, Helzlsouer, & 
Fetting, 1995; Fortner et al., 2002; Savard, Davidson et al., 2004; Shaver & Zenk, 2000), 
and/or long-term side effects that linger after cancer treatment (e.g., pain). There are a 
limited number of studies focusing on the physiological predictors of sleep in cancer 
patients. Prior studies have not consistently examined use of medications that may affect 
sleep (e.g., antiemetics, pain medications, antidepressants). In addition, it is not clear 
whether or how the long-term effects of cancer treatments affect essential neuroendocrine 
and/or other physiological processes (e.g., circadian function) involved in sleep (Berger 
& Farr, 1999; Berger et al., 2002; Davidson et al., 2002; Engstrom et al., 1999; Roscoe et 
al., 2002). 
 Co-morbid conditions. 
 There are a number of co-morbid conditions that negatively impact sleep but, 
generally these are not linked to the occurrence of sleep-wake disturbances in BCS. 
Thyroid and immune dysfunction are two areas that have provided some information 
regarding this link. Those not addressed below such as diabetes, high blood pressure, 
osteoarthritis, or lung disease were not found in the BCS literature but warrant further 
investigation.  
 Thyroid function. There is growing evidence that BCS experience thyroid 
dysfunction after cancer treatment (Anker, Lonning, Aakvaag, & Lien, 1998). Women in 
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general have high prevalence rates of thyroid dysfunction that typically present during 
peri-and post menopause. According to the American Association of Clinical 
Endocrinologists, 1 in 8 women between the ages of 35 and 65, and, 1 in 5 over the age 
of 65 experience thyroid dysfunction (http://www.aace.com/, 2006). 
 Unfortunately, symptoms of menopause experienced by BCS mimic thyroid 
dysfunction, thus, a significant proportion of women are undiagnosed (Anker et al., 
1998). BCS are reported to be more prone to thyroid dysfunction due to cancer treatment, 
premature ovarian failure, and use of estrogen modulators (Anker et al., 1998). The link 
among these factors remains unclear. A current study compared breast cancer patients 
with healthy controls and found 46% (n=102) had thyroid disease after the treatment of 
breast cancer (Giani et al., 1996). Because abnormal thyroid function can be both the 
underlying etiology (e.g., thyroid enlargement) and a consequence of hormonal 
changes/metabolism, clinical evaluation of thyroid function should be performed in 
women complaining of sleep problems. In the BCS, no current studies performed serum 
tests of thyroid function prior when assessing sleep. 
 Post-menopausal symptoms. Estrogen is purposely ablated in women with 
hormone receptor positive cancers. Medications are taken to shut down the estrogen 
supply to certain areas of the body to prevent cancer recurrence. This sudden decrease in 
estrogen can contribute to menopausal symptoms such as hot flashes and low/poor bone 
density. 
 Women who experience hot flashes tend to report poor sleep quality on subjective 
measures (Carpenter et al., 2002). Descriptive studies show that BCS have more frequent 
and more severe hot flashes than healthy women (Carpenter et al., 2002). It has been 
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reported that 48% of BCS report hot flashes that contribute to nighttime restlessness and 
awakenings interfering with sleep (Carpenter, 2000; Carpenter et al., 2001). Savard et al. 
(2004) found significant relationships between nighttime hot flashes and sleep (n=24 
BCS). Findings suggested that nighttime hot flashes contributed to less efficient and more 
disrupted sleep (F=4.98, p=0.038). Fortner et al. (2002) found that 61% of a breast cancer 
sample showed global sleep scores greater than the established cut-off for disturbed sleep 
(n=72). Carpenter & Andrykowski (1999) examined physical menopausal symptoms in 
114 BCS. Trouble sleeping was reported by 68% of these women. 
 Other menopausal symptoms such as urogential changes (e.g., vaginal dryness, 
urinary frequency), increased weight gain, and altered body image have not been linked 
to sleep-wake disturbances. One study reported that 50% of the breast cancer patients 
indicated they woke at least 3 times per week to use the bathroom (Fortner et al., 2002). 
Because a majority of BCS are estrogen deprived, these symptoms could be possible 
predictors of sleep disturbances in this population. 
 Long-term cancer related side-effects. The literature reveals some insight into the 
physiological side effects of cancer treatment and sleep disturbances. Cancer patients 
experience side effects related to the disease itself such as pain and altered activity (Vena 
et al., 2004). It has been well established that sleep is disrupted by pain (Cleeland, 1993; 
Vena et al., 2004). Studies show that up to 80% of cancer patients experience pain during 
and after cancer (Higginson & Hearn, 1997; Vena et al., 2004). Pain can become chronic 
due to multiple breast surgeries and reconstruction resulting in chronic muscular pain. 
Increased sleep in cancer patients was found to decrease pain. One study found that the 
administration of sleep-inducing protein (tryptophan) increased deep sleep and reduced 
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pain (Donovan & Dillon, 1987). Pain can also be related to chemotherapy and 
radiotherapy. Although these side effects typically subside over time, chronic pain has 
been noted in some long-term BCS (Clark et al., 1995). 
 Women with metastatic disease are known to have increased bone pain resulting 
in poor sleep (Cleeland et al., 1994; Dow et al., 1996). However, because women without 
metastatic disease experience frequent nighttime awakenings, it is unclear if chronic pain 
is a factor. Therefore, further investigation is needed to clarify the links between pain and 
sleep disorders in BCS. 
 The use of supportive care medications during cancer treatment is essential to 
reduce unwanted side effects of the treatment (e.g., nausea, vomiting). Such agents as 
steroids used for nausea have been linked to sleep-wake disturbances during and after 
cancer treatment (see APPENDIX D) but often resolve after the drug is stopped. The 
continued use of specific supportive care medications (e.g., anti-anxiety and opioids) has 
not been studied in longitudinal research looking at the negative effects of these 
supportive care medications over-time. 
 Physical activity. The role of physical activity has received some attention in the 
breast cancer literature. The majority of this research focuses on activity level in relation 
to fatigue outcomes for women undergoing active treatment for breast cancer. Studies 
show that activity level decreases during chemotherapy or radiation therapy prompting 
high levels of fatigue (Berger, 1998; Graydon, Bubela, Irvine, & Vincent, 1995; Mock et 
al., 2001). This decrease in activity and high level of fatigue have been related to sleep-
wake disturbances (Berger, 1998; Berger & Farr, 1999). Interventions focus on education 
of sleep hygiene practices (pre-sleep routines) and exercise regimens that increase 
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activity (Berger, 1998; Berger & Farr, 1999; Mock et al., 1997; Mock et al., 2001). This 
increased activity has lead to decreases in sleep-wake disturbances and fatigue levels in 
patients undergoing active treatment. However, it is unclear if the decrease in activity 
experienced during treatment continues into survivorship. It is also unclear if the ability 
to perform certain physical activities, or level of physical functioning (e.g., ability to 
walk up a flight of stairs), has an impact sleep. Therefore, it is important to include 
physical activity or function in the model to determine if it is related to occurrence of 
sleep-wake disturbances. 
 Genetics. The link between genetic polymorphisms and sleep-wake disturbances 
in BCS has been investigated. Although genetic variations are not included in the Elam 
theoretical model, links between circadian genes and breast cancer is receiving more 
attention in the literature. It has been reported that the growth of cancer has been linked 
to the circadian gene expression (Chen et al., 2005; Eriguchi et al., 2003; Filipski et al., 
2002; Mormont & Levi, 2003; Stevens, 2005; You et al., 2005). Tumor cells are 
rhythmically expressed each day within the peripheral tissue but are destroyed by natural 
defense mechanisms. Chen et al. (2005) found specific gene variants to be a risk factor 
for breast cancer in a group of Taiwanese women. The study showed that 95% of breast 
tumors revealed abnormal circadian gene expression compared to non-cancerous cells 
near the tumor (Chen et al., 2005). It remains unclear if abnormal circadian gene 
expression are the reason for the erratic circadian patterns of cortisol and melatonin 
secretion found in BCS (Rich et al., 2005; Sephton et al., 2000). This is one area of 
research that shows great promise in identifying possible genetic links of sleep-wake 
disturbances in BCS. 
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 Psychological predictors. 
 Psychological precipitating and perpetuating factors include cancer related 
distress (concerns of recurrence) and general psychological distress (anxiety and 
depression). Although these issues are found in non-cancer populations, BCS are unique 
in that they live with the constant concerns of cancer recurrence (Turner, Kelly, Swanson, 
Allison, & Wetzig, 2005). In addition, menopausal symptoms are also linked to the 
development of depression, anxiety, and general distress making it difficult to 
differentiate these symptoms from similar cancer related depression, anxiety, and distress 
(Dzaja et al., 2005; Jones & Czajkowski, 2000; Sharkey et al., 2003; Shaver & Zenk, 
2000). 
 The majority of studies that focus on psychological factors target populations that 
are newly diagnosed, undergoing treatment, and/or at the end of life (Berger & 
Higginbotham, 2000; Davidson et al., 2002; Savard et al., 2001). In addition, articles 
reviewed tend to report sleep disturbances as a consequence of life stressors (e.g., low 
social support, work, bereavement) not as a predictor (Berger & Walker, 2001; Clark et 
al., 1995; Davidson et al., 2002; Fortner et al., 2002; Koopman et al., 2002; Savard et al., 
2001). Redeker et al. (2000) found that fatigue, depression, and anxiety during 
chemotherapy treatment predicted insomnia (r=0.26-0.69, p<0.001). In addition, 
Koopman et al. (2002) examined sleep patterns in women with metastatic breast cancer 
and found women with more bone lesions had higher levels of pain and depression 
reflecting the overlapping nature of predictors. Carpenter et al. (2004) looked at sleep, 
fatigue, and depressive symptoms in BCS with hot flashes and found fatigue and 
depressive symptoms were related to poor sleep quality (r=0.43-0.47, p<0.005). These 
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studies are limited by the population studied (women with hot flashes or metastatic 
disease) and exclusion of other potential predictors of sleep disturbances (e.g., 
environmental factors). 
 Environmental and sleep hygiene predictors. 
 Environmental factors have not been fully evaluated in the breast cancer 
literature. Environmental factors include sleep environment, companion sleep, and care 
of dependents in the home (e.g., elderly parents, children). It is known that lingering 
effects of cancer treatment can disrupt environmental cues for sleep (Lavie, 2001). Side 
effects such as nausea, vomiting, diarrhea, and general malaise are most severe during 
treatment and subside 1-2 weeks post treatment. Because of these side effects, normal 
environmental cues can be disrupted by frequent napping, nighttime awakenings, and 
decreased physical activity (Berger & Farr, 1999; Mock et al., 1997). If environmental 
cues are disrupted, the circadian cycle generally becomes out of sync causing shortened 
sleep cycles (Borbely & Achermann, 1992) leading to daytime sleepiness because the 
amount of restorative sleep was not adequate. 
 Sleep hygiene factors (e.g., pre-sleep routines) can also contribute to sleep-wake 
disturbances (Berger et al., 2002). Within the BCS literature, studies did not evaluate 
whether sleep problems existed before treatment and/or when they developed during 
treatment (Davidson et al., 2002; Deimling et al., 2002; Fortner et al., 2002; Savard et al., 
2001). Although sleep hygiene factors were evaluated as part of Berger’s (2003) 
intervention for sleep and fatigue, the intervention did not assess other possible predictors 
of sleep disturbances. In addition, Berger did not report specific factors that emerged 
from the sleep hygiene assessment prior to intervention. These limitations provide little 
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information regarding how sleep hygiene affects sleep in BCS. However, sleep hygiene 
factors are shaded in gray and will not be evaluated in this study due to measurement 
constraints (see Chapter Five). 
 Based on this discussion, it is noted that a complete set of predictors for sleep-
wake disturbances are rarely evaluated in the BCS literature. There are several areas of 
potential interaction among predictive factors and the occurrence of sleep disturbances. It 
is important to examine these predictive factors in order to determine effective 
interventions that prompt sleep in this population. 
Interventions studied in BCS 
 It remains unclear what types of treatments are commonly used by BCS (outside 
of research) and are effective for sleep-wake disturbance. The following is a review of 
the types of sleep interventions that have been studied in BCS. 
Pharmacological studies in BCS 
 Women with breast cancer have been noted to use hypnotics to facilitate sleep. 
Recent studies show, 20%-40% of BCS report using pharmacologic agents to promote 
sleep (Davidson et al., 2002; Savard et al., 2005a). This range is comparable to other 
cancer populations except for lung cancer where over 40% report use of these agents 
(Davidson et al., 2002). No controlled studies were found that examined the efficacy of 
these agents in BCS. Although studies show these agents are commonly used, BCS’s 
desire to take additional medications is low (Vena et al., 2004). This lack of interest is 
reflected in a comment made by a survivor participating in a behavioral hot flash research 
study (Carpenter et al., 2007). 
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“…..we (BCS) don’t want to take medication (for sleep-wake 
disturbances)…We feel like we are dumping enough chemicals into our 
bodies.” 
 
This statement provides only one viewpoint but reflects possible barriers to performing 
controlled drug trials in this population. 
Non-pharmacologic interventions in BCS 
 The review of non-pharmacologic intervention studies produced five articles that 
were specific to BCS (Berger et al., 2003; Davidson, Waisberg, Brundage, & MacLean, 
2001; Quesnel et al., 2003; Savard et al., 2005a; Shapiro, Bootzin, Figueredo, Lopez, & 
Schwartz, 2003). Results were mixed regarding the benefit of non-pharmacological 
interventions for BCS (Berger et al., 2003; Davidson et al., 2001; Quesnel et al., 2003; 
Savard et al., 2005a; Shapiro et al., 2003). First, Berger et al. (2003) conducted a 
prospective, sleep promotion intervention study with 21 BCS. Women were assessed at 
30, 60, and 90 days after completion of cancer treatment. Results showed high adherence 
rates to a sleep promotion intervention (77%-88%) supporting the feasibility of the 
intervention. Although no changes in fatigue were noted over time, the intervention 
decreased sleep latency (less than 30 minutes) and nighttime awakenings (10-11 
times/night), increased sleep efficiency (82-92%) and total sleep time (7-8 hrs) (Berger et 
al, 2003). 
 Davidson et al. (2001) found improvements in sleep, mood, and daily 
functioning using a group sleep therapy intervention. The quasi-experimental study 
examined the efficacy of a sleep therapy program in 15 cancer survivors (some with 
metastatic disease) with insomnia. The sample was a non-depressed, non-anxious group 
with adequate scores on the quality of life measures. Sleep outcomes showed significant 
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decreases in number of nighttime awakenings (F=8.63; p=0.002), wake after sleep onset 
(F=15.61; p=0.001), and sleep impairment ratings (F=29.19; p<0.001) after the 8-week 
intervention. Increases in total sleep time (F=4.12; p=0.030), percent sleep efficiency 
(F=31.29; p<0.001), and feelings of being rested (F=9.50; p=0.003) were also found. 
 Quesnel et al. (2003) found similar results in terms of sleep and mood using 
sleep therapy intervention in a single group of non-metastatic BCS (n=10). Subjects 
participated in group sessions that provided education regarding good sleep hygiene 
practices. Sleep variables improved over time with the use of the group therapy 
intervention. Reductions in wake after sleep onset (s=-15, p=0.02) and increases in sleep 
efficiency (s=13, p=0.04) were found comparing pre-treatment to post-treatment and 
post-treatment to 6 month follow-ups. Depression scores, although non-significant, 
decreased from a baseline mean of 10.8 on the Beck Depression Inventory to a mean of 
5.3. Likewise, anxiety, fatigue, and quality of life improved and although not statistically 
significant, provided support for clinical significance of the intervention for the 
improvement of sleep and mood.  
 Savard et al. (2005a) conducted a randomized-controlled trial of 57 BCS with 
insomnia that was attributed to the diagnosis or treatment of breast cancer. Women were 
randomized to cognitive-behavioral treatment (n=27) or the wait-list control (n=30). 
Results showed significant (p<0.001) group-time interaction for variables except total 
sleep time. Sleep efficiency (F=22.59), total wake time (F=22.77), sleep onset latency 
(F=4.16), and wake after sleep onset (F=16.7) were significantly different between 
groups. Sleep measured by PSG found no significant group-time interactions with any 
sleep variables supporting the disconnect between perceived self-reported sleep and 
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results of objective findings. Quality of life scores did improve reflected by significant 
(p<0.05) group-time interactions on scores of anxiety (F=5.19), depression (F=4.14), and 
global quality of life (F=5.69). Together, the improvement of sleep and quality of life 
were valuable but were not sustained over-time.  
 Finally, Shapiro et al. (2003) conducted a sub-study of the efficacy of a 
mindfulness-based stress intervention for sleep disturbances in non-metastatic BCS 
(n=63). The intervention consisted of 6-weekly sessions using three types of meditation. 
Subjects could self-select into a control group that included only self monitoring practices 
using written materials from the study staff. Results were not generally favorable for the 
reduction in sleep-wake disturbances. Baseline assessments revealed participants had 
mild to moderate degrees of sleep complaints. Those participants with greater levels of 
distress at baseline had significantly lower sleep quality and general feelings of being 
refreshed after sleep throughout the entire intervention and follow-up regardless of group 
assignment. When distress was controlled for in the data analysis, sleep efficiency was 
not significantly improved with the intervention. 
Limitations 
 Although pharmacological interventions have not been formally tested in BCS, 
research suggests that non-pharmacological interventions in BCS can be beneficial but 
these improvements in sleep often are not sustained over-time. Problems with non-
pharmacological interventions were attributed to the time-intensive nature of the 
interventions due to number of therapy sessions needed with a trained sleep specialist. In 
addition, due to high participant withdrawal, adherence over time was not been well-
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established, thus, the long-term benefits are unknown (Berger et al., 2002; Davidson et 
al., 2001; Quesnel et al., 2003; Savard et al., 2005a; Shapiro et al., 2003). 
 In sum, sleep-wake disturbances are a common problem reported by BCS. 
Because sleep is such a vital function, disruptions in sleep can lead to a multitude of 
negative consequences. Unfortunately, sleep disturbances in BCS are often not assessed 
in clinical practice and often go untreated due to complex diagnostic criteria and lack of 
clinical guidelines for non-sleep specialty clinicians (Vena et al., 2004). The use of 
evidence-based guidelines is limited due to the problems with the current literature. 
Limitations in the descriptive and intervention studies decrease our understanding of 
conceptual links between sleep and sleep disturbances. 
 Based on this extensive review of BCS literature, the following research questions 
emerged this study. 
1. Is there a difference in the prevalence of sleep-wake disturbances between BCS 
and WWBC? 
2. Is there a difference in severity of sleep-wake disturbances between BCS and 
WWBC? 
3. Is there a difference in the physiological, psychological, and environmental 
predictors of poor sleep in BCS and WWBC? 
4. Is there a difference in the physiological, psychological and environmental 
predictors of the severity of sleep-wake disturbances between BCS and WWBC? 
 Answering these questions will improve conceptual clarity through knowledge of 
predictors of sleep problems which will help target effective treatments and improve 
quality of life in this unique population. 
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CHAPTER THREE 
METHODOLOGY 
 
 The purpose of this chapter is to describe the proposed methodology for this study 
evaluating predictors of sleep-wake disturbances in BCS compared to age-matched 
WWBC. The chapter is organized into two parts; (1) methods of the parent studies that 
provided data for this study and (2) methods of this study of sleep-wake predictors. 
Part 1: Parent Studies 
 The parent dataset consisted of data being collected from two studies; the 
American Cancer Society Quality of Life Study (ACS) (#RSGPB-04-089-01-PBP, 
Champion PI) and the Survey of Quality of Life in African American Women (AA) (NCI 
#R03 CA-097737 & Walther Cancer Institute, Russell PI). The first part of this chapter 
will describe four aspects of the parent studies; (1) design, (2) sample criteria, (3) 
recruitment, and (4) data collection. Because both parent studies are similar, descriptions 
were combined within each sub-section with differences noted when applicable. 
Design 
 Both parent studies were cross-sectional, descriptive, comparative, case-
controlled designs evaluating an extensive set of quality of life variables in BCS. Data 
were collected via questionnaire survey at a single point in time. 
Sample criteria 
 The parent studies had similar inclusion and exclusion criterion. The overall goal 
of both studies was to compare quality of life in BCS and age-matched WWBC. The 
following is a list of inclusion criterion for BCS and WWBC for both studies. 
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BCS  
1. Provided informed consent. 
2. Able to read, write, and speak English. 
3. In good general health. 
4. First-time diagnosis of breast cancer. 
5. No other known cancer at the time of the study. 
6. Cancer-free at time of study enrollment (stage I-III). 
7. At least two years (Russell study) or three years (ACS study) post-completion of 
surgery, radiation, and chemotherapy. No more than 8 years post-diagnosis for the 
ACS study. 
8. Must be between 18 and 45 years of age or between 55 and 70 years of age at 
diagnosis for the ACS study and over age 18 for the Russell study. 
WWBC 
1. Provided informed consent. 
2. Age 18 years or older. 
3. Able to read, write, and speak English. 
4. In good general health. 
5. No known cancer at the time of the study. 
6. Matched to a BCS on age (+/- 5 years) and education (similar education). 
Recruitment 
 Both parent studies used similar local recruitment strategies while the ACS also 
recruited women outside of the local area. BCS and WWBC participants for the ACS and 
AA study were recruited using the following strategies; (a) telephone and local clinic 
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contacts, (b) referrals from other institutions outside of Indiana (ACS only), and (c) 
acquaintance control referrals. 
Telephone and local clinic contacts 
 Telephone and local clinic contacts were performed as follows. BCS were 
recruited from the Indiana University Simon Cancer Center (IUSCC) and Wishard 
Memorial Hospital. These clinics were chosen based on availability of participants for 
this geographic location. Telephone contacts occurred as follows. Women referred by 
recruiters or physicians were screened via the telephone by a trained study team member 
for eligibility and informed of the purpose and nature of the parent study. Study team 
members completed and passed the “Human Subjects Certification Test” at Indiana 
University School of Nursing (IUSON) prior to participant contact. Eligible women were 
mailed two copies of the consent and Health Insurance Portability and Accountability Act 
(HIPAA) authorization form and a stamped, self-addressed envelope for returning their 
signed consent. 
 Women recruited in-person during clinic hours were approached by a designated 
study member after permission was given by the physician. The purpose and nature of the 
study were reviewed and participants were screened for eligibility if there was expressed 
interest to participate. If women were eligible and interested, they were given two copies 
of the consent and HIPAA authorization forms in the clinic. After review, participants 
were asked for verification of understanding of the consent and HIPAA forms, and then 
asked for signature. One signed copy was given to the participant and the other signed 
copy was kept by the project staff. 
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Referrals from other institutions 
 Institutions affiliated with the Eastern Cooperative Oncology Group (ECOG) 
referred potential participants and acquaintance controls for the ACS study. In addition, 
Vanderbilt University investigators referred potential participants for the ACS study. The 
ECOG Statistical Office identified names of potential participants from a computerized 
database. The ECOG office contacted the physician at the specific institution associated 
with the potential participant and the physician was asked to contact the participant about 
the study. The names of eligible and willing BCS were faxed to a secure location at 
IUSON. Vanderbilt University also provided study referrals for the ACS using a database 
of women who had participated in an epidemiological study and who had agreed to be 
contacted for future studies. The research team from Vanderbilt contacted potential 
participants regarding the ACS and forwarded eligible and willing BCS.  
 For both regional recruitment referrals, once the names were received, a letter and 
study brochure describing the study was sent. After one-week, a study team member from 
IUSON contacted the potential participant by telephone. Women were screened over the 
telephone and verbal permission was obtained to send two copies of the informed consent 
and HIPAA authorization form. Study questionnaire packets were mailed after informed 
consent was received. Those who received mailed consents from any of the above 
recruitment methods and did not return a signed consent received a reminder phone call 
one-week and two-weeks following their initial recruitment date. This telephone call was 
used to provide additional study information and verify women's interest in participating. 
If after two additional weeks the consent was not obtained, the study team member 
mailed a refusal postcard to the potential participant. The postcard was a self-addressed 
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stamped card that described the purpose of the study and provided a checkbox to mark if 
the woman did not want to participate in the study. The card was only identified by the 
study identification number for the purposes of data entry. 
Acquaintance control recruitment 
 Acquaintance controls were recruited by the BCS participants who completed the 
parent studies. Survivors were asked for names of two (AA) or three (ACS) 
acquaintances. Specifically, BCS were asked to identify and provide contact information 
for acquaintances with similar age, gender, education, and race. BCS were asked if the 
investigators could use the patient’s name when contacting acquaintances. The PI of the 
ACS study (Champion) has successfully used this type of acquaintance-identification 
techniques for three separate, externally funded studies. Study team members contacted 
the potential WWBC age-matched control by telephone and explained the purpose of the 
study. If the WWBC agree to participate, an introductory letter, informed consent 
statement, and background questionnaire was mailed. If the WWBC was not willing or 
available to be included in the study, a match was obtained from the pool generated by 
the other BCS participants. 
Protection of human subjects 
 The Human Research Protection Program at Indiana University-Purdue 
University Indianapolis (IUPUI) is an accredited site designated by the Association for 
the Accreditation of Human Research Protection Programs, Inc. It exists to protect the 
rights and welfare of human research participants recruited to participate in research 
conducted under the direction of Indiana University.  
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 In keeping with the policies of the Health Insurance Portability and 
Accountability Act (HIPAA) and Indiana University, the research for both the ACS and 
AA were reviewed and approved by the IUPUI Institutional Review Board and IUSCC 
Scientific Review Committee prior to the implementation with human subjects. Several 
methods were used to protect patient confidentiality. Identifying information was 
collected on paper forms and entered into a secure database in a limited access folder on 
the IU School of Nursing (IUSON) server. Once identifying information was entered into 
the database, paper forms were filed in a locked file cabinet in the investigator’s office. 
Patients were informed of the right to stop participation at any time during the study 
without penalty or adverse ramifications. 
Data collection 
 For both parent studies, eligible and willing BCS and WWBC who return signed 
consents were then mailed study questionnaires. Questionnaires were coded with a 
unique identifier so individuals’ information was only linked by identifier in a secure 
location. When questionnaires were received by study team members, they were visually 
checked for completeness and logged into a secured computerized database.  
If missing items were not complete on the questionnaires, participants were called to 
determine if this was purposeful or oversight. After this initial data check, all 
questionnaires for both studies were scanned through an electronic device by the 
biostatisticians that combined the results into a secure-computerized statistical database. 
All hard copy forms were returned to the ACS or AA office at the IUSON and filed into 
locked file cabinets.  
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 If after two-weeks the questionnaire was not returned, the participant was 
contacted by phone to inquire about questions or problems with the questionnaire. If the 
questionnaires were not obtained after an additional two weeks, the study team member 
mailed a refusal postcard to the potential participant. The postcard was a self-addressed 
stamped card that described the purpose of the card and provided a checkbox to mark if 
women did not want to participate in the study. The card was only identified by the study 
identification for the purposes of data entry. 
Part 2: Study Dataset for this Study 
 The second part of this chapter describes the; (1) design, (2) sample criteria, (3) 
study procedures, (4) measures, and (5) data analysis of the dataset used in this research 
to evaluate predictors of sleep-wake disturbances in BCS. 
Design 
 A convenience sample was used. The study design was a descriptive, cross-
sectional, case-controlled study. 
Sample criteria 
 The sample for this sub-study of sleep-wake predictors in BCS included matched 
participants with completed questionnaires from one of the parent studies. 
Study procedures 
 Data from the ACS and AA databases were merged into one large database. The 
database was kept on a secure university computer server using a secure username and 
password only accessed from the university computer networks. 
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Age and education-matching 
 Age-matching was performed by frequencies on birth-date. BCS and WWBC were 
matched within +/- 5 years of age. For education, BCS and WWBC were matched only if 
frequencies revealed significant differences in each group. Matching was performed by 
placing BCS and WWBC into categories of education such as; (a) high school education 
or less, (b) undergraduate education, or (c) graduate education. A chi-square (education 
by group) assessed for any significant differences. 
Power analysis 
 The proposed sample size was based on power analyses for research questions 3 
and 4. For research question 3, to power for the planned logistic regression, power was 
based on the ability to predict or detect a rarer outcome. Based on prior studies, 65% of 
BCS are poor sleepers, thus, 35% were expected to be categorized as good sleepers (rarer 
outcome) (Carpenter et al., 2004; Elam & Carpenter, 2004a, 2004b; Elam & Carpenter, 
2005). For the WWBC group, based on prior studies 50-60% of WWBC were good 
sleepers, thus, 40-50% were expected to be categorized as poor sleepers (rarer outcome) 
(Shaver, Giblin, & Paulsen, 1991; Shaver & Zenk, 2000). To detect significant predictors 
(p<0.05) in this study using logistic regression, there needed to be at least five 
observations per parameter for the rarer outcome for the final regression model (Grimm 
& Yarnold, 2000). Therefore, if the sample consisted of 242 in each group, 35% of the 
BCS (n=88) and 50% of WWBC (n=125) would be expected to be good sleepers, which 
supported the analysis of up to 17 possible predictors in each group. 
 For research question 4, to power for the multiple regression, there were 10 
participants per predictor variable (Tabachnick & Fidell, 2001). Since the study evaluated 
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17 BCS predictor variables and 14 WWBC predictors, there was a need for at least 170 
participants per group of BCS and WWBC. 
 Based on the largest sample needed to obtain power in this study (research question 
3 in the BCS group), the dataset included 246 BCS and 246 WWBC. The ACS study 
provided a sample of 520 BCS and matched acquaintance controls (WWBC). The AA 
study completed recruitment with complete data on 133 BCS and 75 WWBC. Combining 
both studies provided an ample sample for this analysis.  
Measures 
The following outlines the questionnaires used for this study (see APPENDIX E). 
Each predictor category was measured using specific items or scores (see Table 2). Not 
all questionnaires were applicable to the WWBC because they measured experiences 
specific for breast cancer (see specific items in Table 2). These were analyzed only as 
unique predictors specific for BCS. 
Primary outcome of sleep 
The main outcome of sleep was assessed using a subjective questionnaire. The 
Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 1989) was designed for use in 
clinical populations as a simple and valid assessment of sleep. The tool contains 19-items 
that produce a global sleep quality score based on 7 component scores: sleep quality, 
sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleep 
medications, and daytime dysfunction. PSQI items use varying response categories 
including Likert-type responses. Responses are based on the prior month’s habits. 
Psychometric properties of the PSQI such as internal consistency reliability have been 
widely supported in a variety of populations (Gentili et al., 1995; Pasternak et al., 1994; 
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Tiffin et al., 1995), including non-cancer populations (n=52; α=0.83) (Buysse et al., 
1989) and BCS (n=102; α=0.80) (Carpenter & Andrykowski, 1998). Construct validity 
has also been shown in non-cancer populations through convergent validity (r=0.69) and 
discriminate validity (r<0.37) (Carpenter & Andrykowski, 1998). PSQI global sleep 
scores, component scores, and PSQI cut-off scores (>5) were used for analyses. 
Predictors of sleep-wake disturbance 
The four predictor categories from the psychobiological model (see APPENDIX 
C) included; (a) sample characteristics, (b) physiological, (c) psychological, and (d) 
environmental predictors.  
 Sample characteristics. 
 Demographic data that provided sample characteristics was collected by the 
Personal Characteristics Questionnaire (PCQ). These are common questions collected 
from respondents in past research studies and have performed well in cancer patient 
populations (Giesler et al., 2005). Specifically, the questionnaire assessed items including 
respondents' age and marital status, educational and income level, employment status, 
type of medical insurance, and race. Race and ethnicity were assessed using single item 
measures, but participants had the option of checking multiple categories to best 
represent the individual’s racial or ethnic background. For this study, specific questions 
from the PCQ were used in the evaluation of person characteristics that potentially 
predicted poor sleep. Items that assessed age, education, race, and socioeconomic status 
were evaluated. 
 In addition, in the BCS group, information about breast cancer and treatment was 
obtained from abstracting medical records using a standardized form. Data included date 
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and stage at diagnosis, types and dates of treatment (surgery, chemotherapy, radiation), 
and endocrine therapy. This information was reported as part of the sample description 
but information regarding type of treatment (chemotherapy and radiation) and stage of 
breast disease (stage I, II, III) was used as predictors.  
 Physiological predictors. 
Physiological predictors included co-morbidities, physical symptoms including 
residual side effects of cancer treatment, and hot flashes. 
 Co-morbidity information was obtained from the Medical History Questionnaire 
(MHQ) (Champion).The questionnaire was generated specifically for the ACS study 
(also administered in the AA study) and provided information that is often not explicit in 
medical records. The questionnaire consisted of 21-items regarding the presence of 
disease states and general health. Specifically, the MHQ item #7 provided a total number 
of co-morbidities for BCS and WWBC. Since this was a general medical history 
questionnaire, reliability and validity estimates were not available for this tool.  
 Physical function was measured by the RAND Physical Functioning -10 (PF-10), 
a valid and reliable 10-item scale that provideed an assessment of overall physical 
function. The PF-10 is the physical functioning scale of the MOS SF-36 and one of the 
most commonly used measures of health related quality of life (Haley, McHorney, & 
Ware, 1994; McHorney, Ware, & Raczek, 1993). Cronbach’s alpha coefficient (internal 
consistency reliability) for the PF-10 generally exceeded 0.90 in research studies (Haley 
et al., 1994; McHorney et al., 1993). For this study, the total score was used to evaluate 
the relationship between physical functioning and sleep. 
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 Long-term side effects of cancer were measured using two instruments. First, the 
Medical Record Audit Form (MRAF), specifically designed for the ACS study 
(Champion), was used to abstract medical record information from participant charts. The 
9-item form was used to collect standard disease and treatment information. Trained 
study staff extracted data from medical records. Reliability of the extracted data cannot 
be verified. This form differs from the MHQ in that it was used to obtain specific dates of 
diagnosis, specific treatment (e.g., type of chemotherapy agents), and specific staging 
information. Since this was a general medical history questionnaire, reliability and 
validity are not available for this tool. For this study, besides providing information to 
describe the sample, items 4, 12, and 13 were used to evaluate the relationship between 
the type of cancer treatment and sleep, and stage of breast cancer and sleep. This 
questionnaire was applicable only to the BCS group. 
 Second, the Symptom Experience Report (SER) has been used in prior research to 
assess the presence and severity of various symptoms and was used to measure residual 
and/or current side effects of cancer treatment (Andrykowski et al., 1997; Carpenter, 
Andrykowski, Cordova, Cunningham, & Studts, 1999; Neugarten & Kraines, 1965). The 
SER used in the ACS and AA studies evaluated 12 symptoms of lymphedema and 
neurological symptoms that can occur after treatment, thus, it was only administered to 
the BCS group. Participants indicated if each symptom occurred in the previous week. 
For this study, positive responses to individual items/symptoms were summed to obtain a 
total number of symptoms per subject. This number was used to evaluate the relationship 
between the long-term side effects of cancer and sleep in BCS. Since this questionnaire 
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was a symptom checklist, psychometric properties are not available (Nunnally & 
Bernstein, 1994).  
 Menopausal symptoms were measured using the 14-item Menstrual and 
Gynecological History (MGHQ) questionnaire. Information regarding prevalence of hot 
flashes (item-12 and 13) were obtained from BCS and WWBC and were used to evaluate 
hot flash frequency. No psychometrics properties have been reported on this inventory 
since it is a general history questionnaire.  
 Psychological predictors. 
 Psychological predictors included general distress (depression and anxiety) and 
cancer-related distress (concerns of recurrence, intrusive and avoidant thoughts related to 
cancer). 
 Depressive symptoms were assessed using the Center for Epidemiologic Studies-
Depression Scale (CES-D), a 20-item self-report instrument assessing the presence and 
severity of depressive symptoms occurring over the past week. (Radloff, 1977). Scores   
> 16 are indicative of high depressive symptoms, but are not considered a diagnosis of 
clinical depression (Berkman et al., 1986; Comstock & Helsing, 1976). This cut-off point 
of 16 has been used extensively in other studies, including studies of BCS (Carpenter & 
Andrykowski, 1998). For this study, total scores were used to evaluate the relationship 
between depressive symptoms and sleep-wake disturbances. Internal consistency 
reliability has been shown to be adequate in cancer and non-cancer populations with 
Cronbach’s alpha coefficients of >0.85 (Hann, Winter, & Jacobsen, 1999). 
 State and trait anxiety were measured using the State-Trait Anxiety Inventory 
(STAI) (Spielberger, Gorsuch, & Lushene, 1983). The STAI contains two self-report 
 74 
scales for measuring state and trait anxiety. The S-Anxiety (state) scale includes 20 
statements that assess how an individual currently feels, whereas the T-Anxiety (trait) 
scale includes 20 statements that assess how an individual generally feels. Cronbach’s 
coefficients of the S-Anxiety (state) range from 0.86 to 0.95 while the T-Anxiety ranged 
from 0.89 to 0.96, depending on the sex and employment status of the population to 
which it was administered (Spielberger et al., 1983). For this study, both the state and 
trait total scores were evaluated. 
 Cancer related distress was measured using 2 scales. First, the Concerns about 
Recurrence Scale (CARS) (Vickberg, 2003), a two-part instrument developed for breast 
cancer survivor, evaluated the relationship between concerns of breast cancer recurrence 
and sleep-wake disturbances. The Likert-type response questionnaire (not associated with 
time) was given only to the BCS group. The first part consisted of 4 items assessing 
overall concerns of recurrence; the second part consisted of 29 items grouped into 4 
subscales that assess the reasons for anxiety over recurrence. The 4 subscales assess 
breast cancer recurrence-related worries about death, health, role and womanhood. 
Internal consistency reliabilities ranged from 0.87 to 0.94 (Vickberg et al., 2003). For this 
study, total scores of the first part were used to evaluate the relationship between concern 
of recurrence and sleep-wake disturbances. 
 Second, the Impact of Events Scale (IES) a 15-item self-report questionnaire, 
measured cancer-related distress as intrusive and avoidant thoughts about cancer. The 
IES was designed to assess current subjective distress for any specific life event 
(Horowitz, Wilner, & Alvarez, 1979). Scoring and subscale reliability has been 
established with satisfactory internal consistency in non-cancer populations (n=66; 
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α=0.86 total scale; intrusion α=0.78, avoidance α=0.82). Internal consistency was found 
to be satisfactory in female populations (n=480 non-cancer women; α=0.91 for total 
scale; subscale alphas: intrusion α=0.88, avoidance α=0.84) (Thewes, Meiser, & Hickie, 
2001) and has been used in breast cancer studies (alpha not reported) (Turner et al., 
2005). For this study, the IES intrusion and avoidance total scores were evaluated in both 
BCS and WWBC to determine the relationship between a stressful life event (breast 
cancer in the BCS, other event in the WWBC) and sleep-wake disturbances. 
 Environmental predictors. 
 Sleep environment predictors were gathered from two questionnaires, the PSQI 
and the MGHQ. First, information regarding sleep environment was assessed using item 
19 on the PSQI, a question that is not used for calculating the total score. This item 
addresses the presence of a bed partner or roommate (Buysse et al., 1989). Although this 
was a narrow view of sleep environment, the parent studies did not include a 
comprehensive questionnaire regarding specific environment issues or sleep hygiene  
(see Chapter Five). Second, information regarding presence of children in the home was 
gathered from item #7 in the MGHQ. The question asks if children are living with the 
participant at the present time. This provided information regarding child rearing that can 
create a disrupted sleep environment.  
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Table 2 
List of Measures  
Variable  Measure Item/ 
score 
Level of 
measurement 
Range of 
scores 
Validation 
in BCS 
Validation 
in WWBC 
RQ(s)* 
Outcome Sleep presence 
of sleep 
disturbances 
PSQI Global scores 
(based on 
items 1-18) 
are compared 
to 
standardized 
cutoff scores 
Categorical  Dichotomous
above or 
below cutoff 
Yes Yes 1 
 
Sleep severity 
of sleep 
disturbances 
PSQI Global score 
(based on 
items 1-18) 
Continuous  0-21 Yes Yes 2 
Predictor  
Person Age PCQ #13 Continuous n/a n/a n/a 3,4 
 Education PCQ #7a Continuous n/a n/a n/a 3,4 
 Race PCQ #9 Categorical n/a n/a n/a 3,4 
 SES  
Income 
 
PCQ 
 
#12 
 
Categorical 
n/a n/a n/a  
3,4 
 Employment WI #6 Categorical n/a n/a n/a 3, 4 
 Menopausal 
status 
 
MGHQ #2 Categorical 21 n/a n/a 3, 4 
Physiological   
 Co-morbidities MHQ,  Total score 
based on item 
#7 
 
 
Categorical 0-19 n/a n/a 3, 4 
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Variable  Measure Item/ 
score 
Level of 
measurement 
Range of 
scores 
Validation 
in BCS 
Validation 
in WWBC 
RQ(s)* 
  PSS 1 Total score 
based on items 
#2, 3, or 6 
added to MHQ 
total score 
Categorical True/false n/a n/a 3, 4 
 LT s/e of 
cancer tx 
 
 Type of cancer 
tx 
MRAF 1 #4, 12, 13 Continuous, 
Categorical 
n/a n/a n/a 3, 4 
 Long-term side 
effects 
SER1 Total severity 
 
Continuous 0-48 Yes (longer 
version) 
Yes 3, 4 
 Post-
menopausal 
symptoms 
(HF’s) 
MGHQ # 12, 13, 14 Categorical n/a n/a n/a 3, 4 
 Physical 
functioning 
PF-10 Total score Continuous 10-30 Yes Yes 3, 4 
Psychological Cancer related 
distress 
 
CARS 1 Total scores 
on part 1-3 
Continuous 4-24 (part 1) 
 
Yes n/a 3, 4 
 General 
psychological 
distress 
 
 
 Depression CES-D Total score Categorical 0-60 Yes Yes 3, 4 
 Anxiety STAI Total score for 
both state and 
trait 
 
 
Categorical 20-80 (Y-1) 
20-80 (Y-2) 
Yes Yes 3, 4 
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Variable  Measure Item/ 
score 
Level of 
measurement 
Range of 
scores 
Validation 
in BCS 
Validation 
in WWBC 
RQ(s)* 
 Distress r/t life 
event 
IES Total score for 
both intrusion 
and avoidance  
Categorical 0-35 
(intrusive) 
0-40 
(avoidance) 
Yes Yes 3, 4 
Environment Companion/bed 
partner 
PSQI #19 Categorical See above   3, 4 
 
Family 
developmental 
stage 
MGHQ #7 Categorical See above   3, 4 
*=Research question, 1=measured only in BCS 
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Data acquisition and preparation 
 Permission was granted to obtain electronic copies of the parent datasets by the 
principal investigators for each study. Datasets were received through a password-
protected file folder stored on a secure data server to maintain confidentiality of data. The 
datasets were received in Statistical Package for the Social Sciences (SPSS) (v. 15.0) 
(Chicago, IL) format. The parent datasets contained questionnaires completed by BCS 
and WWBC. It was established that the sample size of both parent datasets provided 
sufficient numbers of subjects to proceed with age-matching. Data was examined by case 
summaries to detect missing items within each questionnaire. This section provides 
details of the following procedures; (a) subject matching, (b) data cleaning, and (c) 
reliability of questionnaires.  
Subject matching 
 The secondary dataset was established by matching BCS and WWBC through 
visual examination of frequency data by age. A pool of 520 BCS and 252 WWBC were 
identified from the parent datasets. A total of 246 BCS were matched within +/-5 years of 
age with 246 WWBC (n=492). A chi-square test for independence showed that levels of 
education were not significantly different between BCS and WWBC (χ2(2)=4.73, p=0.09) 
suggesting that the groups were also education-matched. 
 Of the BCS included in the analysis, 148 were recruited by telephone or local 
clinic referrals (Indiana University Cancer Clinic and Wishard Memorial Hospital) and 
98 from other institutions outside of Indiana (ECOG institutions including Vanderbilt 
University). The recruitment location was not recorded for the WWBC. However, of the 
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women included, 173 were from the ACS study and 73 from the AA study. Only subjects 
that submitted completed questionnaires were considered for this analysis. 
Data cleaning 
 Completed questionnaire packets from each parent study were checked twice 
prior to data entry. For both studies, missing items were addressed by attempting to 
contact subjects by telephone. If the contact was successful, subjects were asked to 
verbally reply to the missing items. If this was not successful, the packets were forwarded 
with missing data to the data management team for scanned entry into a computerized 
database. After scanning, missing items were checked to ensure the scanning process was 
not the reason for missing items. Although completeness of standardized questionnaires 
was evaluated by parent study team members, there were some missing values in the 
secondary dataset. 
 Data cleaning was performed. First, total or mean scores were calculated for each 
questionnaire used in the parent studies. Next, descriptive and frequency statistics 
examined overall patterns of missing values for the new total/mean scores. The second 
step in data cleaning was to examine individual missed items. This was completed 
through frequencies and case summaries by the subject identification number. Patterns of 
missing items were evaluated by subject to determine any patterns within group (BCS or 
WWBC) and/or by subject. Missing data were found to be randomly distributed by 
subject and item/questionnaire. One subject was identified with several missing items and 
was subsequently replaced with a different age-matched subject. Overall, the amount of 
missing data was calculated to be 1.07% of the entire dataset which is relatively low for a 
large dataset (Tabachnick & Fidell, 2001).  
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 After evaluation of the secondary dataset, decisions regarding the best method to 
resolve the missing items were made and can be found in APPENDIX F. For missing 
mean or total scores, mean imputations were completed based on group and race. After 
imputations were completed, frequencies and descriptive statistics were repeated to 
ensure all values were present. Mean or total scores for each continuous questionnaire 
scale were recalculated based on the imputed items. Frequencies and descriptive statistics 
were repeated to ensure all subjects had complete data. 
 During the cleaning process it was found that one of the parent studies did not 
include the measure of anxiety (State and Trait Anxiety Inventory). This prompted a 
preliminary examination of multicollinearity between anxiety and other psychological 
measures. Correlations revealed that the CES-D was highly correlated with state anxiety 
(r=0.67, p=0.00) and trait anxiety (r=0.75, p=0.00) suggesting collinearity between 
depression and anxiety. Since the CES-D was given in both parent studies, it was used in 
the analyses. The STAI was not included in the analyses.  
Reliability analysis 
 The third step in data preparation was to examine the internal consistency 
reliability of each standardized questionnaire per group and in the combined sample using 
Cronbach’s alpha coefficients. Single item variables were not included in this analysis. In 
addition, the Symptom Experience Report (SER) was excluded from the analysis since 
the responses were dichotomous yes/no options that determined the number of symptoms 
present. Since this questionnaire is considered a checklist for cancer related symptoms, 
the items are not linked and would not produce a meaningful internal consistency 
reliability statistic (Nunnally & Bernstein, 1994). For questionnaires that produce a total 
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score (CES-D and CARS), the individual items were entered (Nunnally & Bernstein, 
1994). For questionnaires that produced sub-scales (PSQI, IES), the subscales rather than 
items were entered into the analysis. The rationale for this method is that the subscales 
which include the items provide a more accurate measure of internal consistency 
(Nunnally & Bernstein, 1994). In addition, for the PSQI, the sleep disturbance subscale 
items were evaluated to determine if the subscale was internally consistent.  
 Cronbach’s alpha coefficients greater than 0.80 were desired for this analysis 
since the study used established measures (Polit & Hungler, 1999). Results found in 
Table 3 showed an acceptable range of alpha coefficients per group and in the combined 
sample establishing adequate internal consistency reliability of measures except for the 
Pittsburgh Sleep Quality Index and CES-D (BCS only). This suggests that most measures 
captured the critical attributes of the variable of interest in each group and in the 
combined sample (Polit & Hungler, 1999).
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Table 3 
Estimates of Internal Consistency Using Cronbach’s Alpha Coefficients 
  Alpha Coefficient   
Scale  # 
items 
BCS 
(n=246) 
WWBC 
(n=246) 
 
Combined 
Sample 
(n=492) 
Caucasian  
(n=342) 
Minority 
(n=150) 
Pittsburgh Global 
Sleep Score 1 
7 0.73 0.73 0.74 0.74 0.73 
Pittsburgh Sleep 
Disturbances Items 
9 0.73 0.78 0.76 0.68 0.80 
Physical functioning 
(PF-10) 
11 0.93 0.93 0.93 -- -- 
Concerns about 
recurrence 2 
4 0.89 n/a n/a -- -- 
CES-D 3 20 0.76 0.83 0.79 -- -- 
Impact of Events 
Scale 4 
20 0.92 0.94 0.94 -- -- 
 1=evaluated the 7 component scores, 2=only given in BCS, 3=Center for Epidemiologic 
Studies on Depression Scale, 4=evaluated revised subscales of intrusion and avoidance 
 
 In sum, a secondary dataset was created from two parent datasets matching BCS 
and WWBC women within +/- 5 years of age. A sample of 492 women was established 
providing ample sample size to address the four research questions. Missing data were 
evaluated and resolved. Finally, standardized measures used in the secondary dataset 
were evaluated for internal consistency reliability. All multi-item measures had adequate 
reliability to proceed with data analysis. 
Data analysis  
 Data consisted of a single set of observations. Data analyses were performed 
using SPSS (v. 15.0, SPSS Inc., Chicago, IL). The following address the statistical 
analysis performed for each research question. Demographic variables were evaluated 
using descriptive and frequency statistics. Groups were compared using independent t-
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tests and chi-square. If group differences arose, variables were controlled for during 
analysis. 
Research question 1 
To answer research question 1, “Is there a difference in the prevalence of sleep-
wake disturbances between women surviving breast cancer compared to age-matched 
WWBC?” the following analysis was performed. First, a new variable was created using 
the PSQI global scores. Based on the established cut-off scores in the literature, women 
who scored >5 were coded as “yes” for sleep-wake disturbances. All others were coded 
as “no”. The two groups were compared using a logistic regression to control for group 
differences in demographic characteristics. Percentages of women who scored above the 
cut-off (e.g., poor sleepers) were reported. 
Research question 2 
 To address research question 2, “Is there a difference in the severity of sleep-wake 
disturbances between BCS compared to age-matched WWBC?” analysis of covariance 
was used to control for variables such as group differences in demographic 
characteristics. Pittsburg Sleep Quality Index global scores and seven PSQI component 
scores were compared between groups using ANCOVA.  
Research question 3 
 To address research question 3, “What are the physiological, psychological, and 
environmental predictors of poor sleep (defined by PSQI score >5) in BCS and age-
matched WWBC?” logistic regression was performed using three steps. The first step 
evaluated the relationship among all of the person characteristics, physiological, 
psychological, and environmental predictors (independent variables). Each predictor was 
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placed into categorical groups based on the frequencies for each individual predictor. To 
start, if the number of subjects scoring above and below the established cut-off (if 
applicable) was near the median, the cut-off was used to split the group into two 
categories (e.g., depressed or non-depressed). If there was no established cut-off, or the 
outcome was skewed, the median was used to split the predictor by a standard increment 
of the measure to obtain adequate representation per group (either median split or 
quartiles).  
The second step included chi-square analyses between each predictor and the 
outcome of sleep to determine how each predictor related to the occurrence of poor sleep. 
Relationships were considered significant with a p< 0.25 and were entered into the final 
regression model (Hosmer & Lemeshow, 2000). 
 In the third step, all significant predictors were entered into the final logistic 
regression model. Significant relationships between sleep and the individual predictors 
were based on odds ratios with a 95% confidence interval outside of 1.0 and p<0.05 
(Tabachnick & Fidell, 2001). 
Research question 4 
 To address research question 4, “What are the physiological, psychological, and 
environmental predictors of sleep-wake disturbances (using PSQI global scores) of BCS 
and age-matched WWBC?” multiple regression was performed using three steps.  
 For the first step, the investigator compared relationships between each individual 
variable (predictor) and PSQI global sleep scores. When variables were continuous, 
Pearson correlations were used to determine relationships between the dependent and 
independent variable (e.g., sleep and depression). Pearson correlations greater than r=|0.2| 
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with p<0.25 were considered significant and these variables were placed into the final 
regression equation (Hosmer & Lemeshow, 2000). If the independent variable was 
categorical, a t-test was used to determine if the variable was related to PSQI global sleep 
scores (Munro & Page, 1993; Tabachnick & Fidell, 2001). Since this was an exploratory 
regression to find initial information on predictors of sleep, the r-value and p-value’s set 
for inclusion were broad in order to allow for a comprehensive set of predictors to be 
evaluated. 
 In the second step, all of the significant predictors from step two were entered into 
the final regression model. Model fit for the regression was verified. In addition, the p-
value of each independent variable was evaluated to determine if that individual predictor 
significantly improved the fit of the model. If the fit was worse when that variable was 
omitted from the model (the p-value would be low), therefore, the variable had a 
significant impact on the model (Munro & Page, 1993). Significant relationships between 
sleep and the individual predictors were based on p<0.05. 
 In sum, sleep-wake disturbances in BCS are a significant problem. Few studies 
have evaluated a comprehensive set of predictors of sleep-wake disturbances in BCS. 
Therefore, this analysis evaluated a comprehensive set of predictors to determine the 
occurrence and severity of sleep-wake disturbances in BCS compared to WWBC. 
Finding unique predictors in BCS provides further evidence and support for a unique 
theoretical model. 
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CHAPTER FOUR 
 
RESULTS 
 The purpose of this research study was to gain further knowledge regarding the 
incidence, prevalence, and predictive factors of sleep-wake disturbances in BCS 
compared to age-matched WWBC. This chapter contains data analyzed from quantitative 
questionnaires from two quality of life studies that included BCS and WWBC. The 
chapter focuses on the statistical analyses including sample characteristics and the goals 
of the secondary data analyses which were to determine; (1) if the presence of sleep-wake 
disturbances was different between BCS and age-matched WWBC, (2) if the severity of 
sleep-wake disturbances was different between BCS and age-matched WWBC, (3) the 
physiological, psychological, and/or environmental predictors of sleep-wake disturbances 
in BCS and age-matched WWBC, and (4) if these predictors were different between BCS 
and age-matched WWBC.  
Statistical Analysis 
Sample characteristics of BCS and WWBC 
 In the BCS group, disease and treatment variables are reported using descriptive 
and frequency statistics in Table 4. Demographic variables including age, education, 
race/ethnicity, marital status, income, work status, number of non-cancer health co-
morbidities, and menopausal status were evaluated using descriptive and frequency 
statistics for BCS and WWBC as listed in Table 5. Both groups had a mean age of 48 
years and at least a college education. The groups were mainly Caucasian, non-Hispanic 
or Latino, and married or partnered. Over 70% had incomes over $50,000 with a majority 
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working full or part-time. Both groups reported at least 2-3 co-morbid conditions 
(excluding cancer diagnosis in BCS) and more BCS reported to be post-menopausal 
compared to WWBC.  
 Group differences were evaluated using independent t-tests and chi-square tests 
for independence. Results showed no significant differences on age using an independent 
t-test presented in Table 4. Using chi-squared tests of independence, no differences were 
found between BCS and WWBC on education (high school or less, college, graduate), 
ethnicity (Hispanic/ Latino or not) marital status, (partnered, no partner), income (below 
$50,000 and above $50,000), work status (full-part time, no work), number of non-cancer 
health co-morbidities (yes or no). Group differences were noted for race (Caucasian, 
black, other) and menopausal status (pre-menopausal, post-menopausal) and will be 
addressed in each research question below. 
 
   89 
Table 4      Demographic and Health Characteristics of Subjects 
  BCS 
(n=246) 
WWBC 
(n=246) 
 
 M (SD) M (SD) p 
Age (years) 48.21 (8.50) 48.26 (10.39) 0.94 
 % (n) % (n) p 
Level of education 
    High school or less 
    College or trade 
    Graduate  
 
26 (64) 
59 (144) 
15 (38) 
 
23 (57) 
54 (132) 
23 (57) 
 
0.09 
Race 
    Caucasian 
    African American 
    Asian 
    American Indian 
    Other 
 
76 (186) 
20 (50) 
1 (2) 
 
3 (8) 
 
63 (156) 
33 (81) 
1 (2) 
1 (2) 
2 (5) 
 
0.01* 
Ethnicity 
    Hispanic or Latino 
    Not Hispanic or Latino 
 
2 (4) 
98 (242) 
 
4 (9) 
96 (237) 
 
0.13 
Marital status 
    Married/living with partner 
    Divorced or widowed 
    Single 
    Other  
 
73 (180) 
12 (29) 
14 (35) 
1 (2) 
 
62 (153) 
13 (31) 
24 (58) 
1 (4) 
 
0.07 
Household income in $ (SES) 
    <15,000 per year 
    15,001-30,000 per year 
    30,001-50,000 per year 
    50,001-100,000 per year 
    > 100,001 per year 
 
11 (27) 
13 (32) 
15 (37) 
36 (89) 
25 (61) 
 
15 (37) 
8 (20) 
22 (54) 
32 (79) 
23 (56) 
 
0.18 
Employment status 
    Working full  
   Working part-time 
    Unemployed 
    Retired 
    Student 
 
52 (128) 
21 (52) 
18 (44) 
9 (21) 
0 (1) 
 
48 (118) 
16 (39) 
23 (57) 
10 (25) 
3 (7) 
 
0.07 
Reporting non-BC co-morbidities 
    None 
    1 condition  
    2-3 conditions 
    4 or greater conditions 
 
3 (7) 
43 (106) 
35 (87) 
19 (46) 
 
7 (18) 
44 (108) 
33 (80) 
16 (40) 
 
0.09 
Menopausal status 
    Pre-menopausal 
      Post-menopausal 
 
30 (73) 
70 (173) 
 
47 (115) 
53 (131) 
 
0.00* 
 *p<0.01. All values based on valid percentages and rounded to nearest tenth  
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 Characteristics of the type of breast cancer and treatment were evaluated and can 
be found in Table 5. Results showed a majority of BCS received surgery (100%) and 
chemotherapy (89%) for non-metastatic disease (stage I-III), and had not taken hormone 
modulators such as tamoxifen (67%). The mean time since diagnosis was 5.62 years. 
Table 5 
Breast Cancer Disease and Treatment Information 
 BCS (n=246) 
M(SD) 
Time since diagnosis (years) 5.62 (2.03) 
 % (n) 
    Surgery 
    Lumpectomy 
    Mastectomy 
 
42 (102) 
59 (144) 
    Chemotherapy 
    Received some chemotherapy 
    Received no chemotherapy 
 
89 (211) 
11 (35) 
Use of hormone modulator 
    Never taken  
    Current use 
    Past use     
 
67 (331) 
9 (43) 
24 (118) 
 
Results of standardized questionnaires 
 The following are the results of the standardized questionnaires for each group 
(see Table 6). Significant differences between BCS and WWBC scores were noted for the 
PSQI, CES-D, and IES. BCS mean scores were higher for the global sleep score and 
CES-D compared to WWBC. However, WWBC had higher impact of a life event noted 
by higher mean scores for the IES. 
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Table 6 
Results of Standardized Questionnaires 
 Results 
Scale  BCS 
M(SD) 
 
WWBC 
M(SD) 
p 
PSQI Global Score 7.31 (3.80) 5.80 (3.45) 0.00* 
Physical functioning (PF-10) 2.55 (0.51) 2.62 (0.49) 0.15 
Symptom experience report1 3.74 (3.62) ---- ---- 
Concerns about recurrence1 12.15 (5.51) ---- ---- 
Center for Epidemiological Studies 
Depression Scale (CES-D) 
11.53 (9.60) 9.00 (9.20) 0.00* 
Impact of Events Scale (IES) 1.50 (1.23) 1.86 (1.36) 0.00* 
 *p<0.05, 1=BCS measure only 
 
Research question 1 
 To answer research question 1, “Is there a difference in the prevalence of sleep-
wake disturbances between women surviving breast cancer compared to age-matched 
WWBC?” a chi-square test of independence and a logistic regression were performed. 
 The first step in this analysis was to create a new variable based on the established 
global sleep score (>5) from the Pittsburgh Sleep Quality Index (PSQI) to distinguish 
between good and poor sleepers. In the second step, chi-square tests of independence 
were performed to determine if good/poor sleep was significantly related to race and 
menopausal status to determine if these needed to be controlled in the analysis. Results 
showed that both race (χ2(1)=8.63, p=0.02) and menopausal status (χ2(1)=28.17, p=0.00) 
were significantly related to sleep. Thus, these were controlled in the analysis for 
research question 1. 
 A crosstabulation analysis was performed to determine the number of poor 
sleepers per group, race and menopausal status. Results showed that 65% of BCS and 
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55% of WWBC scored at or above the cut-off for poor sleep quality. In addition, more 
Caucasian (χ2(1)=4.45, p=0.04) and postmenopausal (χ2(1)=16.96, p=0.00) women 
scored above the cut-off for poor sleep quality.  
 Since there were differences in sample characteristics related to the variable of 
good vs. poor sleep, a logistic regression was performed to control for sample 
characteristics. No prior assumptions were examined regarding distributions since 
normality, linearity, and equal variance are not factors for this type of regression 
(Tabachnick & Fidell, 2001). The independent variables were coded in dichotomous 
categories to facilitate interpretation of results (Tabachnick & Fidell, 2001). The binary 
logistic regression revealed that BCS were 1.96 times more likely to be poor sleepers 
compared to WWBC (p<0.01) when controlling for race and menopausal status (listed in 
Table 7).  
Table 7 
Logistic Regression to Determine Prevalence of Poor Sleep by Group  
95% CI  B p OR 
Upper Lower 
Group 1 0.67 0.00* 1.96 1.31 2.92 
Race 2 0.50 0.03* 1.65 1.06 2.56 
Menopausal status 3 0.60 0.00* 1.82 1.23 2.71 
χ
2
 38.06     
df 3     
p 0.00     
1=BCS vs. WWBC, 2=Caucasian vs. all other, 3=Premenopausal vs. postmenopausal, 
overall model statistic χ2(3)=38.06, p<0.00) 
 
 
 In summary, the prevalence of sleep-wake disturbances was significantly different 
between BCS and WWBC. BCS were more likely to experience sleep-wake disturbances 
compared to WWBC. 
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Research question 2 
 To answer research question 2, “Is there a difference in the severity of sleep-wake 
disturbances between women surviving breast cancer compared to age-matched 
WWBC?” the continuous dependent variables of sleep (PSQI global score and 7 
component scores) were evaluated between groups using an independent t-test. Since 
there were group differences in race and menopausal status, analysis of covariance 
(ANCOVA) models were performed to control for these variables. The ANCOVA was 
selected over multivariate analysis of covariance (MANCOVA) since group, race and 
menopausal status were not significantly different for each dependent variable of sleep, 
thus, each variable of sleep was evaluated separately to control only for those 
relationships that were significant. In addition, since this question focused on differences 
in severity between BCS and WWBC when controlling for race and menopausal status, 
only group differences in sleep are presented below. These variables (race and 
menopausal status) will be addressed in research questions 3 and 4 when evaluating 
possible predictors of sleep-wake disturbances. 
 First, covariates were determined through examination of means using 
independent t-tests of sleep variables for group, race, and menopausal status. Results 
showed significant group differences (BCS vs. WWBC) for global sleep scores, sleep 
quality, sleep latency, sleep disturbance, and daytime dysfunction (p<0.01). Results also 
showed significant group differences by race for global sleep scores, sleep quality, sleep 
latency, sleep duration, sleep disturbance, and sleep efficiency (p<0.01) and by 
menopausal status for global sleep score, sleep quality, sleep latency, sleep disturbance, 
sleep medication, and sleep efficiency (p<0.01).  
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 Based on the above findings, the ANCOVA analysis was performed. However, 
for daytime dysfunction, a one-way analysis of variance (ANOVA) was performed since 
this variable was not significantly different by race or menopausal status. Group was the 
independent variable in the ANCOVA (BCS, WWBC) and race and/or menopausal status 
were considered covariates. Prior to the analysis, assumptions were evaluated and 
showed no violations of normality of sampling distributions, linearity, homogeneity of 
variance, homogeneity of regression, and reliability of covariates. 
 After adjusting for covariates as appropriate, group differences in the severity of 
sleep disturbances were noted (Table 8). BCS had higher PSQI scores indicating poorer 
sleep quality and higher sleep disturbances. ANCOVA results showed that compared to 
WWBC, BCS had significantly poorer overall sleep quality (global scores) with subscales 
indicating poorer sleep quality, longer sleep latency, less sleep duration, greater sleep 
disturbance, and more daytime dysfunction when controlling for race and/or menopausal 
status. Use of sleep medications and sleep efficiency were not significantly different 
between groups.  
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Table 8 
ANCOVA Tests for Differences in PSQI Sleep Scores for BCS and WWBC 
 Adjusted Adjusted  
Variable Mean 
(BCS) 
Mean 
(WWBC) 
F p 
Global sleep score1 7.26 5.85 17.87 0.00* 
Sleep quality1 1.20 0.85 25.24 0.00* 
Sleep latency1 1.39 1.00 14.69 0.00* 
Sleep duration2 0.98 0.84 4.65 0.03* 
Sleep disturbance1 1.50 1.31 11.21 0.00* 
Sleep medication3 0.65 0.61 0.15 0.70 
Daytime dysfunction4 0.96 0.70 16.9 0.00* 
Sleep efficiency1 0.59 0.57 0.09 0.77 
1=controlling for race and menopausal status, 2=controlling for race only, 3=controlling 
for menopausal status only, 4=no control variables-ANOVA performed 
 
 Since global scores and 5 of 7 component scores (six sleep variables) were 
significantly different between BCS and WWBC after adjusting covariates, correlations 
were performed to determine if there were significant relationships between global sleep 
quality scores and corresponding component scores. The purpose was to determine if the 
component scores should be considered as separate measures of sleep for research 
questions 3 and 4. As expected, Pearson correlations showed strong-to-moderate 
relationships between global sleep scores and the seven subscales presented in Table 9. 
Based on these relationships, only the global sleep score from the PSQI was evaluated for 
research questions 3 and 4 since this variable incorporates all of the subscales and best 
represents the overall measurement of sleep. 
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Table 9 
Pearson Correlation Coefficients for Global Sleep Quality Score with 7 Component 
Scores 
  Global sleep score  
Global sleep quality  0.77* 
Sleep latency 0.75* 
Sleep duration 0.59* 
Sleep disturbance 0.63* 
Sleep medications 0.56* 
Daytime dysfunction 0.50* 
Sleep efficiency 0.63* 
 *p<0.01 
 
 In summary, chi-square tests indicated the need to control race and menopausal 
status in some analyses. Sleep variables were evaluated using ANCOVA and ANOVA 
statistics and revealed that the sleep-wake disturbances were more severe in BCS 
compared to WWBC. Sleep quality, latency, duration, disturbance, and daytime 
dysfunction, when controlling for race and/or menopausal status, were significantly 
worse in BCS than WWBC. Finally, Pearson correlations showed that global sleep scores 
had strong to moderate relationships with all component scores which indicated that only 
one sleep variable (e.g., global scores) could be used for subsequent analyses. In the next 
section, a set of comprehensive variables from the Elam Psychobiological Model are 
examined to determine which variable(s) contribute(s) to the occurrence of sleep-wake 
disturbances in BCS and WWBC. 
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Research question 3 
 To answer research question 3, “What are the physiological, psychological, and 
environmental predictors of poor sleep (defined by PSQI scores >5) in BCS and age-
matched WWBC?” logistic regression was performed using three steps; (1) creation of 
dummy variables, (2) determine relationship between sleep and predictors, and (3) 
perform models of logistic regression. For logistic regression, there are no statistical 
assumptions such as normality, linearity, and equal variance within groups prior to 
analysis (Tabachnick & Fidell, 2001) eliminating several steps compared to multiple 
regression. 
Step 1: Creation of dummy variables 
 To begin, the first step in establishing a list of predictors for sleep-wake 
disturbances was to determine the relationships among the person characteristics, 
physiological, psychological, and environmental predictors (independent variables) to be 
examined from the Elam Psychobiological Model. This was accomplished by creating 
new variables based on the number of members scoring above and below the standard 
cut-off scores (if applicable) for each questionnaire as shown in Table 10. If the cut-off 
score was near the median, the cutoff score was used to split the group into two 
categories (e.g., depressed or non-depressed). If there was no established cut-off, the 
median was used to split the predictor by a standard increment of measure to obtain 
adequate representation per group (either median split or quartiles) (Field, 2005; 
Tabachnick & Fidell, 2001).  
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Table 10 
Recoding of Variables for Logistic Regression 
Variable  Measure Range of 
scores 
Variable split n 
Sleep  PSQI 0-21 Based on cut-off for measure 
Group 1=good sleepers < 5     
Group 2=poor sleepers >5       
 
222 
270 
Group n/a n/a Group 1=WWBC 
Group 2=BCS 
246 
246 
Age PCQ 28-80 Based on median split 
Group 1=27-48 yrs 
Group 2=49-80 yrs 
 
255 
237 
Education PCQ n/a Based on level of education 
Group 1=high school or less 
Group 2=college education 
Group 3=graduate education 
 
121 
276 
95 
Race PCQ n/a Based on race category  
Group 1=Caucasian 
Group 2=Minority 
 
342 
150 
SES status 
 
Income 
PCQ n/a Based on income categories  
Group 1=>$50,001 or more  
Group 2=<$50,000 per year or 
less 
 
 
285 
207 
Work status 
 
 n/a Based on employment status 
Group 1=Works full- or part- 
time 
Group 2=Does not work 
 
337 
155 
Menopausal 
status 
MGHQ n/a Based on last menstrual period  
Group 1=Premenopausal  
(period within 12 months) 
Group 2=Post menopausal 
(no period within past 12 
months) 
 
204 
 
288 
Co-morbidities MHQ  n/a Based on presence co-
morbidities 
Group 1=0-1 
Group 2- Two or more 
 
214 
253 
Type of cancer 
treatment 
MRAF 1 n/a Based on medical records 
Group 1=Chemotherapy only 
Group 2=Surgery only 
Group 3=Chemotherapy plus 
surgery 
 
 
 
0 
35 
211 
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Variable  Measure Range of 
scores 
Variable split n 
Long-term side 
effects 
SER1 0-12 Based on quartiles of # of 
symptoms 
Group 1=0-2 symptoms 
Group 2=3-5 symptoms 
Group 3=6-12 symptoms  
 
 
 
 
121 
59 
66 
Post-menopausal 
symptoms 
 (Hot flashes) 
MGHQ n/a Based on presence of hot 
flashes 
Group 1=No hot flashes 
Group 2=Yes hot flashes 
 
247 
245 
Physical 
functioning 
PF-10 10-30 Mean split 
Group 1=10-25 
Group 2=25-30 
 
336 
156 
Cancer related 
distress 
CARS 1 4-24 
(part 1) 
 
Based on quartile 25, 50, 75 to 
get equal distribution 
Group 1=Scores 4-8 
Group 2=Scores 9-11 
Group 3=Scores 12-24 
 
 
81 
43 
122 
Depression CES-D 0-60 Based on cut-off score for 
depressive symptoms > 16 
Group 1=no depressive 
symptoms 
Group 2=depressive symptoms 
 
 
382 
110 
Distress r/t life 
event 
IES Mean of 2 
subscales 
(intrusion, 
avoidance) 
 Based on the quartiles  
Group 1=0 
Group 2=1-2 
Group 3=3-above 
 
28 
390 
74 
Bed partner PSQI 
item 19 
n/a Based on companion in bed  
Group 1=No companion 
Group 2=Yes companion 
 
180 
312 
Children in the 
home 
MGHQ  Based on presence of children 
in the home  
Group 1=No children 
Group 2=Yes children in the 
home 
 
 
230 
262 
1=variables only for BCS, n/a=not applicable 
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Evaluation of variables 
 Crosstabulation analyses revealed adequacy of the observed and expected 
frequencies for each of the independent variables after the creation of the dummy 
variable. This step established that no table had more than 20% of cells with frequencies 
less than 5, thus, the goodness-of-fit criteria for the model were not violated (Tabachnick 
& Fidell, 2001).  
Step 2: Relationships among sleep and predictors 
The second step of research question 3 evaluated chi-square tests of independence 
between individual independent variables and the outcome of sleep. Relationships with a 
p< 0.25 were considered significant and entered into the final regression model (Hosmer 
& Lemeshow, 2000). This liberal p-value was to allow for marginal relationships in the 
exploratory evaluation of variables. Results of the chi-square tests showed significant 
bivariate associations between sleep and group, race, menopausal status, presence of at 
least one co-morbid condition, presence of hot flashes, level of physical functioning, 
long-term effects of cancer, depressive symptoms, impact of a life event, presence of a 
bed partner, and having children in the home (Table 11). 
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Table 11 
Associations Between Dichotomous PSQI Global Score and Predictors 
 df χ2 p 
Group  1 20.52 0.00* 
Age 1 1.16 0.28 
Education 2 1.42 0.49 
Race 1 4.45 0.04* 
Income 1 13.74 0.06* 
Work status 1 0.00 0.99 
Menopausal status 1 16.96 0.00* 
Co-morbidities 1 5.57 0.02* 
Type of cancer treatment1 
Treatment type 
Hormone use 
 
1 
1 
 
0.21 
0.01 
 
0.66 
0.92 
Hot flashes 1 36.24 0.00* 
Physical functioning 1 39.76 0.00* 
Long term effects of cancer1 2 9.79 0.01* 
Concerns about recurrence (cancer 
related distress)1 
2 1.59 0.45 
Depressive symptoms 1 39.55 0.00* 
Impact of life event 2 8.56 0.01* 
Having a bed partner 1 2.79 0.10* 
Children in the home 1 1.55 0.21* 
 1=BCS only, *p<0.25 
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 The percentage of poor sleepers and mean global scores for each of the significant 
predictors included in the logistic regression are shown below (see Table 12).  
Table 12 
Percentages of Poor Sleep and Mean Global Scores for Significant Variables 
Variable  Poor sleep2 
(%) 
Global score 
M(SD) 
Group BCS  
WWBC 
65 
55 
7.31 (3.8) 
5.80 (3.5) 
Race 
 
Caucasian 
Minority 
52 
63 
6.18 (3.5) 
7.40 (4.0) 
Income 
 
$50,000 or less 
$50,001 or more 
64 
49 
7.40 (4.0) 
5.95 (3.0) 
Menopausal status 
 
Pre-menopausal 
Post-menopausal 
44 
63 
5.62 (3.3) 
7.22 (3.8) 
Co-morbidities 
 
0-1 
2 or more 
46 
65 
5.59 (3.2) 
7.56 (3.5) 
Hot flashes 
 
Yes 
No  
67 
43 
7.59 (3.4) 
5.53 (3.7) 
Physical functioning 
 
10-25 
26-30 
76 
45 
8.31 (3.8) 
5.74 (3.4) 
Long term effects of cancer1  0-2 symptoms 
3-5 
6-12  
56 
64 
76 
6.39 (3.4) 
7.34 (3.8) 
8.98 (3.9) 
Depressive symptoms Yes 
No 
85 
46 
9.40(3.9) 
5.94 (3.9) 
Impact of life event 0 score 
1-2 
3-above 
36 
53 
73 
5.21 (3.4) 
6.28 (3.5) 
8.46 (4.5) 
Having a bed partner Yes 
No 
52 
61 
6.16 (3.4) 
7.24 (3.1) 
Children in the home Yes 
No 
52 
59 
6.24 (3.5) 
6.92 (3.3) 
1=BCS only, 2=PSQI global scores >5 
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Step 3: Models of logistic regression 
 Step three evaluated all above variables that had significant associations (p<0.25) 
with sleep in a logistic regression model. Of the three possible types of logistic regression 
(direct, sequential, stepwise), direct entry was performed so that all slated variables were 
evaluated simultaneously. This method was preferable since there were no initial 
hypotheses about importance or order of independent variables (Tabachnick & Fidell, 
2001). All variables entered were dichotomous or categorical with no more than 3 
categories present for one variable. The categories were coded as 0 for the reference 
group and 1 as the response group for the comparison. Results are evaluated in terms of 
(1) multicollinearity among variables, (2) test of overall model, (3) test of individual 
predictors, and (4) interpretation of residuals.  
Multicollinearity 
 Although not an assumption of logistic regression, multicollinearity can have an 
impact on logistic regression posing a problem with biasing effect among variables 
(Field, 2005). For logistic regression, collinearity diagnostics were performed by 
evaluating tolerance and variance inflation factor values (VIF) using linear regression 
statistics in SPSS (Field, 2005). Results found in Table 13 suggests that there were no 
issues with collinearity between sleep and predictor variables since tolerance levels were 
greater than 0.10 and VIF values were less than 10 (Field, 2005). Additional collinearity 
diagnostics supported these findings through examination of eigenvalues of scaled, 
uncentered cross-products, condition indexes, and variance proportions for each 
predictor. Eigenvalues and condition indexes were consistent, meaning that regression 
parameters would not be affected by changes in the predictors (Field, 2005). Lastly, the 
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variance proportions, or the variance of each regression coefficient, did not show any 
predictors with high proportions and small eigenvalues, thus supporting the lack of 
collinearity (Field, 2005). 
Table 13 
Test for Multicollinearity of Logistic Regression Variables  
 Variable Tolerance VIF 
Group 0.64 1.56 
Race 0.71 1.41 
Income 0.63 1.60 
Menopausal status 0.74 1.35 
Co-morbid conditions 0.81 1.24 
Hot flasher 0.88 1.13 
Physical functioning  0.64 1.56 
Symptoms after cancer 0.78 1.28 
Depressive symptoms 0.77 1.30 
Impact of life event 0.83 1.21 
Presence of bed partner 0.67 1.49 
Children living at home 0.84 1.19 
 
 
 Three separate logistic regression models were performed. The first model 
included all predictors to determine which variables accurately predicted the presence of 
poor sleep. The second model was specific for BCS and included type of cancer 
treatment and long-term effects of cancer treatment. The third model was specific for 
WWBC only. The logistic regression output provided inferential tests of the overall 
models and goodness-of-fit tests of individual variables (Tabachnick & Fidell, 2001).  
Test of overall models 
 Goodness-of-fit tests indicated the statistical models fit the set of observations 
(Field, 2005). Goodness-of-fit is based on how accurately the data predicted by the 
regression model is related to the collected data (Field, 2005). If there is no difference 
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between a model with the slated variables and a model without the variables, then those 
variables entered have no influence on the dependent variable (Field, 2005). This is an 
important assumption of regression and must be established before further evaluation of 
the findings can be completed. 
 Results showed adequate goodness-of-fit for model 1 (B=0.20, SE=0.09, p<0.05), 
model 2 (B=0.62, SE=0.13, p<0.00), and model 3 (B=.21, SE=0.13, p<0.05) (Field, 2005; 
Tabachnick & Fidell, 2001) based on the significant values of the constants. This 
suggested that the addition of one or more of the independent variables into the 
regression would significantly change the predictive power (Field, 2005). In addition, 
chi-square tests of goodness-of -fit (Hosmer-Lemeshow) were not significant for model 1 
(χ2(8)=10.17, p=0.25), model 2 (χ2(8)=5.20, p=0.74), or model 3 (χ2(8)=11.07, p=0.20) 
which is optimal (Field, 2005). The output also showed that the residual chi-square 
statistic for model 1 (χ2(12)=122.35, p<0.00), model 2 (χ2(12)=62.24, p<0.00), and 
model 3 (χ2(11)=61.73, p<0.00) suggested that the coefficients for the independent 
variables when not included in the model were significantly different from 0 which meant 
the addition of one more of the variables affects the predictive power of the model (Field, 
2005). Based on the goodness-of-fit, the analysis proceeded to test the significance of 
each independent variable.  
Test of individual variables for models 
 Significant relationships between sleep and the individual predictors were based 
on odds ratios with a 95% confidence interval outside of 1.0 and p<0.05 (Tabachnick & 
Fidell, 2001). Results showed that when group was entered into the logistic regression 
model, significant predictors of poor sleep included being a BCS having hot flashes, poor 
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physical functioning, depressive symptoms, and impact of a life event (see Table 14). 
Results were evaluated on the basis that odds ratios greater than 1 related to increased 
odds for poor sleep. After adjusting for all other predictors, the poorest sleepers were 
women who were BCS (OR=1.70), had hot flashes (OR=2.32), had poor physical 
functioning (OR=3.02), had depressive symptoms (OR=4.17), or had moderate 
(OR=2.92) or high levels of distress related to a life event (OR=4.09 to 5.70). 
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Table 14 
Summary of Model 1: Logistic Regression Analysis Predicting Poor Sleep 
95% CI Predictor β SE Odds 
ratio 
Wald 
statistic 
Lower Upper 
Group (BCS) 1 0.53 0.22 1.70 5.69* 1.10 2.63 
Race (Minority)2 0.46 0.27 0.05 0.03 0.61 1.78 
Post-menopausal3  0.70 0.27 0.05 2.07 0.63 1.81 
Low income4 0.20 0.23 1.21 0.69 0.77 1.92 
2 or more co-
morbidities5 
0.43 0.47 1.54 0.83 0.61 3.91 
Hot flashes6 0.84 0.22 2.32 14.57* 1.50 3.58 
Poor physical 
functioning7 
1.10 0.26 3.02 17.20* 1.51 5.08 
High depressive 
symptoms8 
1.43 0.33 4.67 19.34* 2.21 7.87 
High impact of life 
event 
Mean score=1-2 
Mean score=3 or more 
 
 
1.07 
1.44 
 
 
0.45 
0.53 
 
 
2.92 
4.2 
 
 
5.70* 
4.09* 
 
 
1.21 
1.48 
 
 
7.04 
11.99 
Having bed partner9 0.01 0.27 1.01 0.00 0.60 1.70 
Children in the home10 -0.02 0.23 0.98 0.01 0.63 1.53 
*p<0.05, 1=Referent WWBC, 2=Referent Caucasian, 3=Referent pre-menopausal, 
4=Referent income over $50,000/yr, 5=Referent 1 comorbidity or less, 6=no hot flashes, 
7=PF-10 scores 26-30, 8=Referent no depressive symptoms, 9=Referent no bed partner, 
10=Referent no children in the home 
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 The second regression model evaluated the predictors of poor sleep in BCS (see 
Table 15).  
Table 15 
Summary of Model 2: Logistic Regression Predicting Poor Sleep for BCS  
95% CI 
 
Predictor β SE OR Wald 
statistic 
Lower Upper 
Race (Minority) 1 1.14 0.47 3.14 5.99* 1.26 7.83 
Post-menopausal2  0.52 0.35 1.67 2.15 0.84 3.33 
Low income3 0.40 0.39 1.49 1.08 0.70 3.20 
2 or more co-morbidities4 -0.09 0.83 0.91 0.01 0.18 4.69 
Hot flashes5 0.99 0.33 2.68 9.10* 1.41 5.00 
Poor physical functioning6 0.94 0.42 2.57 4.99* 1.12 5.86 
Effects of cancer** 
# symptoms=0-5 
# symptoms=6 and above  
 
0.36 
0.26 
 
0.43 
0.47 
 
1.43 
1.30 
 
 
0.69 
0.32 
 
0.61 
0.52 
 
3.33 
3.26 
High depressive 
symptoms7 
1.53 0.45 4.62 11.50* 1.91 11.78 
High impact of a life event 
Mean score=1-2 
Mean score=3 or more 
 
 
0.72 
1.02 
 
 
0.70 
0.90 
 
 
2.06 
2.77 
 
 
1.06 
1.29 
 
 
0.52 
0.48 
 
 
8.11 
16.10 
Having bed partner8 0.45 0.41 1.56 1.21 0.70 3.46 
Children in the home9 -0.53 0.32 0.59 2.71 0.32 1.11 
*p<0.05, **BCS only, 1=Referent Caucasian, 2=Referent pre-menopausal, 3=Referent 
income over $50,000/yr, 4=Referent 1 comorbidity or less, 5=no hot flashes, 6=PF-10 
scores 26-30, 7=Referent no depressive symptoms, 8=Referent no bed partner, 
9=Referent no children in the home 
 
 After adjusting for all other predictors, the poorest sleepers among BCS were 
minorities (OR=3.14), those with hot flashes (OR=2.68), those with poor physical 
   109 
functioning (OR=2.57), and those with depressive symptoms (OR=4.62) (p<0.05). Long 
term cancer treatment effects (symptoms) did not significantly add to the model. 
 The third regression model evaluated the predictors of poor sleep only in the 
WWBC. Results shown in Table 16 suggest WWBC with hot flashes, low levels of 
physical functioning, or high depressive symptoms significantly predicted poor sleep. 
Significant relationships between sleep and the individual variables were based on odds 
ratios with a 95% confidence interval outside of 1.0 and p<0.05 (Tabachnick & Fidell, 
2001). 
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Table 16 
Summary of Model 3: Logistic Regression Predicting Poor Sleep for WWBC 
95% CI 
 
Predictor β SE OR Wald 
statistic 
Lower Upper 
Race (Minority)1 -0.70 0.39 0.50 3.26 0.23 1.06 
Post-menopausal2  -0.24 0.35 0.79 0.46 0.40 1.57 
Low income3 -0.32 0.41 0.72 0.63 0.33 1.61 
2 or more co-
morbidities4 
0.82 0.64 2.27 1.66 0.65 7.89 
Hot flashes5 0.78 0.32 2.18* 5.89 1.16 4.09 
Poor physical 
functioning6 
1.29 0.38 3.61* 11.55 1.72 7.58 
High depressive 
symptoms7 
1.93 0.52 6.92* 13.69 2.48 19.28 
High impact of a life 
event 
Mean score=1-2 
Mean score=3 or 
more 
 
 
1.01 
1.38 
 
 
0.65 
0.73 
 
 
2.74 
3.99 
 
 
2.42 
3.52 
 
 
 
0.77 
0.93 
 
 
9.74 
3.68 
Having bed partner8 -0.34 0.39 0.71 0.76 0.33 1.53 
Children in the 
home9 
0.61 0.35 1.85 3.04 0.93 3.68 
 *p<0.05, 1=Referent Caucasian, 2=Referent pre-menopausal, 3=Referent income over 
$50,000/yr, 4=Referent 1 comorbidity or less, 5=no hot flashes, 6=PF-10 scores 26-30, 
7=Referent no depressive symptoms, 8=Referent no bed partner, 9=Referent no children 
in the home 
 
 After adjusting for all other variables the poorest sleepers in the WWBC group 
were women with hot flashes (OR=2.18), poor physical functioning (OR=2.18), and 
depressive symptoms (OR=6.92) (p<0.05) 
Interpretation of residuals 
 Finally, the residuals of the logistic regression models were examined through 
frequency analysis for possible cases that poorly fit each model and cases that exert 
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unwarranted influence on the model through Studentized residuals, standardized residuals 
and deviance statistics (Field, 2005; Tabachnick & Fidell, 2001). Cook’s distance, 
DFBeta, and leverage statistics revealed no values greater than 1 for any of the models 
suggesting no influential cases were found that negatively impacted the regression model 
(Field, 2005; Tabachnick & Fidell, 2001). 
 In summary, research question 3 evaluated predictors of poor sleep. Chi-square 
tests of independence showed variables significantly associated with a dichotomous sleep 
variable, which were then entered into the logistic regression models. Results showed that 
BCS status, hot flashes, physical functioning, depressive symptoms, and distress related 
to a life event predicted the presence of poor sleep when group was included in the 
regression. Specific predictors for BCS included minority status, hot flashes, physical 
functioning, and depressive symptoms. Specific predictors for WWBC included hot 
flashes, poor physical functioning, and high depressive symptoms. 
Research question 4 
 To answer research question 4, “What are the physiological, psychological, and 
environmental predictors of the severity of sleep-wake disturbances (defined by PSQI 
global scores) of BCS and age-matched WWBC?”, multiple regression was performed 
using three steps: (1) evaluate relationships between sleep and predictors; (2) examine 
multiple regression assumptions; and (3) perform multiple regression.  
Step 1: Relationships between independent variables and sleep 
 Relationships between global sleep scores and continuous variables were 
evaluated using Pearson correlations shown in Table 17. Relationships were considered 
significant if the p-value was p<0.25. These variables were then entered into the 
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regression model. As with research question 3, using a liberal p-value allowed for 
marginal relationships to be evaluated. Results showed that number of non-cancer related 
co-morbid conditions was correlated with global sleep scores. In addition, sleep was 
highly correlated with physical functioning, depressive symptoms, long-term effects of 
cancer, and impact of a life event. There was a weak correlation with concerns about 
recurrence and no correlation with age. 
Table 17 
Pearson Correlations Between Sleep and Continuous Predictors 
 Age Co-morbid PF-10 CES-D CARS1 SER total1 IES 
PSQI    r 0.02 0.35* -0.37* 0.47* 0.15* 0.37* 0.27* 
1=BCS only, 2=non-cancer related co-morbid conditions, *p<0.25 
 
 The remaining categorical predictors were evaluated using t-tests and analysis of 
variance (ANOVA) with post-hoc Scheffe tests (Field, 2005; Tabachnick & Fidell, 2001). 
Results showed that BCS had higher global sleep scores compared to WWBC t=4.62 
(490), p<0.01). For education, women with a high school education or less did not have 
significantly higher global sleep scores compared to women with college or grad school 
education F(2, 489)=1.44. In terms of race, minority women had higher sleep scores  
t=-.43 (490), p<0.01 compared to Caucasian women. Socioeconomic predictors included 
income and work status. Those with higher income had lower global scores compared to 
lower income women F(7, 484)=19.00, p<0.01). Women working full or part-time did 
not have significantly different sleep scores compared to unemployed women t=0.02 
(490). For menopausal status, women who were post-menopausal had significantly higher 
global sleep scores t=-4.81 (490), p<0.01 than pre-menopausal women. Women with hot 
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flashes had significantly higher sleep scores t=-6.42 (490), p<0.01. Lastly, women with a 
bed partner t=3.13 (490), p<0.01 and women with children living in the home t=-2.05 
(490), p<0.05 had significantly higher sleep scores. Variables were entered into the 
multiple regression model with a significance level of p<0.25. 
 Breast cancer-specific categorical predictors included type of treatment and use of 
hormone modulators. Results showed that those not currently taking a hormone 
modulator had significantly higher global sleep scores F(2, 244)=5.37, p<0.01 than 
women who were taking hormone modulators. Type of cancer treatment was not related 
to high sleep scores (t=1.88 (244), p=0.70) and not included in the regression model. 
 Relationships among the predictors are shown in Table 18. Bivariate correlations 
(Pearson r) were performed for continuous variables and dichotomous variables (Field, 
2005). Chi-square tests of independence were performed for the categorical predictors 
with three or more groups. 
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Table 18 
Test of Association Among Predictors  
  2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
1. Age S S S S NS .02 .31* .50* .07 -.33* .02 .03 -.24* -.04 S S 
2. Race  S S S S S S S S NS S NS S S S S 
3. Education 
  NS S NS NS S NS S NS NS S S S NS S 
4. Work status 
   NS NS NS NS NS NS NS NS NS NS NS S S 
5. Income 
    S S S S S S NS S NS S S S 
6. Sleep      .33* S .31* S -.38* .37* .47* .15* .27* S S 
7. Co-morbid       .27* .08 NS -.51* .25* .36* .01 .14* NS S 
8. Menopausal 
       .33* S -.27* .13* .15* -.02 .03 S S 
9. Hot flashes 
        NS -.10 .12 .13* .10 .02 S NS 
10. BCS tx1 
         NS NS NS NS NS S S 
11. PF-10 
          -.38* -.40* .04 -.15* S S 
12. Cancer s/e1 
           .38* .22* .43* NS NS 
13. CES-D  
            .31* .48* NS S 
14. CARS1 
             .51* NS NS 
15. IES                NS S 
16. Children 
               NS 
17. Bed partner 
                
*p<0.05, 1=BCS only, numeric values represent Pearson correlation coefficient, NS=non-significant chi-square, S=significant chi-
square p<0.05
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Step 2: Testing assumptions 
  The assumptions of regression were evaluated before and after the analysis to 
establish that assumptions of; (1) non-collinearity, (2) absence of outliers, (3) normality, 
linearity, homoscedasticity of residuals, and (4) independence of errors were not violated. 
The third and forth assumptions evaluated residuals of the regression models. This 
evaluation was performed after the regression models were completed and is discussed in 
step three. 
 First, multicollinearity and singularity were examined prior to the multiple 
regression analysis by group. This step established a list of predictors that had strong 
relationships and determined if two measures were evaluating the same predictor 
variable. Strong collinearity between measures creates a situation where variables are 
competing for variance which would make it difficult to determine the importance of the 
competing predictors (Field, 2005). Although results showed significant relationships 
among certain predictors for both BCS and WWBC, for the test of collinearity, Pearson 
correlation coefficients > |0.70| were considered significant and would require 
examination (Tabachnick & Fidell, 2001). Based on that cut-off, no questionnaires were 
considered to have collinearity that would pose a problem for the multiple regression 
models (Table 19).  
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Table 19 
Pearson Correlations for Test of Multicollinearity 
 1 2 3 4 5 6 
1 PSQI global --- -0.36* 0.48* n/a n/a 0.32* 
2 PF-10 -0.37* --- -0.44* n/a n/a -0.11 
3 CES-D 0.44* -0.36* --- n/a n/a 0.50* 
4 CARS1 0.15* 0.04 0.31* --- n/a n/a 
5 SER1 0.37* -0.38* 0.38* 0.21* --- n/a 
6 IES  0.30* -0.23* 0.52* 0.53* 0.43* --- 
Above diagonal =WWBC, below diagonal=BCS, *p < 0.05, * p<0.01, n/a=not 
administered. 
 
 In addition, frequency distribution curves were examined to determine the 
presence of outliers for categorical and continuous independent and dependent variables. 
This was a necessary step to determine if transformations were necessary prior to the 
multiple regression equations in question 4. Based on histogram frequency distributions, 
three scales were identified to have minor skewness due to outliers, including the IES 
(positively skewed), CES-D (positively skewed), and PF-10 (negatively skewed). All 
other items or scores showed normal distribution curves. For these measures, it was 
determined that the amount of skewness (based on the equation [skewness/standard 
error]) was less than 2.5 for the IES, CES-D, and PF-10 which is considered allowable, 
thus, scores were not transformed prior to the regression (Morgan, 2007). 
 The first step of the regression analysis evaluated significant relationships among 
the continuous and categorical person characteristics, physiological, psychological, and 
environmental predictors. Multiple regression can be used with predictor variables that 
are correlated with each other and with the dependent variable to a degree (Tabachnick & 
Fidell, 2001). However, according to Tabachnick and Fidell, it is optimal to have 
   117 
independent predictor variables that are strongly correlated with the dependent variable 
but not strongly related to the other independent variables being evaluated. Having 
uncorrelated independent variables makes the interpretation of each variable contribution 
to the regression model more clear-cut (Field, 2005; Tabachnick & Fidell, 2001). 
Relationships were examined using collinearity diagnostics as part of regression models. 
Step 3: Regression models of predictors and sleep 
 The standard model approach of multiple regression was selected for the final 
analysis. Although this method is considered atheoretical because it enters all 
independent variables at once with no hypotheses, the use of the standard approach 
answered the exploratory question of relationships among variables and how they impact 
the severity of sleep (Tabachnick & Fidell, 2001). Relationships were considered 
significant for all comparisons if p<0.05.  
 Three separate multiple regression models were performed based on significant 
relationships with global sleep scores. The first model evaluated all predictors applicable 
to both BCS and WWBC after preliminary examination of variables. The second model 
evaluated predictors and cancer specific variables for BCS only. The third model 
evaluated predictors for WWBC only. 
Variables included in each model 
 To begin, significant predictor variables related to sleep (p<0.25) were entered 
into all three multiple regression models; group (model 1 only), race, income, 
menopausal status, number of co-morbid conditions, hot flashes, mean PF-10 scores, 
mean CES-D scores, mean scores from IES using two-subscales, presence of a bed 
partner, and presence of children in the home. For specific predictors of sleep-wake 
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disturbances in BCS, multiple regression procedures were repeated for the second model 
and included cancer specific variables. To determine specific predictors of sleep-wake 
disturbances in WWBC, multiple regression procedures were repeated for the third 
model. Field (2005) recommends entering all predictors in a standard entry regression 
then selecting the significant predictors and running a second regression model for 
interpretation. Based on the findings of the preliminary multiple regression model, a 
second and final model was executed and included only significant predictors of group, 
number of co-morbid conditions, hot flashes, PF-10 scores, CES-D scores, and IES 
scores. The final regression models showed the following significant relationships and 
are presented in Table 20.  
 Model 1 overall fit. 
 The interpretation of results included overall model summary and model 
parameters. First, the model summary for the final regression model showed that the 
predictors in the model accounted for 34% of the variability in the outcome (R=0.58, 
R2=0.34). The ANOVA results showed that the model with the predictors was 
significantly different from the model without the predictors (F=40.69 (6, 485), p<0.00), 
thus, the model is a better predictor of poor sleep when the variables are included (Field, 
2005) establishing goodness-of-fit.  
 Model 1 parameters. 
 The model parameters evaluated the unique contribution of each predictor 
variable in the regression model. Significant predictors of sleep included group, number 
of co-morbid conditions, hot flashes, level of physical functioning, depressive symptoms, 
and impact of a life event. The β values show that higher global sleep scores were 
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reported by women in the breast cancer group, women with a higher number of co-
morbidities, those having hot flashes, lower levels of physical functioning, higher 
depressive symptoms, or reporting a greater impact of a life event (see Table 20).  
 The standardized beta value (β) provides information about the number of 
standard deviations that would change global sleep scores as a result of one standard 
deviation change of the predictor variable (Field, 2005). To interpret findings, the 
standard deviation of the global sleep score was multiplied by the final beta value for 
each significant predictor (β*SD). The result was interpreted as the number of points that 
the global sleep score would be projected to increase with one standard deviation change 
of the predictor. This would only be a valid if the other predictors were held constant 
(Field, 2005). This method of interpretation was used for all three models.  
 For model 1, the interpretation of results was based on the standard deviation of 
global sleep scores for the entire sample (SD=3.71). For group (β=0.11), since it is a 
dichotomous variable with no standard deviation, it was a challenge to interpret the 
unique contribution of the outcome. Therefore, it was projected that as more women were 
classified as BCS, global sleep scores would be projected to increase by 0.41 points 
(0.11*3.71). In terms of co-morbid conditions, as the number of co-morbid conditions 
increases by one standard deviation (SD=1.76), global sleep scores would increase by 
0.11 standard deviations (β=0.11). Therefore, for each additional 1.76 co-morbid 
conditions, global sleep scores are projected to increase by 0.41 points (0.11*3.71). For 
every 1.57 increase in the number of hot flashes, global sleep scores are projected to 
increase by 0.74 points (0.20*3.71). For every 0.50 decrease in physical functioning 
scores, global sleep scores will increase by 0.63 points (-0.17*3.71). For every 9.48 
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increase in CES-D scores (depressive symptoms), global sleep scores are projected to 
increase by 1.04 points (0.28*3.71). 
 Model 2 overall fit. 
 The summary for the second regression model showed that the variables in the 
final BCS model accounted for 33% of the variability in the outcome (R=0.57, R2=0.33). 
The ANOVA results showed that the final BCS model with the predictors was 
significantly different from the model without the predictors (F=29.53 (4,241 ), p<0.00), 
thus, the model is a better predictor of poor sleep when the variables are included (Field, 
2005) establishing goodness-of-fit. 
 Model 2 parameters. 
 Significant predictors of sleep specific for BCS included number of co-morbid 
conditions, hot flashes, side effects of cancer, and depressive symptoms. The β-values 
showed that BCS with higher number of co-morbidities, reporting hot flashes, more long-
term side effects from cancer, and higher depressive symptoms reported higher global 
sleep scores (poorer sleep quality and higher sleep disturbances) (see Table 20).  
 For model 2, the interpretation of results was based on the standard deviation of 
BCS global sleep scores (SD=3.80) multiplied by the final beta value for each significant 
predictor. For every 1.49 increase in the number of hot flashes, global sleep scores are 
projected to increase by 0.95 points (0.25*3.80). For every 3.62 increase in long-term 
effect of cancer, global sleep scores would increase 1.06 points (0.28*3.80). For every 
9.60 increase in CES-D scores, global sleep scores are projected to increase by 0.68 
points (0.18*3.80). 
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 Model 3 overall fit. 
 The interpretation of results included overall model summary and model 
parameters. First, the model summary for the final regression model showed that the 
predictors in the WWBC model accounted for 31% of the variability in the outcome 
(R=0.54, R2=0.29). The ANOVA results showed that the model with the predictors was 
significantly different from the model without the predictors (F=19.92 (10, 235), p<0.00), 
thus, the model is a better predictor of poor sleep when the variables are included (Field, 
2005) establishing goodness-of-fit.  
 Model 3 parameters. 
 Significant predictors of sleep specific for WWBC included hot flashes, level of 
physical functioning, depressive symptoms, and impact of a life event. The B-values 
showed that WWBC reporting hot flashes, lower levels of physical functioning, higher 
depressive symptoms, or with distress related to a life event predicted higher global sleep 
scores (see Table 20). 
 For model 3, the interpretation of results was based on the standard deviation of 
WWBC global sleep scores (SD=3.45) multiplied by the final beta value for each 
significant predictor. For every 1.27 increase in the number of hot flashes, global sleep 
scores are projected to increase by 0.48 points (0.14*3.45). For every 0.49 decrease in 
physical functioning scores, global sleep scores would increase 0.59 points (0.17*3.45). 
For every 9.20 increase in CES-D scores, global sleep scores are projected to increase by 
1.07 points (0.31*3.45). For every 1.39 increase in the impact of life event score, global 
sleep scores would increase 0.48 (0.14*3.45) 
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Table 20 
Summary of Multiple Regression Results 
 PSQI Global 
Both groups 
combined 
PSQI Global 
BCS only 
PSQI Global 
WWBC only 
 Prelim Final Prelim Final Prelim Final 
Variable β β β β β β 
Group                       0.11* 0.11* ---- ---- ---- ---- 
Race 0.03 ---- 0.11 ---- -0.09 ---- 
Income -0.01 ---- -0.06 ---- -0.05 ---- 
Menopausal status 0.01 ---- 0.04 ---- -0.01 ---- 
Co-morbid 
conditions 
0.11* 0.11* 0.13* 0.20* 0.05 ---- 
Hormone modulator1 n/a n/a -0.07 ---- ---- ---- 
Hot flashes 0.20* 0.20* 0.24* 0.25* 0.14* 0.14* 
Physical functioning -0.16* -0.17* -0.10 ---- -0.15* -0.17* 
Long term effects of 
cancer1 
---- ---- 0.14* 0.28* ---- ---- 
Concerns about 
recurrence1 
---- ---- 0.10 ---- ---- ---- 
Depressive 
symptoms 
0.28* 0.28* 0.23* 0.18* 0.20* 0.31* 
Impact of life event 0.11* 0.11* -0.02 ---- 0.14* 0.14* 
Having bed partner -0.10 ---- 0.01 ---- -0.06 ---- 
Children in the home -0.02 ---- -0.01 ---- 0.00 ---- 
Model      
F    
 
22.19 
 
22.05 
 
10.46 
 
29.53 
 
10.74 
 
19.92 
p 0.00 0.00 0.00 0.00 0.00 0.00 
R2 0.34 0.34 0.37 0.33 0.31 0.29 
  *p<0.05, 1=BCS only 
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Checking of assumptions for all models 
 The last step of the data interpretation evaluated the assumptions of the regression 
equations. First, based on the tolerance and VIF scores, no variables approached 0 or 
exceeded 10 which would indicate concern of multicollinearity (Field, 2005; Tabachnick 
& Fidell, 2001). In addition, standardized and studentized residuals (differences between 
predicted and obtained dependent values) for linearity, homoscedasticity, normality, and 
independence of error were evaluated. Normality of the residuals for global sleep scores 
showed histograms with normal curve distribution verifying that the errors of the 
predictor were normally distributed around the predicted dependent scores (Tabachnick 
& Fidell, 2001). Linearity was verified by examination of plotted residuals on a scatter 
plot diagram that was rectangular in shape with a positive direction. Homoscedasticity 
was verified that standard deviations of errors for the predicted values were nearly the 
same for global sleep scores (Tabachnick & Fidell, 2001) through visual interpretation of 
the scatter plot that showed a band of residuals with equal width. Lastly, independence of 
error showed a Durbin-Watson statistic of 1.83 for model 1, 1.76 for model 2 and 1.93 for 
model 3. The three results were near 2.0 which is optimal to show that the errors of 
prediction are independent (Field, 2005; Tabachnick & Fidell, 2001). Based on this 
examination of residuals, no assumptions of the multiple regression models were 
violated.  
 In sum, the multiple regression models showed significant predictors of sleep 
quality when group was included in the equation were group membership, hot flashes, 
physical functioning, depressive symptoms, and impact of a life event. However, level of 
physical functioning and impact of a life event were non-significant in the BCS only 
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model. Significant predictors for WWBC include hot flashes, level of physical 
functioning, depressive symptoms, and impact of a life event. Finally, the assumptions of 
the regression models showed no violations that would negatively impact the results. 
Summary 
 The purpose of this chapter was to determine the difference in prevalence, 
severity, and predictors of sleep-wake disturbances between BCS and WWBC. Four 
research questions were addressed and showed that BCS had greater prevalence and more 
severe sleep-wake disturbances compared to age-matched WWBC. Predictors of sleep-
wake disturbances were evaluated between BCS and WWBC with cancer related 
variables of long-term effects of cancer also predicting sleep problems specific to BCS. 
Findings showed some similarity in predictors for prevalence and severity between BCS 
and WWBC (hot flashes, depression) but differences were also noted. The final chapter 
will discuss these findings in relation to current literature regarding sleep-wake 
disturbances in BCS. In addition, strengths and limitations will be addressed as well as 
implications for nursing practice and recommendations for future research.  
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CHAPTER FIVE 
DISCUSSION 
 
 The purpose of this research study was to gain further knowledge regarding the 
prevalence, severity, and predictive factors of sleep-wake disturbances in BCS compared 
to age-matched WWBC. The secondary analysis of quantitative questionnaires provided 
data to answer the following research questions: 
1. Is there a difference in the prevalence of sleep-wake disturbances between BCS 
and age-matched WWBC? 
2. Is there a difference in the severity of sleep-wake disturbances (defined by PSQI 
global scores and 7 component scores) between BCS and age-matched WWBC? 
3. What are the physiological, psychological, and environmental predictors of poor 
sleep (defined by PSQI scores >5) in BCS and age-matched WWBC? 
4. What are the physiological, psychological, and environmental predictors of the 
severity of sleep-wake disturbances (defined by PSQI global scores) of BCS and 
age-matched WWBC? 
 The purpose of this chapter is to; (1) present research findings and relate findings 
to existing sleep-wake disturbance literature, (2) present strengths and limitations of the 
study, (3) describe implications for practice, and (4) provide recommendations for future 
research. A brief summary will close the chapter. 
Research Findings 
 In this section, findings are discussed and related to results from current literature 
regarding sleep-wake disturbances in BCS. The following results are discussed below: (1) 
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sample characteristics, (2) prevalence and severity of sleep-wake disturbances, (3) 
predictors of prevalence and severity, and (4) revisions for the Elam Psychobiological 
Model. Recalling the gaps in the BCS sleep literature, the discussion will show how this 
study built upon previous findings by (a) including a comparison group, (b) using 
standardized conceptual and operational definitions of sleep-wake disturbances, (c) 
validating that sleep is a primary problem in long-term survivors, and (d) supporting the 
need for a unique psychobiological model of sleep-wake disturbances for BCS.  
Sample characteristics 
 This section focuses on differences in sample characteristics including possible 
explanations for the findings. Differences in sample characteristics can be common when 
groups are not matched on certain criteria such as race, education, and menopausal status. 
Only one previous study of sleep disturbances compared BCS to a group of WWBC. In 
that study, no group differences were found after matching on age, race, and menopausal 
status (Carpenter et al., 2004). The current study found significant differences in race and 
menopausal status after matching for age. For race, even with the inclusion of a large set 
of minority women from the one parent study (AA study), there were more Caucasian 
women (73%) than minorities (27%) in this sample. These findings were reflected in 
previous BCS studies where racial categories ranged from 73-95% Caucasian (Carpenter 
& Andrykowski, 1999; Carpenter et al., 2004; Ganz, 2005). One possible explanation is 
the lack of long-term African American survivors (Northouse et al., 1999). African 
Americans with breast cancer tend to have more aggressive disease with lower survival 
rates (Jemal et al., 2008) reducing the number of subjects available for recruitment. In 
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addition, the geographical location or setting of the study could have reduced the number 
of minority women who were available for study recruitment.  
 As expected, this study contained more BCS (70%) than WWBC (53%). who 
were post-menopausal. When menopausal status was reported in BCS samples, previous 
findings were similar (Carpenter & Andrykowski, 1998, 1999; Carpenter et al., 2004). 
Even though this study included younger survivors that theoretically should be pre-
menopausal, early menopause is a potential result of cancer treatment. BCS tend to 
experience premature ovarian failure, or early onset of menopause, as a result of breast 
cancer treatment such as surgery, chemotherapy, and use of hormone modulators 
(Crandall et al., 2004). This early menopause experience in younger BCS could be the 
reason for this large percentage of post-menopausal women. 
Prevalence and severity of sleep-wake disturbances 
 The current study showed that sleep disturbances were more common and more 
severe among BCS (65%) than age-matched WWBC (55%). The prevalence rate for the 
problem in this study was within the range of prior BCS studies that included questions 
about sleep. These studies found that 19-90% of BCS complained of poor sleep or 
insomnia compared to 67% of WWBC (Carpenter & Andrykowski, 1999; Carpenter et 
al., 2004; Crandall et al., 2004; Davidson et al., 2002; Fortner et al., 2002; Northouse et 
al., 1999; Savard et al., 2001; Schultz et al., 2005). Three of these BCS studies had lower 
prevalence rates (19-49%), possibly because samples and sleep measures differed from 
this current study (Davidson et al., 2002; Northouse et al., 1999; Savard et al., 2001). 
These studies did not include comparison groups. One study of 98 African American 
BCS who were 4 years post-diagnosis used a single-item sleep question embedded in an 
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assessment of quality of life (Northouse et al., 1999). The other two studies used 
standardized questionnaires for specific types of sleep disturbance. Davidson et al. 
evaluated symptoms of insomnia, leg restlessness, and excessive sleepiness in a sample 
of 302 BCS (racial characteristics not reported) who were 2-5 years post-diagnosis. 
Savard et al. (2001) used a standardized measure of insomnia to evaluate sleep in 300 
BCS who were 4 years post-diagnosis (racial characteristics not reported). 
 Three studies reported similar prevalence rates (61-67%) to the current study. 
These three prior studies used various measures and samples of BCS (Carpenter & 
Andrykowski, 1999; Crandall et al., 2004; Fortner et al., 2002). Fortner et al. (2002) used 
the PSQI to evaluate sleep in 72 breast cancer subjects that were mainly Caucasian and a 
mix of pre-treatment, in-treatment, and post-treatment women. This study included a 
comparison group but found no group differences in sleep variables. Carpenter & 
Andrykowski (1998) used a single-item question embedded in an assessment of 
menopausal symptoms in 114 BCS who were mainly Caucasian and a mean of 3 years 
post-diagnosis. Crandall et al. (2004) also used a single-item question for sleep in relation 
to menopausal symptoms in 476 BCS who were mostly Caucasian and 2-10 years post-
diagnosis. It is interesting that these studies produced similar prevalence rates, despite 
differences in sample sizes, sample characteristics, and measures.  
 The studies with higher prevalence rates of 73% (Carpenter et al., 2004) and 90% 
(Schultz et al., 2005) used the PSQI or a single-item assessment of sleep in BCS. 
Carpenter & Andrykowski (1998) used the PSQI to evaluate sleep in 15 BCS who were 
mostly Caucasian and mean of 5 years post-diagnosis. This was the only study to report 
prevalence of sleep disturbances in a comparison group of WWBC. Schultz et al. (2005) 
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assessed sleep in relation to menopausal symptoms in 287 BCS. These women were 
mostly Caucasian and a mean of 16 years post-diagnosis. Although it was a study of 
menopausal symptoms, menopausal status of the women was not reported. Even with a 
varied sample size, both studies found higher prevalence of sleep complaints compared to 
this study. 
 In the current study, the severity of sleep disturbances (M=7.26 for BCS) was 
within the range reported in prior BCS studies (range=6.8-7.3) (Berger et al., 2003; 
Carpenter & Andrykowski, 1998; Carpenter et al., 2004; Fortner et al., 2002). The current 
study also found that WWBC had less severe sleep disturbances compared to two other 
comparison groups that reported means of 6.7 (n=50) (Fortner et al., 2002) and 6.9 
(n=15) (Carpenter et al., 2004). In these studies and the current study, BCS had more 
severe sleep disturbances compared to WWBC.  
 In addition, this study suggests that long-term BCS are at greater risk of poor 
sleep and report more severe sleep disturbances compared to an age-matched group of 
WWBC. However, this comparison is only based on one previous study with a small 
sample size of women with hot flashes (Carpenter et al. 2004). The current study also 
showed that prevalence and severity of sleep disturbances in BCS is problematic in long-
term survivors. In studies with similar findings, BCS were more than 2 years post-
diagnosis suggesting that sleep disturbances are a problem for BCS after treatment and 
well into survivorship. These findings suggest that BCS are experiencing underlying 
problems that contribute to poor sleep and severe sleep disturbances such as depressive 
symptoms and menopausal symptoms such as hot flashes (discussed in detail below).  
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Predictors of poor sleep and severity of sleep disturbances 
 Current literature describing sleep disturbances in BCS used a variety of 
theoretical models to guide their research (e.g., Spielman’s Three Factor Model) (Savard 
et al., 2001). Reflecting back to Chapter Two, no one model included physiological, 
psychological, and environmental predictors specific to BCS. This study was the first to 
examine a more comprehensive set of predictors specific to BCS. Findings from this 
study showed that predictors of poor sleep and severity of sleep disturbances in BCS 
were slightly different compared to age-matched WWBC. This information supports the 
need for a unique model with specific predictors that describe sleep-wake disturbances in 
BCS. 
Revised models 
 Based on the significant predictors of poor sleep and sleep disturbances in BCS, 
the Elam Psychobiological Model could be revised as follows. Study findings suggested 
that minority BCS, with hot flashes, low levels of physical functioning, or depressive 
symptoms are at greatest risk for poor sleep. In addition, BCS with poor sleep tend to 
have more co-morbid conditions, hot flashes, long-term effects of cancer, or depressive 
symptoms. The revised models (see Figures 2 and 3) are based on these findings. Two 
models were produced to distinguish between prevalence and severity since predictors 
were slightly different for these two outcomes. Figure 2 targets predictors of poor sleep 
whereas Figure 3 targets severity of sleep disturbances. Both figures support the need for 
a psychobiological model since significant predictors were found in the person, 
physiological, and psychological categories. The models also provide visual depiction of 
which categories contain the majority of significant predictors. Figure 2 shows that 
   131 
predictors are dispersed evenly for poor sleep whereas Figure 3 has more physiological 
predictors for severity. Even though the non-significant variables were tabled in the 
visual depiction of the revised models, it may be premature to remove the non-significant 
variables such as age, socioeconomic status, and sleep environment as these factors have 
been shown to contribute to poor sleep in previous studies. Even though some factors 
were not supported by this study, future studies with different sample characteristics or 
that include sleep hygiene factors could produce a different view of the model. In 
addition, asking women to answer questions in the context of sleep disturbances could 
also produce different results. Therefore, it is recommended to maintain these as possible 
predictors until other samples of BCS can be compared to WWBC to determine if the 
current findings can be replicated.  
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Figure 2: Revised Elam Psychobiological Model Prevalence of Poor Sleep 
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Figure 3: Revised Elam Psychobiological Model of Severity of Sleep-Wake Disturbances 
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Kravitz et al., 2003; Morin, Stone, Trinkle, Mercer, & Remsberg, 1993; Owens & 
Matthews, 1998; Polo-Kantola & Erkkola, 2004; Purves et al., 2004; Roehrs & Roth, 
2004). Although this study found that being BCS and race were significant predictors of 
sleep disturbances, other variables were not significant. Each characteristic is discussed 
below.  
 As expected, having had breast cancer predicted both prevalence of poor sleep 
and severity of sleep disturbances. This supports a previous study that found BCS had 
poorer sleep and more severe sleep disturbances compared to WWBC (Carpenter et al., 
2004). However, that study was not examining predictors of sleep but rather group 
differences in PSQI sleep variables. No other studies were found that included a 
comparison group in predicting sleep disturbances. The current study provides new 
information that being classified as a BCS is a risk factor for poor sleep and more severe 
sleep disturbances compared to WWBC. 
 An unexpected finding from this study was that minority BCS were at higher risk 
for poor sleep. Only one prior study evaluated sleep in African American (AA) BCS. The 
study focused on quality of life outcomes but reported 49% of the AA women had sleep 
problems based on a single-item question (Northouse et al., 1999). However, no prior 
sleep studies in BCS looked at race as a predictor of sleep disturbances. The only 
comparable study that looked at risk factors did not report the racial characteristics of the 
sample (Savard et al., 2001). The current study provides important information that 
minority BCS could be considered at higher risk for sleep disturbances compared to both 
Caucasian BCS and WWBC.  
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 Interestingly, although previous studies found that age contributes to sleep 
disturbances in non-cancer populations (Morin et al., 1993; Shaver et al., 1991; Shaver & 
Giblin, 1989; Shaver & Zenk, 2000), age was not evaluated as a predictor of prevalence 
or severity of poor sleep for BCS or WWBC. The age range for BCS and WWBC in this 
study was 27-80 years of age. Based on prior studies, it was expected that younger BCS 
and WWBC might sleep better compared to older BCS and WWBC. For severity of sleep 
disturbances, age was not correlated with sleep scores for BCS or WWBC (r=0.02) and 
thus was not evaluated in the multiple regression. However, age was related to sleep as a 
dichotomous variable (good vs. poor). When evaluated with other variables, age did not 
predict prevalence of poor sleep. Non-significant findings suggest that poor sleep was 
problematic across ages in both BCS and WWBC. In addition, chronologic age of this 
sample is not consistent with menopausal status. Since the majority of BCS (young and 
old) were post-menopausal, it could be that menopausal status or the symptoms related to 
menopause are more important than chronologic age in this population. For example, 
sleep in a 30 year old post-menopausal BCS with hot flashes may not be the same as in a 
30 year old BCS who is still pre-menopausal. It may be important in future studies to 
match samples on menopausal status.  
 This study did not support previous findings that socioeconomic factors, 
education, or marital status influence sleep. One prior study found that missed work time 
(OR=14.1), unemployment (OR=3.8), university education (OR=4.0), and widowhood 
(OR=4.7) were risk factors for symptoms of insomnia in BCS (Savard et al., 2001). 
Although missed work time was not evaluated as a predictor in this study, employment 
status, income, educational status, and marital status were not factors in predicting poor 
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sleep or severity of sleep disturbances in BCS or WWBC. One possible explanation for 
the difference is that Savard et al. focused on symptoms of insomnia, a specific type of 
sleep-wake disturbance instead of a general complaint of sleep disturbances.  
 Finally, this study also showed that menopausal status was not a predictor of poor 
sleep or severe sleep-wake disturbances in multivariate analyses. This was an interesting 
finding since univariate analyses indicated that menopausal status was related to poor 
sleep and sleep disturbances independently. There were no prior studies that looked at 
menopausal status as a predictor of sleep disturbances. However, prior studies showed 
that post-menopausal BCS with menopausal symptoms report sleep disturbances 
(Carpenter & Andrykowski, 1999; Carpenter et al., 2004; Schultz et al., 2005). This 
suggests that menopausal symptoms, rather than menopausal status, may be the most 
important factors in predicting prevalence and severity of sleep disturbances.  
 Physiological predictors. 
 No previous studies in BCS have evaluated physiological predictors of poor sleep. 
This study provided new information regarding physiological predictors such as; (a) 
presence of co-morbid conditions, (b) hot flashes, (c) levels of physical functioning, (d) 
presence of long-term side effects of cancer (e.g., lymphedema), and (e) breast cancer 
treatments.  
 There are a number of co-morbid conditions and their respective treatments that 
can negatively impact sleep. No prior studies were found that examined non-cancer 
medical conditions in relation to sleep-wake disturbances in BCS. Also, a comparison of 
the type of co-morbid conditions in BCS compared to WWBC was not found. This study 
provided new information regarding these two gaps. First, the mean number of co-morbid 
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conditions was the same for BCS and WWBC (M=2.0). However, the three most 
common types of co-morbid were slightly different between BCS and WWBC. The three 
most common co-morbidities in BCS were; first psychological disorders (depression, 
anxiety) (29%), second ‘other’ diseases not specified (18%), and third circulatory 
disorders (hypertension, hyperlipidemia) (19%), whereas, WWBC were; first circulatory 
disorders (19%), second psychological disorders (18%), and third ‘other’ diseases not 
specified (14%). These findings show that although the number of co-morbid conditions 
was similar, the types of co-morbid conditions for BCS are slightly different than 
WWBC. This information is useful since both depression and circulatory conditions can 
impact sleep (Savard & Morin, 2001). 
 Second, findings showed that the presence of co-morbid conditions (yes/no) did 
not predict poor sleep. However, the number of co-morbid conditions predicted severity 
of sleep disturbances in BCS and WWBC. This suggests that greater numbers of co-
morbid conditions contribute to greater severity of sleep disturbances. This could mean 
that the side effects or treatments for these co-morbid conditions contribute to more sleep 
disturbances. Unfortunately, it is unknown whether the negative effects or treatments for 
these conditions were the underlying problem since this information was not available. 
Previous studies suggest that medications for co-morbid conditions, such as psychotropic 
and anti-hypertensive drugs, can negatively impact sleep (Bowman & Moshenin, 2003). 
It could be that side effects of these drugs were problematic for both BCS and WWBC in 
this study. Although findings were not unique to BCS, information that BCS with 
psychological and circulatory co-morbid conditions are at risk for greater severity of 
sleep disturbances is interesting. Future studies are needed to determine the impact of 
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these conditions (or the corresponding treatments) to the occurrence and severity of sleep 
disturbances in BCS. 
 It has been established that BCS who experience hot flashes report poor sleep 
(Carpenter et al., 2002; Savard, Davidson et al., 2004). Although this was not a unique 
factor for BCS, it has been reported that BCS tend to have more severe and distressing 
hot flashes when compared to WWBC (Carpenter, 2000; Carpenter et al., 1998). Hot 
flashes can be related to the use of hormone modulators which are used in breast cancer 
treatment. Interestingly, the majority of BCS in this study were not taking hormone 
modulators (67%). These findings suggest that BCS with poor sleep have hot flashes that 
were not caused by hormone modulators. This suggests that hot flashes are a 
physiological problem that should be examined when assessing complaints of sleep-wake 
disturbances in BCS. 
 The level of physical activity has been shown to decrease during breast cancer 
treatment contributing to sleep disturbances (Berger, 1998; Berger & Farr, 1999). It is 
unclear whether the decrease in activity during treatment continues into survivorship. It is 
unclear if physical functioning contributes to this lowered activity in BCS. Physical 
functioning, the ability to perform routine daily activities such as lifting groceries or 
climbing stairs, could be a factor in lowered activity. No prior studies have looked at the 
relationship between physical functioning and sleep disturbances in long-term BCS. For 
this study, low levels of physical functioning (limitations in daily function) predicted 
poor sleep in BCS and WWBC. However, physical functioning did not predict severity of 
sleep disturbances BCS. This suggests both BCS and WWBC with low levels of physical 
functioning are at risk of having sleep disturbances. This was an unexpected finding that 
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suggests low physical functioning or performance leads to prevalence of sleep 
disturbances. Although this finding was not specific to BCS, it suggests that future sleep 
research should examine physical functioning as a possible predictor of poor sleep. 
Determining the reason for the lowered functioning (e.g., arthritic pain) could provide 
information to facilitate effective interventions that improve sleep. 
 Although most side effects related to cancer treatment typically subside over time, 
some BCS experience residual effects that negatively impact quality of life (Dow et al., 
2004). Such side effects include lymphedema, peripheral neuropathy, and chronic breast 
pain (Dow et al., 1996; Ganz, 2005; Ganz et al., 2002). No prior studies have determined 
if long-term effects of cancer are related to sleep-wake disturbances. For this study, long-
term effects of cancer did not predict the presence of poor sleep. However, higher 
numbers of long-term effects predicted severity of sleep disturbances. This suggests that 
BCS with these symptoms are at greater risk for having more severe sleep disturbances. 
Although the symptom list was somewhat limited, this is an important finding since it 
identified a factor specific to BCS. In addition, this suggests that a complete assessment 
of cancer related symptoms is warranted since the reduction of such side effects can 
potentially reduce the severity of sleep disturbances. 
 Breast cancer treatment factors (chemotherapy, surgery, use of hormone 
modulators) did not predict poor sleep or severity of sleep disturbances. This an 
unexpected finding and contradicts previous findings from Savard et al. (2001) that found 
surgery (OR=5.2), chemotherapy (OR=4.3), and cancer stage (OR=0.46) predicted 
symptoms of insomnia. Radiation therapy was a constant for all subjects in that study and 
was not evaluated in the current study due to lack of data. Almost all subjects in the 
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current study received surgery and chemotherapy. This lack of sample variability could 
explain the lack of significant findings. In addition, the majority of BCS were not taking 
hormone modulators such as tamoxifen since they were more than 5 years post-diagnosis. 
Hormone modulators are designed to reduce estrogen in order to decrease breast cancer 
recurrence in hormone positive tumors. Decreased estrogen has been shown to increase 
sleep latency (Schiff et al., 1980). This suggests that the absence of estrogen itself can 
lead to sleep disturbances. However, it is unclear if other side effects of low estrogen, 
such as hot flashes, are the underlying reason for this disturbance.  
 Psychological predictors. 
 It has been well documented that psychological factors such as depression and 
anxiety are related to increased sleep disturbances (Anderson et al., 2003; Baker, 
Simpson, & Dawson, 1997; Carpenter et al., 2004; Miller, 2004; O'Connell, 2005; 
Okuyama et al., 2000; Roscoe et al., 2002). However, it is unclear if such disorders are 
predictors or consequences of sleep disturbances. For this study, these factors were 
considered predictors. Psychological factors evaluated included (a) cancer related distress 
(concerns of recurrence), (b) depression, and (c) distress related to a life event (non-
cancer). First, distress related to concerns of breast cancer recurrence are problematic 
during survivorship (Cappiello, Cunningham, Knobf, & Erdos, 2007; Ferrell et al., 1996; 
Vickberg, 2003). It was thought that this concern could be related to general distress 
which is a common factor in sleep disturbances (Deimling et al., 2002). However, no 
previous BCS studies have linked this concern to sleep-wake disturbances. Results 
showed that although concern of recurrence was related to global sleep scores, it did not 
predict poor sleep or severity of sleep disturbances in BCS. This was an unexpected 
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finding since scores indicated that the BCS had moderate concerns regarding the 
recurrence of cancer (M=12.15, SD=5.51). Scores were also highly related to sleep when 
evaluated as an independent predictor suggesting it was important to include in the 
regression. This suggests that although BCS had concerns of recurrence, this concern did 
not contribute to sleep-wake disturbances. It could be attributed to other psychological 
problems such as depressive symptoms discussed below. 
 Second, depression is highly related to sleep-wake disturbances both in cancer 
and non-cancer populations (Baker et al., 1997; Carpenter et al., 2004; Clark et al., 1995; 
Deimling et al., 2002; Fava, 2004; Kloss, Tweedy, & Gilrain, 2004; Thase, 2005). 
Descriptive studies show that BCS report moderate to high levels of depressive 
symptoms during survivorship (Couzi et al., 1995; Dow et al., 1996; Ganz, 2005; Ganz et 
al., 2002; Northouse et al., 1999). One prior study looked at the combined effect of sleep, 
fatigue, and depressive symptoms in BCS compared to WWBC. Results showed that 
depressive symptoms were related to poor sleep in BCS (Carpenter et al., 2004). 
However, this was a small sample where the WWBC were more depressed than the BCS 
and did not evaluate predictive factors of the sleep. No prior BCS studies have looked at 
depression as a predictor of sleep-wake disturbances. This study provided new 
information that moderate levels of depressive symptoms were related to poor sleep and 
severity of sleep disturbances in BCS. In addition, higher levels of depressive symptoms 
were associated with more severe sleep disturbances in BCS and WWBC. This suggests 
that long-term survivors have high depressive symptoms that should be addressed and 
which are an important factor in poor sleep and sleep disturbances. Future studies will 
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need to distinguish whether depression is better modeled as a predictor or an outcome of 
poor sleep. 
 Lastly, BCS can experience distress related to the diagnosis of cancer (Bleiker et 
al., 2000; Cappiello et al., 2007; Dow et al., 1996; Tatrow, Montgomery, Avellino, & 
Bovbjerg, 2004). Only one study found that BCS reported high levels of distress related 
to cancer and poor sleep (Dow et al., 1996). No other BCS study looked at distress as a 
predictor of poor sleep or severity of sleep disturbances. The current study provides new 
information that distress related to breast cancer was not associated with poor sleep or 
severity of sleep disturbances. However, distress related to life event in WWBC was 
related to prevalence and severity of sleep disturbances. This can be attributed to the 
higher distress ratings by WWBC and that they answered questions based on any 
stressful life event that was not likely to be a cancer diagnosis. These were unexpected 
since the breast cancer experience has been found to be distressing and the Impact of Life 
Events scores were moderate for both intrusion and avoidance. These scores were also 
related to sleep independently. Since depression symptoms were high in BCS, it could be 
that depression and not distress experienced by long-term survivors contributes to poor 
sleep and/or sleep disturbances. Unfortunately, it is unclear if distress related to a non-
cancer life event in BCS contributes to poor sleep and this requires further investigation. 
 Environmental predictors. 
 Sleep environment such as excessive light, noise, presence of a restless sleep 
partner, and child rearing have been shown to negatively impact sleep (Cheek et al., 
2004; Dogan et al., 2005; Gentili, Weiner, Kuchibhatil, & Edinger, 1997; Shinkoda et al., 
1998). Prior studies typically focus on inpatient hospital or nursing home settings where 
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excessive activity is routine (Dogan et al., 2005; Gentili et al., 1997). In addition, child 
rearing has been found to disrupt sleep due to frequent nighttime awakenings by a 
newborn or child (Miller, 2004). Although most BCS are at an age where children are no 
longer living at home, this study found a majority of women had children at home. 
Having a companion or bed partner with disrupted sleep can also contribute to the 
woman’s own disrupted sleep (Fry, 1987; Jefferson et al., 2005; O'Donnell, 2004). No 
prior BCS studies evaluated if such factors contribute to poor sleep and sleep 
disturbances. 
 Two environmental factors were evaluated in this study; (a) having a bed partner 
and (b) having children in the home. Results showed that having a bed partner and 
children living in the home (child rearing) were not associated with poor sleep or sleep 
disturbances in BCS or WWBC. However, environmental factors included in the analyses 
were limited to one item questions and did not include factors such as noise, light, and 
sleep habits of the bed partner (restless sleeper). Since these other factors were not 
assessed, it is unclear whether these factors contribute to poor sleep and sleep severity in 
BCS. It could also be that these factors are not problematic and do not need to be 
assessed in BCS with poor sleep. 
 In summary, findings from this study were compared to previous research 
regarding sleep disturbances in BCS. These comparisons showed similarities and 
differences adding new knowledge to the literature and conceptualization of sleep 
disturbances in BCS. Overall, the results from this study suggest that there are unique 
factors associated with sleep-wake disturbances in BCS.  
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Strengths and Limitations 
 Strengths of this study included; (1) lack of missing data, (2) use of a large sample 
size of long-term survivors, (3) use of a standardized measure of sleep, and (4) 
assessment of a comprehensive set of variables. Each strength is discussed below. 
 First, a major strength was the lack of missing data in the parent datasets which 
can be a pitfall when conducting a secondary data analysis (Polit & Hungler, 1999). 
Missing items were randomly dispersed and less than 1% of the entire combined dataset. 
This reduced the number of subjects and/or cases that required deletion from the 
analyses. 
 A second strength was the large sample of long-term survivors and age-matched 
WWBC from the parent datasets. The current study sample was 16 times larger than one 
previous study reviewed (Carpenter et al., 2004). Study findings validated that women 
with BCS have more severe sleep problems compared to age-matched WWBC. This 
supports the notion that having breast cancer alone puts women at risk for greater sleep 
problems. In addition, having a sample of long-term survivors validated that sleep is a 
problem in BCS more than 5 years from diagnosis suggesting that sleep problems may 
persist over time. 
 Third, the study used the Pittsburgh Sleep Quality Index (PSQI) which is a 
validated measure of sleep disturbances in BCS. This facilitated comparisons with 
previous data adding to existing knowledge regarding the reliability of the PSQI in other 
samples of BCS and WWBC. Using the PSQI also provided standardized terminology to 
describe poor sleep and sleep disturbances based on the established cut-off for global 
sleep scores. 
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 Finally, the comprehensive nature of the parent datasets provided a large number 
of variables to be evaluated. No previous studies have looked at a set of predictors in this 
manner. These results provided new information regarding predictors of sleep-wake 
disturbances specific to BCS. In addition, this study provided new knowledge that 
predictors of prevalence and severity are different for BCS suggesting the need for two 
separate conceptual models. This improves upon prior research in the conceptualization 
of sleep-wake disturbances in BCS.  
 There were also several limitations to this study. Limitations included; (1) 
matching only on age, (2) use of secondary data, (3) measurement issues and, (4) 
statistical issues. Each limitation is discussed below. 
 First, the sample was matched only on age and significant differences in race and 
menopausal status were found. In addition, because this was a convenience sample, the 
subjects may not have been representative of all BCS with and without sleep 
disturbances. Using a convenience sample has the potential for response bias by subjects 
that strive to convey either a positive or negative outlook of quality of life, thus, all 
responses are positive or negative (Polit & Hungler, 1999). For example, the sample 
included in this study could have been negative responders, thus, inflating the prevalence 
and severity of sleep disturbances for both BCS and WWBC. Because of this limitation, 
the results may not be representative of the greater population of BCS. However, this is 
unlikely due to the large sample size included in this study. 
 Next, the use of secondary data for this analysis had several limitations. First, 
several suggested variables could not be evaluated such as sleep hygiene behaviors, 
detailed sleep environment factors, and detailed breast cancer treatment information. 
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Findings showed 34% of the variance for sleep severity was explained by the variables 
evaluated. This leaves a moderate amount of unexplained variance in terms of severity of 
sleep disturbances. Factors such as thyroid function, genetic polymorphisms, sleep 
hygiene, and additional sleep environment factors could have been some of the missing 
pieces needed to increase the percentage of explained variance. Second, answers to 
questionnaires were completed from a quality of life perspective. Responses may have 
been different, such as higher global sleep scores, if subjects were completing 
questionnaires that focused solely on sleep disturbances.  
 Third, limitations included measurement issues. The reliability of the PSQI for 
both BCS and WWBC was near the cut-off for adequate reliability and lower than 
reported in a previous study that reported alphas of 0.80 for BCS and 0.83 in a non-
cancer cancer population (Carpenter & Andrykowski, 1998). This lower reliability 
suggests that the items in the PSQI may not have captured the critical attributes of sleep 
disturbances for this sample. This could be attributed to the fact women did not 
understand the questionnaire, or, that the results reflected response burden since the 
parent studies included over 15 questionnaires. Women generally answered 
questionnaires in their home environment suggesting that distraction while completing 
the questionnaires could have led to misunderstanding. In addition, the lack of an 
objective measure of sleep limited knowledge regarding the type of sleep-wake 
disturbance experienced by BCS. It is not clear whether more BCS experience insomnia 
or some other type of physiological sleep disorder not captured by a subjective measure. 
This type of measurement is relevant since a recent study showed that physiological sleep 
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disorders, such as sleep apnea, are common in menopausal women (Freedman & Roehrs, 
2007). 
 Lastly, statistical limitations are as follows. First, the use of standard entry can 
mask unique contributions of certain independent variables in the regression equation and 
appear unimportant to the model when actually there is some relationship present 
(Tabachnick & Fidell, 2001). Second, a generous alpha level (α=0.25) was used to 
evaluate significant relationships between sleep and the independent variables. Those 
with significant relationships were then entered into the regression models. By using a 
generous alpha there is higher probability that a Type II error was committed (accepting a 
false null hypothesis) (Polit & Hungler, 1999). Committing a Type II error means that the 
significant predictors reported from this study could in fact be insignificant. However, 
using a higher alpha was acceptable for this study since it was an exploratory analysis. 
 In addition, the term ‘predictor’ used to describe variables associated with sleep-
wake disturbances could be misleading to readers. The term ‘predictor’ is typically used 
to make forecasts about how certain independent variables behave in a new setting with 
different populations (Polit & Hungler, 1999). The results provide support for the 
probabilistic estimate of future events based on those interactions. In research, regression 
using longitudinal designs, or data that has been collected over-time is used to evaluate 
predictor variables (Polit & Hungler, 1999). In the current study, the variables listed in 
the Elam Psychobiological Model were termed ‘predictors’ using a cross-sectional 
design. Some may argue that these variables should be labeled ‘contributing factors’ 
because the data was not evaluated over-time. However, recalling that factors associated 
with sleep disturbances can be precipitating (root cause) or perpetuating (cause over-
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time), it would be difficult to determine which one is the source of the current sleep-wake 
disturbance. Therefore, the term ‘predictor’ was used to describe these relationships since 
the independent variable could be a perpetuating cause occurring over-time. 
Implications for Practice 
 Nurses and other health care professionals play a vital role in the assessment of 
clinical issues among BCS. Nurses and other health care professionals who practice in all 
types of clinical settings (e.g., primary care, women’s health) should be aware that BCS 
experience poor sleep and severe sleep disturbances. Since BCS are more at risk for 
having poor sleep and severe sleep disturbances, practitioners need to target BCS for 
enhanced screening of sleep-wake disturbances. Additionally, findings from this study 
suggest those at highest risk included BCS in the minority, having hot flashes, having 
than two co-morbid conditions, or with high depressive symptoms. BCS who are more 
then 5 years post-diagnosis tend to visit oncology clinics only once per year and return to 
primary care settings for acute health needs. This suggests that in long-term survivors, it 
is the primary-care practitioners that will be more likely to identify sleep problems in 
BCS. 
 Screening for sleep-wake disturbances can start with a simple one sentence 
question such as, ‘How are you sleeping?’ This could prompt a conversation regarding 
problems with sleep. Practitioners can then identify those BCS that would require more 
detailed assessments of sleep-wake disturbances. Including family members in this 
assessment is essential to gain additional information such as snoring or frequent limb 
movements during sleep. This could result in a referral to sleep specialists to rule out 
clinical sleep problems such as sleep apnea or restless leg syndrome. In addition, if a 
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clinical assessment reveals psychosocial or behavioral problems such as depression and 
poor sleep hygiene habits, referrals should be considered an important resource to 
determine the best intervention. Practitioners can perform initial teaching regarding sleep 
hygiene practices such as establishing a bed-time routine that includes avoiding eating 2 
hours prior to bed, excessive activity prior to bed, or excessive caffeine intake. If patient 
education is completed, it is important to establish an appropriate follow-up to determine 
if further evaluation is needed. 
 Although negative consequences were not addressed in this study, general 
findings suggest that sleep-wake disturbances can lead to immediate and delayed 
physiological and psychosocial health related outcomes (Engstrom et al., 1999; Koopman 
et al., 2002; Moe, 2004; Northouse et al., 1999; Schultz et al., 2005). Problems such as 
daytime sleepiness, decreased immune function, and loss of job productivity could 
prompt BCS to seek health care intervention (Savard et al., 2003; Savard et al., 2001). 
Practitioners need to not only identify those with sleep problems but also evaluate 
negative outcomes associated with lack of sleep. 
 Since the number of women surviving breast cancer is projected to increase each 
year and BCS constitute the largest survivorship population (National Center for Chronic 
Disease Prevention and Health Promotion, 2004), sleep-wake disturbances will continue 
to be a clinical problem in need of intense evaluation by practitioners in both oncology 
and primary are settings. Addressing these issues from a clinical perspective can 
potentially decrease the negative outcomes related to sleep, thus, improving quality of 
life.  
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Future Research 
 Research findings from this study can guide future research. The following 
section outlines how these findings will; (1) guide measurement of poor sleep and sleep 
disturbances, (2) guide further conceptualization of sleep and sleep disturbances, and (3) 
guide development of targeted interventions of sleep-wake disturbances in BCS.  
 Findings showed that BCS reported poorer sleep and higher sleep disturbances 
compared to WWBC. Sleep was measured using the Pittsburgh Sleep Quality Index 
(PSQI). This measurement was successful in identifying poor sleep and sleep 
disturbances in BCS even with a suboptimal Cronbach’s alpha coefficient. Using the 
standardized questionnaire facilitated comparison to prior BCS sleep studies. Future 
studies should continue to use the PSQI to provide consistency in data findings. Addition 
of objective measurement, such as polysomnography, will help identify those with 
physiological problems not captured in subjective measures. Additional objective 
measurement should include hot flash monitoring since this was a strong predictor of 
poor sleep and sleep disturbances in BCS. In addition, using both subjective and 
objective measures provides the opportunity to determine if these are correlated.  
In terms of conceptualization of sleep in BCS, future research should focus on 
refining predictors of specific groups and formulating targeted interventions for BCS. 
Studies should be conducted in a clinical setting to ensure accuracy and understanding of 
completed questionnaires by subjects. Further describing predictors of sleep specific to 
race will refine knowledge regarding those BCS at risk. In addition, longitudinal studies 
are needed using structural equation modeling or path analysis to validate pathways of 
this model and determine if predictors are consistent over time. Further model testing will 
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need to evaluate the portions of the model that have not been fully investigated such as 
sleep hygiene factors, types of sleep-wake disturbances, and health related outcomes such 
as marital satisfaction and sexual relationships of couples. This information will provide 
additional support to the model and refine current knowledge.  
Overall, the model provides a more comprehensive theoretical framework that is 
lacking in current studies. This information is needed to guide research designs and test 
interventions to help treat this problem. There has been a national response to this type of 
research in the cancer population. The importance of understanding sleep disturbances in 
cancer populations has been highlighted by national funding agencies such as the 
National Institute of Aging, National Heart, Lung, and Blood Institute, National 
Institute of Neurological Disorders and Stroke (www.nih.gov), and continues to be a 
research priority of the Oncology Nursing Society (www.ons.org). 
 Future research could include constructing tailored interventions for sleep 
disturbances specific for BCS. However, before these interventions can be tested, 
additional descriptive work is needed. There is a lack of knowledge about the type sleep-
wake disturbance experienced by BCS. A pilot study should be conducted that evaluates 
BCS for the presence of various types of physiological sleep disturbances such as sleep 
apnea and restless leg syndrome. This is supported by one study that showed 43% of BCS 
experienced restlessness in the legs (Davidson et al., 2002). In a study of non-cancer 
women, a study also found that a higher than expected percentage of menopausal women 
who reported poor sleep had undiagnosed physiological sleep disorders (Freedman & 
Roehrs, 2007). This type of assessment would include 1 or 2 nights of polysomnography 
study in a sleep laboratory.  
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In addition, concurrent psychological and behavioral interviews would need to 
also be conducted to obtain information regarding other factors contributing to sleep 
disturbances and health-related outcomes specific to poor sleep would also be 
recommended. Based this pilot data, an algorithm of tailored interventions could then be 
established based on the common types of sleep disturbances encountered specific to 
BCS. During recruitment for any BCS sleep studies, efforts to recruit more minority BCS 
should be strongly considered since minority BCS had the poorest sleep. Eventually, 
translation of research outcomes into primary care and medical oncology settings will 
further prompt identification and treatment of this problem. 
Summary 
 This secondary analysis evaluated data from 246 BCS and 246 WWBC to 
determine prevalence, severity, predictors of poor sleep, and predictors of severity of 
sleep-wake disturbances. A comprehensive list of variables was evaluated to determine 
what factors predicted the prevalence and severity of poor sleep and sleep disturbances. 
BCS were more at risk for having poor sleep and more severe sleep disturbances 
compared to age-matched WWBC. Predictors of poor sleep specific to BCS were race, 
hot flashes, level of physical functioning, and depressive symptoms. Additionally, co-
morbidities and long-term effects of cancer predicted severity of sleep disturbances. 
Results of this study supported findings in the current literature showing that sleep 
disturbances are problematic in long-term survivors. Contrary to previous studies, this 
study did not find that age, concerns about recurrence, or sleep environmental factors 
were factors in predicting poor sleep and sleep disturbances.  
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 This study provided new information regarding predictors of poor sleep and sleep 
disturbances for BCS. Results provide a basis for recommendations for practice and 
future research that examines sleep over time in BCS. Findings of this study suggest that 
understanding sleep disturbances in BCS is multifaceted. Further examination of the 
health-related outcomes will provide additional further conceptual knowledge and drive 
research to develop effective interventions. The goal will be to reduce the negative 
outcomes through such interventions and improve the quality of life of BCS. 
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APPENDIX A 
 
 
Summary of Theoretical Models 
Author 
 
Critical Attributes 
Borbely, et al. 
(1999).  
 
 
 
Domain-
medicine 
 
• Physiological model of sleep. 
• Homeostatic process (Process S) rises during waking and declines 
during sleep. 
• Process S interacts with circadian process (Process C). 
• Course of daytime vigilance accounted by interaction of Process S 
and C. 
• Process S is from physiological variable (EEG slow wave). 
• Circadian dynamics includes non-REM and REM interactions with 
the process S and C. 
• PSG used for evaluation (not explicit). 
Harvey (2002) 
 
 
 
 
 
 
 
 
Domain-
psychology 
• Cognitive model of sleep. 
• Developed in order to explain characteristics between sporadic vs. 
chronic insomnia. 
• Insomniacs experience unpleasant intrusive thoughts, worry during 
pre-sleep. 
• During wake periods, prone to increased anxiety, worry, 
neuroticism, obsessionality, dysphoria, hypervigilance, tension. 
• Cognitive processes trap: increases absorption and anxiety 
regarding sleep problem.  
• Excessive negative tone cognitions: getting enough sleep and how 
lack of sleep impacts health and daytime functions. 
• Excessive worry/ruminations: triggers autonomic arousal/emotional 
distress which lead to anxious state. 
• Selective attention/monitoring: monitor of internal sleep-related 
threats (not getting enough sleep, and not coping/functioning 
during day. 
• Overestimates extent of the perceived deficit of sleep and daytime 
performance.  
• Ultimate deficit/disruptions in sleep-wake cycles. 
• The perceived deficit then becomes a real sleep deficit. 
• Model accounts for nighttime awakenings. 
Spielman et al. 
(1987) 
 
 
 
 
 
 
Domain-
psychology 
• Psychobiological model of sleep. 
• Multidimensional model of chronic insomnia provided interactions 
between predisposing, precipitating, and perpetuating factors of 
insomnia. 
• Explains the evolution of insomnia and how individual differences 
cause initiation of disturbed sleep. 
• Heightened arousal states (wake up easily) prone to poor sleep.  
• Lack of sleep continues, perpetuating factors of frustration, 
agitation about inability to sleep contribute to further cognitive and 
physiological arousal = increased lack of sleep.  
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Author 
 
Critical Attributes 
• Maladaptive strategies include increased time to fall asleep, anxiety 
about daytime performance, and progression of psychological 
disorders such as anxiety and depression. 
Espie (2002) 
 
Domain-
psychology 
• Psychobiological model of sleep. 
• Sleep is a default state of humans that contains involuntary, 
harmonious interactions between homeostatic and circadian 
processes in association with self-perception of good sleep quality. 
• Allows for normal variability of day-to-day sleep patterns 
(plasticity) and cognitive ability to deal with this variability. Failure 
of automated sleep activation and maintenance through 
precipitating factors that lead to persistent, chronic inhibition and 
prevention of natural recovery of good sleep. 
• Addresses the automaticity and plasticity of sleep and how it is 
weakened by inhibitory feedback from one or more 
psychobiological processes. 
 Elam,  
(unpublished) 
 
 
 
Domain-
nursing 
• Psychobiological model of sleep. 
• Predictors of sleep are unique to BCS and include physiological, 
psychological, environmental, and behavioral (sleep hygiene) 
factors. 
• Predictors can occur singly or clustered within and among each 
category of factors. 
• Predictors contribute to the occurrences of sleep-wake disturbances.  
• Precipitating factors can then become perpetuating.  
• Sleep-wake is operationalized by both subjective and objective 
measures. 
• Consequences include both immediate and distal outcomes that 
negatively impact quality of life.  
• Immediate outcomes include further sleep-wake disturbances due 
to negative cognitions about sleep.  
• Distal outcomes can also contribute to additional disturbances over 
time. 
  
156
APPENDIX B 
 
 
Descriptive Literature Tables 
Predictors and outcomes 
 Predictors  
Author/Year Sample Physiological Psychological Environmental/ 
Sleep hygiene 
Outcomes 
(Ancoli-Israel et al., 
2001) 
Cancer 
patients 
(review) 
Pain 
 
Cancer treatment 
(chemotherapy, 
radiotherapy) 
Psychiatric 
disorders (e.g., 
depression, 
anxiety) 
 
 Main variable: fatigue in cancer patients 
but reported on sleep issues 
Review states sleep is a common problem 
in cancer patient. 
Unknown: the relationship between 
treatment, distress, and/or palliative 
medication side effects and sleep-wake 
problem. 
Unknown: role of circadian rhythm 
disruption due to cancer itself, treatment 
for cancer, and long-term manifestations 
of that disruption. 
True cause of sleep-wake problems not 
identified in cancer patients. 
Common complaints: sleep latency, 
duration, awakenings, daytime 
dysfunction, daytime sleepiness, poor 
sleep quality. 
Pre-treatment cancer showed increased 
insomnia due to distress. 
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 Predictors  
Author/Year Sample Physiological Psychological Environmental/ 
Sleep hygiene 
Outcomes 
(Anderson et al., 
2003) 
n=354 cancer 
patients 
n=psychiatric 
patients 
n=290 non-
patient 
volunteers 
Treatment-
induced 
abnormalities in 
cytokine levels 
  Compared severity of fatigue between 
groups. 
Fatigue does not significantly differ 
between non-patient and depressed 
patients.  
62% cancer patients reported moderate-
severe sleep disturbance. 
Sleep disturbance significant predictor to 
severe fatigue.  
Links sleep disturbances and fatigue. 
(Andrykowski et al., 
1998) 
n=88 breast 
cancer (BC) 
n=88 age 
matched 
benign breast 
problems 
   Main variable: fatigue after cancer 
treatment. 
Correlated various subjective fatigue 
questionnaires to find predictors of 
fatigue. 
PSQI results: no group differences in 
subscales except BCS had decreased 
sleep quality. 
(Anker et al., 1998) N=26 
postmenopau
sal BCS  
   Thyroid function. 
Non-sleep specific. Reviewed to provide 
support for thyroid issues in BC. 
(Berger, 1998) n=72 BCS    Patterns of fatigue/activity/rest during 
adjuvant BC tx.  
Fatigue negatively correlated with 
activity. 
Evaluates sleep via activity and rest cycle 
(actigraphy). 
(Berger & Farr, 1999) n=72 BC 
patients 
Treatment 
(chemotherapy) 
 
  Main variable: fatigue and sleep. 
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 Predictors  
Author/Year Sample Physiological Psychological Environmental/ 
Sleep hygiene 
Outcomes 
Disrupted 
circadian cycles 
due to inactivity 
Women less active had increased night 
awakenings reporting higher fatigue 
during treatment. Disrupted sleep at mid-
treatment are at risk for chronic fatigue. 
Less activity correlated with increased 
naps and higher fatigue. 
(Berger & 
Higginbotham, 2000) 
n=14 BC 
patients 
Disrupted 
circadian cycles 
due to inactivity 
 
 
Symptom 
distress 
 Main variable: fatigue and sleep. 
Fluctuating patterns of decreased activity, 
disturbed sleep, mild-moderate symptom 
distress correlated with moderate fatigue. 
Patterns of sleep (total sleep, latency, 
WASO, efficiency) differed from healthy 
norms. 
Highest fatigue and symptom distress 
during treatment. 
Fatigue correlated with: increased 
symptom distress, lower activity, poor 
physical/social health status. 
(Berger & Walker, 
2001) 
n=60 BC 
patients 
 Reaction to 
diagnosis of BC 
 
Distress 
reaction to 
diagnosis of BC 
 Fatigue model: sleep is outcome variable. 
Person antecedents correlated with 
activity change (sleep) causing fatigue. 
(Berger et al., 2003) n=21 BC 
patients 
 Psychological 
factors (non-
specific) 
 
 Sleep hygiene intervention followed over 
time. 
Adherence remained high for follow-up. 
Sleep-wake patterns were comparable to 
standard norms except for duration of 
nighttime awakenings.  
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 Predictors  
Author/Year Sample Physiological Psychological Environmental/ 
Sleep hygiene 
Outcomes 
(Bleiker et al., 2000) n=170 BCS    Used Impact of events Scale (IES) to 
determine distress after diagnosis of BC 
at baseline (prior to surgery, and two 
years post).  
16% reported high levels of intrusive 
psychological distress and 8% reported 
high avoidance post pre and diagnosis.  
Predictors of distress: intrusive thoughts 
about dx, trait-anxiety, health complaints, 
problems sleeping  
 
(measured by health complaints check 
list). 
Sleep problems were correlated with 
intrusive psychological distress. 
(Broeckel et al., 1998) n=61    Compared to women with no cancer, 
adjuvant treated women reported more 
severe fatigue (p<.01), worse QOL 
(p<.05). 
Severe fatigue r/t poor sleep quality 
(p<.05), greater use of catastrophizing as 
a coping strategy, and presence of 
psychiatric disorder. 
Sleep problems a predictor of fatigue. 
 
(Carpenter & 
Andrykowski, 1998) 
n=155 bone 
marrow 
transplant 
n=56 renal 
transplant 
Hot flashes 
Pain 
  Evaluated PSQI for cancer patients. 
Presented validity reliability data. 
Global sleep >=8 (higher then standard) 
indicates poor sleep and a predictor of 
fatigue. 
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 Predictors  
Author/Year Sample Physiological Psychological Environmental/ 
Sleep hygiene 
Outcomes 
n=102 BC 
n=159 
benign 
changes 
 
 
 
 
Mean score for BC=7.0 for global sleep. 
Carpenter et al. 1999 N=114    Main variable: menopausal symptoms 
(prevalence and severity) in BCS. 
Interview of several symptoms check-
lists-75% reported trouble sleeping.  
(Carpenter & Elam, J. 
L. et al., 2004) 
n=15 BCS 
n=15 healthy 
matched 
Nighttime hot 
flashes  
  Primary variables: sleep, fatigue, hot 
flashes, depression. 
73% BCS=poor sleep quality and high 
sleep disturbance with PSQI scores>=5. 
Sleep duration significantly shorter in 
BCS. 
No other significant group differences. 
(Cimprich, 1999) n=74 BC 
patients, 
newly 
diagnosed 
   Main variable: symptom distress in newly 
diagnosed BC patients. 
Reported insomnia via symptom distress 
scale: m=2.88 (30% of population 
reported symptoms of insomnia). 
  
161
 Predictors  
Author/Year Sample Physiological Psychological Environmental/ 
Sleep hygiene 
Outcomes 
(Clark et al., 2004) Sleep-wake 
w/cancer 
(review) 
Pain 
 
Cancer related 
distress  
 
 Sleep-wake disturbances are salient to 
cancer experience reported by patients. 
Includes nocturnal sleep and daytime 
sleepiness. 
Different prevalence rates by site specific 
cancers. 
Survival of cancer can be affected by the 
negative outcomes of sleep-wake 
disturbance. 
Noted relationships between age, gender, 
setting (hospitalization) for disturbances. 
Interventions include pharmacologic and 
non-pharmacologic. 
Regulated by the Two-Process Model of 
sleep regulation. 
Measured by subjective, objective 
measures. 
Phenomena requires multidisciplinary 
team approach for treatment. 
 
(Couzi et al. 1995) 
 
n=222 BC 
survey 
regarding 
attitudes of 
estrogen tx 
   Main variable: attitude toward estrogen 
replacement. Reported 44% complained 
of sleep disturbances.  
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 Predictors  
Author/Year Sample Physiological Psychological Environmental/ 
Sleep hygiene 
Outcomes 
(Davidson et al., 
2002) 
N=982 
cancer 
patients 
Co-morbidities: 
(cardiovascular, 
respiratory, pain)  
 
Radiotherapy  
Emotional/ 
physical 
distress at 
diagnosis  
 
 Sleep disturbances can lead to emotional, 
cognitive, physical dysfunction. 
Effective psychological interventions can 
improve negative consequences. 
44% reported excessive fatigue. 
41% reported restless leg. 
31% reported symptoms of insomnia. 
28% reported excessive sleepiness. 
48%reorted insomnia prior or around 
time of cancer diagnosis. 
 
(Deimling et al., 
2002) 
n=180 older 
adult, long-
term cancer 
survivors, 
some BCS 
included 
   25% showed clinical levels of depression. 
Survivors displayed psychological 
distress r/t continued negative effects of 
cancer and treatment. 
Cancer-related symptoms predicted 
depression (b-0.27, p<0.05). 
Effects persist after even if stressors and 
non-cancer illness are controlled. 
Stressors: diagnosis, fear of recurrence, 
memories of trauma r/t dx or tx. 
Body image changes in BC=distress. 
Proposed conceptual model. 
 
Listed stressors but did not correlate with 
primary sleep variable. 
Insomnia was a negative consequence 
listed in the findings. 
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 Predictors  
Author/Year Sample Physiological Psychological Environmental/ 
Sleep hygiene 
Outcomes 
(Dow et al., 1996) n=294 BCS Pain 
Sleep problems 
  Evaluated distress among BCS via 
subjective questionnaires. 
Fatigue, aches, pain, sleep problems 
persistent s/e after treatment. 
Over time: 
Psychological distress (fear of recurrence, 
metastatic disease), family distress, 
sexuality concerns, family burden, fear of 
uncertainty regarding future. 
Sleep an outcome, no predictors listed. 
(Engstrom et al., 
1999) 
n=150 cancer 
patients 
(phase 1) 
 
n=42 cancer 
patients 
(phase 2) 
Pain followed by 
emotional 
reaction that 
prevented further 
sleep 
 
 
Side effects of 
chemotherapy, 
medications 
 
 
Psychological 
distress 
 
 44% report sleep problems during month 
prior to interview. 
(x=5.82; p<.05). 
16% reported sleep problems to health 
care provider. 
Phase two: 45% reported sleep problems 
one month prior to interview (qualitative). 
90% reported nighttime awakenings. 
People often attributed sleep problems as 
side effect of chemotherapy. 
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 Predictors  
Author/Year Sample Physiological Psychological Environmental/ 
Sleep hygiene 
Outcomes 
(Fortner et al., 2002) n=72 BC 
patients 
Chemotherapy/ra
dio-therapy side 
effects 
 
Chronic 
insomnia 
(occurring prior 
to cancer 
treatment) 
 
Lingering side 
effects of 
treatment 
 
 
Chronic pain 
Depression due 
to diagnosis and 
treatment 
 
 61% had poor sleep quality. 
Sleep problems predict deficits in quality 
of life. 
Poor sleep causes deficits in work 
performance, daily task performance, 
physical limitations. 
Poor sleepers report lower energy levels 
for daily activities, daytime sleepiness, 
fatigue. 
Sleep has negative correlation with 
chemotherapy and radiotherapy. 
Breast cancer patients reporting poor 
sleep report increased emotional 
disturbances also contributing to 
decreased work performance, difficulty 
maintaining daily tasks, QOL. 
Disturbances: using bathroom, pain, 
awakenings, too hot. 
Suggests those with strong negative 
outlook on cancer diagnosis have worse 
sleep. 
(Koopman et al., 
2002) 
n=97 BC 
metastatic 
disease 
Cancer pain 
 
Education  
 
 
Lack of social 
support 
 
Depressive 
symptoms 
 
 63% reported one or more sleep 
disturbance. 37% used sleeping pills. 
Sleep latency r/t pain and depressive 
symptoms. 
Nighttime awakenings r/t depression and 
low education. 
Morning awakenings problematic r/t 
depressive symptoms and less social 
support. 
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 Predictors  
Author/Year Sample Physiological Psychological Environmental/ 
Sleep hygiene 
Outcomes 
Daytime sleepiness did not have 
significant predictors. 
Decreased duration r/t metastases, bone 
pain, depressive symptoms, greater social 
support. 
(Lee et al., 2004) Sleep and 
cancer 
patients 
(review) 
Individual 
differences in 
chronotype and 
circadian  
Gender, age, 
prior sleep 
history,  
Stage/type of 
cancer,  
Treatment side 
effects  
Other s/e: pain, 
apnea,  
narcolepsy, 
restless leg 
syndrome 
 
 Poor individual 
sleep hygiene 
 
Environment of 
sleep 
Sleep is defined as multidimensional 
phenomena. 
Physiology of sleep cycle discussed 
(circadian pattern): 24 hr wake/sleep 
rhythm that allows normal human 
functioning. 
Sleep disturbance (insomnia): difficulty 
falling asleep, problems maintaining 
sleep, nighttime awakenings, excessive 
daytime sleepiness. 
Daytime sleepiness can mimic signs of 
fatigue. 
In breast cancer patients: tamoxifen side 
effects, menstrual/hormonal changes after 
treatment. 
Progressive disease states may lead to 
greater sleep disturbances. 
Medications prescribed for anxiety, 
depression, can cause increased reported 
sleep disturbances. 
Non-pharmacological interventions can 
be helpful but, initial accurate diagnosis 
of specific problem related to sleep (e.g., 
restless leg) is needed prior to 
intervention. 
  
166
 Predictors  
Author/Year Sample Physiological Psychological Environmental/ 
Sleep hygiene 
Outcomes 
(Miaskowski & Lee, 
1999) 
n=24 cancer 
patients with 
bone 
metastases  
Low Karnofsky 
Performance 
scores (pain) 
 
High doses of 
radiotherapy 
 
 
  Main variable: sleep. 
70% sleep efficiency per actigraphy (85% 
optimal for normal sleep). 
Pain is a predictor of fatigue and sleep 
disturbances. 
No correlations between objective 
measures and self-ratings of feeling 
rested and quality of sleep. 
91% watch TV for self-care behavior 
82% read. 
(Mourits et al., 2002) n=98 BC 
patients 
Tamoxifen   Main variable: sexual well-being r/t  tam 
use. 
85% reported hot flashes. 
55% reported sleep disturbance  
(Northouse et al., 
1999) 
n=98 BCS Sleep 
disturbances 
Distress  Used stress/coping model for QOL in 
African American BC patients. 
Looked for predictors for increased QOL. 
Symptoms of distress were low. 
Problems reported were energy loss, sleep 
disturbance, pain. 
Explained QOL factors by means of 
appraisal (stress/coping model).  
Sleep disturbance was an antecedent to 
QOL. 
 
(Okuyama et al., 
2000) 
n=134 BCS    Main variable: fatigue. 
Sleep was listed as significant correlate of 
fatigue. 
Dyspnea and depression also correlated 
with fatigue. 
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 Predictors  
Author/Year Sample Physiological Psychological Environmental/ 
Sleep hygiene 
Outcomes 
Three variables accounted for 46% 
variability. 
 
(Redeker, Lev, & 
Ruggiero, 2000) 
n=263 cancer 
patients  
Radiation 
therapy 
  Sample undergoing chemotherapy. 
Main variables: insomnia, fatigue, 
depression, anxiety- positively correlated 
(r=.26 to r.69, p<.001). 
All negatively correlated with QOL (r=-
.28 to r=-.63, p<.001). 
Women>men. 
Depression explained most of the 47% 
variance. 
Insomnia and fatigue explained only 4%. 
Age associated with increased QOL, less 
insomnia, fatigue, anxiety, depression. 
Sleep latency more intense in BC. 
44-48% BC patients report sleep 
disturbance with radiotherapy. 
 
(Roscoe et al., 2002) n=78 BC 
patients 
Circadian rhythm 
dysfunction  
  States sleep disturbances related to cancer 
can be alleviated by periods of rest. 
Circadian rhythms are endogenous, 
genetically based physiological 24 hr 
cyclic patterns. 
Cancer may alter circadian rhythms. 
Melatonin production (maintains sleep 
control), might be negatively correlated 
with BC.Central serotonin involved in 
sleep.No antecedents for sleep-wake 
disturbances listed. 
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 Predictors  
Author/Year Sample Physiological Psychological Environmental/ 
Sleep hygiene 
Outcomes 
States circadian rhythm disruption 
antecedent to depression and fatigue. 
(Savard et al., 2001) n=300 BC 
patients 
Lumpectomy 
 
Chemotherapy 
 
Low tumor stage 
 
 
  Non-metastatic patients undergoing 
radiotherapy. 
19% met criteria for insomnia syndrome. 
95% of the insomnia cases were chronic. 
Onset: 33% prior to dx. 58% after 
diagnosis or aggravated by diagnosis. 
Risk: those on sick leave, unemployed, 
widowed, completed lumpectomy, 
chemotherapy, and had less severe cancer 
stage. 
Those with insomnia symptoms at risk for 
diagnosed syndrome: separated from 
spouse and had university degrees. 
(Savard et al., 2004a) n=24 BCS Hot flashes   Variable: Hot flashes (objective) and 
sleep (PSG). 
Nights with hot flashes=lower Stage 2, 
longer REM latency, less efficient, more 
disrupted sleep. 
 
 
(Servaes et al., 2002a) n=57 
fatigued BCS 
n=57 age-
match 
chronic 
fatigue 
patients 
   Main variable: fatigue. 
BCS similar to CF in reporting 
psychological well-being, sleep and 
concentration. 
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 Predictors  
Author/Year Sample Physiological Psychological Environmental/ 
Sleep hygiene 
Outcomes 
(Spelten et al., 2003) n=235 cancer 
patients post 
treatment 
   Main variable: how fatigue impacts time 
to return to work. 
Fatigue, diagnosis, treatment type, age, 
gender, depression, physical complaints 
(sleep) related to time to work return. 
(Vena et al., 2004) (review of all 
cancer 
patients) 
 lifestyle, 
disease-related, 
treatment-related  
 
Psychological 
factors such as 
depression, 
anxiety 
 Main variable: Sleep is a passive state. 
Process regulated by behavioral, 
neuroendocrine, central nervous system 
factors. 
Sleep is a cyclic function with several 
stages and cycles (sleep architecture). 
Sleep disturbances diagnosed as: 
Dyssomnias. 
Parasomnias. 
Proposed sleep disorders. 
(Weitzner et al., 2002) n=13 
BC patients 
with hot 
flashes 
Hot flashes   Main variable: hot flashes. Tx with 
paroxetine. Improved sleep quality noted 
to be significant after intervention sing 
self report. Paired t-test showed M=0.77, 
SD 0.60 p<0.0003.  
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Theoretical models and measurement 
Source 
 
Theoretical framework Measurement of sleep 
Anderson, 2003 Did not specify  Sleep Disturbance Scale. 
Andrykowski, 1998  Did not specify PSQI. 
Berger, 1998  Piper Integrated Fatigue Model 
(IFM) 
Wrist actigraphy. 
Berger, 1999  IFM Wrist actigraphy. 
Berger, 2000 IFM Morin Sleep Diary. 
Wrist actigraphy. 
Berger, 2003 IFM Generic daily sleep 
diary. 
PSQI. 
Wrist actigraphy. 
Bleiker, 2000  Did not specify Symptom Check List-90 
(SCL-90). 
Broeckel, 1998  Did not specify PSQI. 
Carpenter, 1999 Did not specify Symptom check-lists. 
Carpenter, 1998  Did not specify PSQI. 
Carpenter, Elam et al., 
2004 
Lenz Model of Unpleasant 
Symptoms 
PSQI. 
Cimprich, 1999 Did not specify Symptom distress scale. 
Clark et al., 2004 Two Process Model Review. 
Couzi et al., 1995 Did not specify Generic survey. 
 
Davidson et al, 2002 Did not specify Generic questionnaire. 
Deimling, 2002  Stress and coping model for cancer 
survivors  
None. 
Dow, 1996  Quality of Life Model-adapted for 
cancer survivors 
Symptom distress scale. 
Engstrom, 1999 Did not specify Telephone survey-
generic sleep questions. 
Fortner, 2002  Did not specify PSQI. 
Koopman, 2002  Did not specify 27-item Sleep 
Questionnaire (from a 
tool called Structured 
Insomnia Interview). 
Miaskowski, 1999 Did not specify Activity log. 
Generic sleep questions. 
Wrist actigraphy. 
 
Mourits, 2002  Did not specify Generic questions 
regarding sleep. 
Northouse, 1999  Stress and coping framework Inventory of Current 
Concerns. 
Okuyama, 2000 Did not specify Generic questions 
regarding sleep in 
demographics. 
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Source 
 
Theoretical framework Measurement of sleep 
Redeker, 2000  Lenz Theory of Unpleasant 
Symptoms 
Functional Assessment 
of Cancer Therapy. 
Roscoe, 2002  Did not specify Actigraph. 
Savard, 2001  Spielman’s Psychobiological Model Insomnia Screening 
Questionnaire. 
Insomnia interview 
Schedule. 
Savard, 2004  Did not specify Insomnia Severity Index 
in Cancer Patients (ISI). 
Servaes, 2002 Did not specify Causal Attribution List 
(contains sleep 
subscale). 
Spelten et al., 2003 Model of impact of cancer related 
symptoms 
PSQI. 
Vena et al., 2004 Two-process model of sleep Review. 
Weitzner et al., 2002 Did not specify PSQI. 
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APPENDIX C 
 
 
Elam Psychobiological Model Sleep-Wake Disturbances Model in Breast Cancer Survivors 
Self-reported  
 
 
Physiological 
Co-morbidities  
Post-menopausal symptoms (hot flashes)  
Physical functioning or activity 
Long –term side effects of cancer treatment 
 
Predictors 
 
Psychological 
Cancer related distress (fear of recurrence) 
General psychological distress (anxiety, 
depression) 
Environmental 
Sleep environment 
Family developmental stage 
Sleep hygiene practices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sleep-Wake 
Disturbances  
 
in Breast Cancer 
Survivors 
 
Proximal Outcomes 
Objective  
 
Delayed Outcomes 
 
Physical 
Chronic daytime sleepiness 
 Fatigue 
 Immune function 
 
 
Psychological 
    Impaired cognitive processes 
    Attention deficits 
    Processing deficits 
    Memory deficits 
    Anxiety 
    Depression  
 
Social 
    Job performance 
    Tasks at home 
    Socialization  
Distal Outcomes/ 
Consequences 
 
Immediate outcomes 
Daytime sleepiness 
Distress related to lack of 
sleep 
 
 
Person characteristics 
Age 
Education 
Race 
Socio-economic status (SES) 
Menopausal status 
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APPENDIX D 
 
 
Drugs that Effect Sleep 
 
Drug Category Drug Sleep Disruption 
Opioids Decrease 
• REM 
• Stage II 
• arousal 
Analgesics 
Nonsteroidal anti-
inflammatory drugs 
 
Increase 
• stage II 
Decrease 
• slow wave sleep 
Alters: thermoregulatory system 
Tricyclic 
 
Decrease 
• REM 
• Total sleep time 
Antidepressants 
Selective serotonin 
reuptake 
Decrease 
• REM 
• Total sleep time 
Dopamine antagonists Increase  
• Drowsiness, sedation 
Decrease 
• REM 
Anticholinergic agents Decrease 
• REM 
Increase 
• Stage II 
• Body movements 
Antiemetics 
5-HT3 antagonists Increase  
• Drowsiness 
Anxiolytics Benzodiazepines Decrease 
• slow wave sleep 
• REM 
Increase 
• Stage II 
Alters: thermoregulatory system 
Corticosteroids Prednisone and 
dexamethasone  
 
Insomnia with bad dreams 
Hypnotics Benzodiazepines  Decrease 
• slow wave sleep 
• REM 
Increase 
• Stage II 
Alters: thermoregulatory system 
 
 Non-benzodiazepines Minimal effect on slow wave sleep and 
REM 
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Drug Category Drug Sleep Disruption 
Decrease 
• Sleep latency 
Radiotherapy  None Unknown  
 
Anthracyclines Unknown 
 
Chemotherapy 
Taxanes Unknown 
 
Tamoxifen Unknown 
 
Hormone Modulators 
Aromotase Inhibitors  
 
Unknown 
*All drug effects have been noted with acute and chronic drug administration. 
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APPENDIX E 
 
BCS and WWBC Measures 
 
 The following are snapshots from the measures used for the American Cancer 
Society Quality of Life Study (#RSGPB-04-089-01-PBP, Champion PI). 
 
Medical Record Audit Form (MRAF) 
 
1. Diagnosis and stage 
 Date of diagnosis __________ 
 Initial stage  ________ 
 T = _______  N = ________ M = __________ 
 T (1) < 2 cm _____T (2) 2.1 - 5.0 cm ______T (3) > 5 cm_____T (4) ___ 
 ER______  PR______  Her-2 Neu______ 
 Local recurrence  Y______ No________ 
 Systemic recurrence (except lymph nodes)  Y_____ N____ 
 Time since diagnosis (Date of diag - date of survey)___________ 
2. Treatment history- adjuvant therapy, reconstructive surgery, hormone therapy 
 Surgery____ 
 Lumpectomy____ 
 Sential lymph node____ 
 Lymph node dissection____ 
 Simple mastectomy____ 
 Modified mastectomy____ 
 Completion mastectomy ____ 
 Type of reconstruction: 
  None_____ 
  TRAM______ 
  Latissimus Dorsi _____ 
  Implant ______ 
3. Systemic treatment 
 Chemotherapy ________________________________________ 
 Drugs_______________________________________________ 
 Adjuvant_________ 
 Neoadjuvant _________ 
 Tamoxifen _______ # yr ________________ 
 AI ____________# yr ________________ 
 Herceptin _________ 
4. Radiation therapy _______ 
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APPENDIX G 
 
 
Data Cleaning Procedures 
 
Variable Measure Items Missing Decision 
 
Sleep PSQI 38 out of 8856 items 
0.43% missing 
Mean substitution of hours of 
sleep by a narrow mean of 
group (BCS, WWBC) and race 
or age.  
For Q14-since it is an ‘other’ 
category assuming no was 
imputed. 
Type of cancer 
treatment 
MRAF 1 No radiation treatment 
information for ACS 
women 
Radiation therapy will not be 
included in treatment items 
and is listed as a limitation of 
the study. 
Anxiety STAI All AA=160 and 
ACS=7 (questionnaires 
not answered) 
Total missing 
items=305 out of  
13000 
2.35% missing for 
those that completed. 
 
STAI measure was eliminated 
due to Multicolinearity with 
the CES-D. CES-D scores 
were entered into a correlation 
matrix with state and trait 
STAI scores since anxiety and 
depression are typically highly 
correlated. A correlation near 
or above .7 would mean the 
two questionnaires are highly 
related (Tabachnick & Fidell, 
2001). 
The correlation for State/CES-
D 0.67 and Trait/CES-D 0.75. 
This would mean that the 
STAI and CES-D are 
correlated with possible 
redundancy in variables 
(depression and anxiety).  
Distress r/t life 
event 
IES-
revised  
98 out of  9840 
1% missing 
 
 
Mean substitution by group 
was performed for missing 
values. 
Scores were averaged to 
produce scores for items 13 
and 19 were inadvertently not 
included in the measure. 
Scales and total were 
recalculated. 
 
SES PCQ  
WI 
21 single-items out of 
492 
4.26% missing 
Mean substitution imputed 
based on mean income by 
group and race. 
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Variable Measure Items Missing Decision 
 
Long-term side 
effects 
SER1 30 items out of 9852 for 
BCS 
0.30% missing 
Imputed response of 0 
meaning ‘no’ for responses for 
missing values since using a 
mean might make the false 
assumption that the symptom 
was present without severity 
rating being present.  
Physical 
functioning 
PF-10 4 items total of 4920  
0.06% missing 
No action needed.  
 
Mean imputation did not 
change scores included in 
dataset. 
Cancer related 
distress 
CARS 1 3 items total of 984  
0.30% missing  
Mean responses were 1 for 
missing items. The mean 
changed only by .01 from 
current scores provided by 
parent dataset. 
Depression CES-D 85 out of 9840 items 
0.86% missing 
 
Used mean imputation from 
SPSS which places a mean of 
that item into missing values. 
When performed, the mean 
scores did not significantly 
change. 
Race PCQ 0 out of 492 Those that listed multiple 
races or no race were 
categorized as “other”. 
Menopausal status MGHQ 0 out of 492 after 
missing values entered  
New variable created based on 
question 2 of questionnaire. 
For missing values, questions 
regarding gynecology history 
were evaluated for any 
indication of hysterectomy, 
oophorectomy, or time 
menstrual cycles stopped, if a 
date was listed status was 
changed in this variable to 
reflect pre-post menopause 
status. 
This process identified the 
status of the 6 that were 
missing. Two decisions were 
made based on age-below 45 
the women were considered 
pre-menopausal because they 
responded ‘no’ to surgery or 
other indicators of being post-
menopausal (e.g., hot flashes). 
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Variable Measure Items Missing Decision 
 
Co-morbidities 
(number of) 
MHQ 0 out of 492 The list of co morbidities was 
grouped into categorical #’s. 
These questions had only a 
‘yes’ response in the 
questionnaire thus if blank-
assumption is that it is a ‘no’ 
response.  
Post-menopausal 
Hot flashes Yes/No 
MGHQ 0 out of 492 Created a variable for hot 
flashes yes/no based on item 
12 in MGHQ. No missing 
values found. 
Companion/bed 
partner 
PSQI 0 out of 492 None-no missing values. Also 
verified with a different 
question in database regarding 
marital status and partnered 
yes/no. This question from 
PSQI captures those that are 
partner and not sleeping in 
separate rooms. 
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